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Abstract 
Alzheimer’s disease (AD) is widely recognised as a growing global health issue with 
far ranging social and economic implications. The accumulation of Amyloid-β (Aβ) 
in the brain is a pathological hallmark of AD. A recently discovered lymphatic–like 
system in the central nervous system (termed the glymphatic system) has been 
postulated to be both implicit in the clearance of Aβ from the brain, and most 
effective during sleep—making sleep an important consideration in the investigation 
of AD. Central nervous system expressed water channel proteins, namely Aquaporin 
1 and 4, have been suggested to play a pivotal role in glymphatic function and thus, 
clearance of Aβ from the brain. However, to-date this has only been investigated in 
AD rodent models and one human study of aquaporin/Aβ protein co-localisation in 
post mortem brain tissue. 
To partially address this gap in knowledge, the current study sought to investigate 
whether genetic variations (single nucleotide polymorphisms, SNPs) within the 
genes encoding aquaporin 1 (AQP1) and aquaporin 4 (AQP4), were associated with 
AD risk, brain Aβ burden and self-reported sleep parameters. Further, this study 
aimed to determine whether genetic variation moderated the relationship between 
sleep parameters and brain Aβ burden. This study was observational and cross-
sectional in design, and utilised Genome-Wide Association Study, Pittsburgh Sleep 
Quality Index (PSQI), and Aβ positron emission tomography data from the larger 
Australian Imaging, Biomarkers and Lifestyle (AIBL) study. 
Genetic variation in AQP1 and AQP4 SNPs was not associated with either an 
increased AD risk or differences in brain Aβ burden. However, genetic variation in 
AQP4, specifically rs12968026, was associated with altered, self-reported, “overall” 
sleep quality (PSQI total score). Further, this study reports that several SNPs in 
AQP1 and AQP4 moderate the conditional effect that three PSQI-determined sleep 
parameters, namely, sleep latency (time taken to fall asleep, in minutes), sleep 
duration (length of sleep, in hours) and daytime dysfunction (disruption of daytime 
activities due to sleepiness), had on brain Aβ burden. 
Taken together, the results of this study add weight to the argument that the 
glymphatic system, is a major biological mechanism underpinning Aβ clearance 
from the brain. The findings also engender a greater understanding of what factors 
may moderate a sleep-AD phenotype relationship, and suggest that interventions 
ii 
 
targeted at improving suboptimal sleep parameters may be most effective at delaying 
AD onset when tailored to the genetics of the individual.  
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1.0 Introduction 
The ultimately lethal neurodegenerative condition known as Alzheimer’s disease 
(AD) is the most common form of dementia, and the second leading cause of death 
in Australia throughout 2013–2015 (Australian Bureau of Statistics, 2016). The 2017 
prevalence of AD in Australia is > 413,100 persons, with 55% of those being female 
(Alzheimer's Australia, 2017), and an Australian Institute of Health and Welfare 
(AIHW) report disclosed Australia’s AD prevalence is expected to increase to 
900,000 persons by 2050 (AIHW, 2012). L. Brown, Hansnata, and La (2017), 
reported the projected estimated incidence (of dementia in Australia) to be > 6.5 
million persons from 2016–2056. Furthermore, the 2017 estimated cost of dementia 
in monetary terms is $14.67 billion (L. Brown et al., 2017). The projected increase in 
cases poses a dramatic social and economic burden to the Australian healthcare 
system, and to the family and carers of persons living with AD. AD is, however, a 
global problem, and Alzheimer’s Disease International (ADI) has reported a global 
prevalence of 46 million persons (with AD) during 2015—with an estimated increase 
up to 131.5 million persons by 2050 (Prince et al., 2015). Additionally, it is estimated 
that the global financial cost of AD is expected to rise to a staggering two trillion 
United States dollars by 2030. Furthermore, the World Health Organization (WHO) 
in collaboration with ADI have insisted that dementia awareness should be forefront 
in public health policy and investigated further with scientific inquiry (ADI & WHO, 
2012). 
AD is complex and multifactorial, with the common symptomology pertaining to: 
progressive memory loss, apathy, emotional instability; with cognitive deficits in 
language, visuospatial function, reasoning, judgement and attention (Cacace, 
Sleegers, & Van Broeckhoven, 2016; Y. Y. Lim et al., 2014; Scheltens et al., 2016). 
It has been estimated that genetic factors contribute 70% of AD aetiology and by 
inference the remaining percent is related to environmental and lifestyle determinants 
(Ballard et al., 2011), including sleep quality and quantity. 
A recently postulated paravascular clearance system (or ‘glymphatic system’) that 
clears toxins from the brain (Holth, Patel, & Holtzman, 2017) functions best during 
sleep. The aim of this Honours investigation was to explore if variation within genes 
encoding water channel proteins (specifically aquaporin 1 and 4) of the brain’s 
glymphatic system were associated with AD pathophysiology and/or whether these 
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genetic variations modified the relationship between sleep quality and AD 
pathognomonic features. 
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2.0 Literature Review 
2.1 Alzheimer’s disease 
The nomenclature, dementia, considered an umbrella term (Alzheimer's Association, 
2013), is used to describe many forms of neurodegenerative diseases with associated 
neuropsychiatric symptoms, including AD; the most common form (McKhann et al., 
2011). 
Due to a large spectrum of complications (and severity of these) that arise, a broad 
definition of AD would be that it is a variety of cognitive and behavioural deficits, 
which are not part of normal senescence, and are characterised by the progressive 
worsening of symptomology. These neuropsychiatric symptoms include: memory 
loss, language difficulties, mood changes; deteriorated judgement and initiative 
(Budson & Kowall, 2011), that interfere with usual social or occupational 
functioning. 
 
2.2 AD characteristics 
Jack et al. (2013) define neurodegeneration as “a progressive loss of neurons or their 
processes (axons and dendrites) with a corresponding progressive impairment in 
neuronal function” (p. 207). As such, AD exhibits these neurodegenerative 
characters, plus two major gross morphological changes of the central nervous 
system (CNS): cortical and hippocampal atrophy. These morphological changes to 
the brain engender synaptic deficiency and are likely to begin about 20 years before 
symptomatic presentation (Masters et al., 2015). 
Before an individual is diagnosed with fully developed AD there exists a pre-
dementia, or prodromal AD stage, which is known as mild cognitive impairment 
(MCI) (Petersen, 2004). MCI refers to a substantial cognitive decline that fails to 
hinder one’s daily living tasks. MCI is a spectrum disorder that can be broadly 
dichotomised into amnestic or non-amnestic, with the former usually (but not 
always) progressing to AD, and the latter proceeding to dementia (mainly 
frontotemporal dementia (FTD), or dementia with Lewy bodies (DLB)) (Petersen, 
2016). Additionally, Gauthier et al. (2006) explain that the global prevalence of MCI 
might reach up to 19% of people aged > 65 years and the authors assert that the 
cognitive changes are subtle and these may even revert back into the spectrum of 
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what is considered normal senescence. It would be most beneficial to identify 
individuals at risk of AD prior to a diagnosis of MCI because this gives the largest 
window of opportunity to modify disease course through pharmacological therapy or 
lifestyle modifications. 
 
2.2.1 Clinical 
Individuals with AD exhibit a range of neuropsychiatric symptoms mainly 
concerning gradual decline of memory together with impairment of judgement and 
reason (Cacace et al., 2016). Amnestic complaints are common, and AD individuals’ 
recall of past events becomes worse until they forget completely, plus they have 
impaired learning and recall of new details. Additionally, accompanying these 
amnestic manifestations, AD affected persons may cease to remember: the meaning 
of words, how to read and write, what year or season it is, how to get dressed (or to 
pick suitable attire for the climatic conditions) (McKhann et al., 2011). Further, 
apraxia along with agnosia (relating to problems recognising previously familiar 
faces and objects) often present, and as AD progresses and worsens, it is possible for 
one to become aphasic and completely lose their capacity for language and 
communication (McKhann et al., 1984). 
Behaviourally, AD patients increasingly disengage from social activity, demonstrate 
a depressed mood; are apathetic, agitated or aggressive; lose their motivation and 
empathy; plus, display inappropriate deportment (for instance, being overtly sexual 
in the wrong circumstances) (Nair & Sabbagh, 2014). These behaviours are likely to 
occur along with other deficits of executive function such as a compromised ability 
to solve problems, disorientation and confusion (Gauthier et al., 2006; McKhann et 
al., 2011). 
 
2.2.2 Pathological hallmarks 
Concomitant with hippocampal and cortical atrophy are well described 
pathognomonic hallmarks that are characteristic of AD. These hallmarks include the 
formation of extracellular neuritic (senile) plaques; neurofibrillary tangles (NFT) (see 
Figure 1), otherwise known as dystrophic neurites; plus, associated astrocytosis and 
microgliosis (Serrano-Pozo, Frosch, Masliah, & Hyman, 2011). Microgliosis and 
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astrocytosis are both downstream events that occur after the formation of NFT and 
senile plaques. Specifically, microgliosis pertains to the migration and 
superabundance of microglia; the CNS’ resident macrophage-like cells. Whereas, 
astrocytosis is one of the final responses to brain injury generally responsible for the 
formation of scar tissue (Boche, Perry, & Nicoll, 2013; Sajja, Hlavac, & VandeVord, 
2016; Selkoe & Hardy, 2016). 
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Figure 1: Pathognomonic hallmarks of Alzheimer’s disease. 
The major pathognomonic features of Alzheimer’s disease include: Cortical and 
hippocampal atrophy; an aggregation of hyperphosphorylated intra-neuronal 
neurotoxic tau protein; and extracellular build-up of amyloid-beta (Aβ) that aggregates 
into plaques (senile plaques). Adapted from Delgado-Morales (2014). 
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The foremost hypothesis pertinent to the pathological process of AD is the ‘amyloid 
hypothesis’ (see Figure 2) (Hardy & Higgins, 1992; Hardy & Selkoe, 2002), which 
posits that the peptide amyloid-beta (Aβ) is deposited in the neural tissue (as 
insoluble extracellular plaques), preceding other events such as the formation of 
dystrophic neurites and glial responses (Selkoe & Hardy, 2016). Notably, Aβ is a 
product expressed from the transmembrane amyloid precursor protein (APP), that 
has undergone enzymatic (protease processing) cleavage of its N terminus by β-
secretase. The C terminus of Aβ is cleaved per the action of γ-secretase, which is a 
key function of the protein products encoded by the presenilin 1 and 2 (PSEN1 and 
PSEN2) genes (Goedert & Spillantini, 2006). Furthermore, Aβ has various isoforms 
ranging from 38–43 amino acids in length, and it is generally considered that Aβ42 is 
the more neurotoxic species because it easily aggregates into amyloid plaques 
(Masters et al., 2015). The measurement of soluble Aβ forms is possible from 
individuals’ cerebrospinal fluid (CSF) and blood plasma (Selkoe & Hardy, 2016). 
Moreover, recent advancement in medical imaging technology has enabled scientific 
investigators to utilise positron emission tomography (PET) scans with radio-labelled 
(Carbon-11 or Fluorine-18) tracers, to provide in vivo quantitative analyses of non-
soluble amyloid deposits in the brain of living individuals (Jack et al., 2013; 
Villemagne et al., 2013). Previously, such quantitation was only achievable via post 
mortem and specific histopathologic examination of the autopsied brain (Jack et al., 
2010). Furthermore, prospective investigation by Villemagne et al. (2013) indicates 
that there is a CNS Aβ plaque build-up (and amyloid burden) for about 20 years 
before an individual’s cognitive deficits and diminishing brain volumetrics are 
observed. 
NFT, are formed from the hyperphosphorylated tau protein which is microtubule 
associated, and expressed from the microtubule-associated protein tau (MAPT) gene 
located on chromosome 17 (Biomedical Research Forum, 2016). These NFT are 
intracellular and cytotoxic and considered a defining hallmark of AD (Gendreau & 
Hall, 2013). Nevertheless, it is common to have mixed pathognomonic features of 
AD with another form of dementia, commonly AD with vascular infarcts, and or 
Lewy bodies (LB) (Schneider & Yang, 2014).  
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Figure 2: The sequence of major pathogenic events leading to Alzheimer’s disease 
proposed by the amyloid cascade hypothesis. 
The curved blue arrow indicates that amyloid-beta (Aβ) oligomers may directly injure 
the synapses and neurites of brain neurons, in addition to activating microglia and 
astrocytes. Adapted from Selkoe and Hardy (2016). 
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2.3 Non-modifiable AD risk factors 
A major non-modifiable risk factor for developing AD and other neurodegenerative 
conditions is advancing age (Riedel, Thompson, & Brinton, 2016). Other non-
modifiable risk factors include familial history and sex, with females having a higher 
prevalence of dementia and AD (Masters et al., 2015). The aforementioned risk of 
AD that has a genetic basis (70%) will be described in the following section. 
 
2.3.1 Genetic risk of AD 
Broadly, AD can be dichotomised into early onset AD (EOAD) and late onset AD 
(LOAD), where the former presents before the age of 65 years and comprises < 10% 
of AD cases, whilst the latter occurs beyond 65 years and makes up the remaining 
AD cases (with a reduced penetrance of its genetic risk). These classifications may 
be divided further into familial and sporadic forms, with a proportion of the former 
presenting with the rare (less than 1% of all AD) autosomal dominant AD (ADAD), 
with a mean onset of 45 years and heritability spanning 92–100% with a highly 
penetrant Mendelian pattern (see Figure 3) (Cacace et al., 2016; Masters et al., 2015). 
There are currently three genes susceptible to mutation (having >280 
polymorphisms) which are attributed to the development of ADAD. These include 
the amyloid precursor protein gene (APP, located on chromosome 21), the presenilin 
1 (PSEN1, located on chromosome 14) and presenilin 2 (PSEN2, located on 
chromosome 1) genes (Cacace et al., 2016; Gaiteri, Mostafavi, Honey, De Jager, & 
Bennett, 2016; Masters et al., 2015). These mutations mostly cause an 
overexpression of Aβ, giving rise to faster onset and more pronounced detrimental 
phenotypes (Selkoe & Hardy, 2016). 
It has been well established that variants in the apolipoprotein E gene (APOE, located 
on chromosome 19q13.2) constitute the greatest risk for LOAD: specifically carriage 
of the ε4 allele (Gaiteri et al., 2016). Furthermore, ε4 allele positive persons’ have 
been shown in a recent study to display faster cognitive decline (especially episodic 
memory) compared to non-ε4 genotypes (Y. Y. Lim et al., 2016). However, as 
opposed to mutations in the aforementioned ADAD, the APOE ε4 allele is neither 
essential, nor sufficient, for development of AD, rather the combination of alleles 
increases or decreases risk. In the case of the ε4 allele, risk increases in a “gene-
10 
 
dosage” dependent manner (Riedel et al., 2016). Karch and Goate (2015), outline in 
their review that the combination of data from global genome-wide analysis studies 
(GWAS) has supplemented scientific understanding of the risk genes attributed to 
LOAD. These risk genes can be subdivided into broad categories of immune 
response, endocytosis and cholesterol metabolism. Regarding the latter, GWAS 
studies have elucidated—aside from the APOE genotype—that polymorphisms in 
the: clusterin gene (CLU, located on chromosome 8p21.1), adenosine triphosphate-
binding cassette transporter A7 gene (ABCA7, located on chromosome 19p13.3) and 
sortilin related receptor 1 gene (SORL1, located on chromosome 11) play a role in 
AD risk (Karch & Goate, 2015). 
The immune response, particularly neuroinflammation along with immune 
dysfunction, is also implicit in the pathogenesis of AD (Heneka et al., 2015). 
Correspondingly, variants of the GWAS elucidated risk genes (CR1, CD33, MS4A, 
EPHA1 and TREM2) also modify risk. Furthermore, disruption of the normal 
processing of APP via endocytosis dysfunctionality related to variants in genes: 
BIN1, PICALM and CD2AP (derived from GWAS data) also contribute to LOAD 
risk (Karch & Goate, 2015). Notwithstanding, this Honours investigation 
concentrated on the sporadic form of LOAD. 
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Figure 3: Alzheimer’s disease (AD): relationship of the various forms in a 
diagrammatic representation. 
EOAD, Early-onset AD; LOAD, Late-onset AD; FAD, Familial AD; ADAD, 
Autosomal Dominant AD; EOFAD, Early-onset Familial AD; LOFAD, Late-onset 
Familial AD. Figure courtesy of Laws, S. M., adapted from Wu et al. (2012). 
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2.3.2 Lifestyle as a modifiable AD risk factor 
Potentially modifiable AD risk factors include lifestyle components such as exercise 
(or physical activity), diet and sleep (Nair & Sabbagh, 2014). All of these represent 
good targets for potential preventative AD strategies and are discussed below. 
Increasing an individual’s level of physical activity by means of exercising has been 
demonstrated to reduce risk of dementia, and slow cognitive decline. The benefits of 
exercise positively improve one’s mood (that is, depression is reduced), help insulin 
signalling pathways (impaired glucose tolerance and diabetes are risk factors for 
dementia), reduce pro-inflammatory mechanisms, and increase neuronal growth, 
particularly in the hippocampal region, thus promoting better memory retention 
(Cholerton, Skinner, & Baker, 2014). Exercising also improves cardiovascular and 
cerebrovascular health which by themselves (in the diseased state) contribute to 
increased AD and neurodegenerative risk (Hamer & Chida, 2009). Moreover, 
findings from B. M. Brown et al. (2013) suggest that higher levels of total physical 
activity are associated with lower PET-determined Aβ burden in the brain of 
individuals carrying the APOE ε4 allele. 
A transition to healthier eating in the form of a Mediterranean style diet may also 
reduce AD risk. This healthy dietary pattern includes consumption of a variety of 
fresh fruit and vegetables (and a combination of anti-oxidant rich berries), olive oil, 
minimal meat consumption (excluding fish and seafood, which are increased), and 
moderate intake of red wine that contains resveratrol and other anti-oxidants. 
Adherence to such a dietary pattern has been shown to decrease the decline of 
cognitive function, probably via positive benefits on the cardio-vascular system or 
via anti-inflammatory properties (Gardener, Rainey-Smith, Barnes, et al., 2015). In 
contrast, the typical unhealthy and pro-inflammatory western diet, involving 
excessive consumption of refined sugar, saturated and trans-fat that are constituents 
of most fast-food, is associated with increased cognitive decline. Thus, unhealthy 
eating behaviours are inflammatory in nature, which may exacerbate current AD 
symptomology or lead to a premature death through the detrimental co-morbidity of 
cardiovascular disease (Gardener, Rainey-Smith, & Martins, 2015). These dietary 
choices are not a stand-alone, lifestyle panacea, but should be combined with the 
previously mentioned increase of physical activity (if possible) and a healthy sleep 
routine for maximal benefit (Landry & Liu-Ambrose, 2014). Indeed, sleep represents 
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a third lifestyle factor of growing interest in AD research: it is the lifestyle factor of 
focus for this research project, and is discussed in greater depth below. 
 
2.4 Sleep 
Inadequate or dysfunctional sleep is a major concomitant morbidity associated with 
AD, and sleep loss has been demonstrated to impair cognition as well as memory 
consolidation (Harper, 2011). In fact, sleep is so critically important that flies, 
cockroaches, rats and humans (elucidated from studying the rare autosomal 
dominant, fatal familial insomnia) die after prolonged sleep deprivation (Cirelli & 
Tononi, 2008; Luyster, Strollo, Zee, & Walsh, 2012).  
Sleep is a complex activity that invokes many physiological processes in humans and 
may be thought of as a perceptual disengagement from one’s surroundings as one 
enters a state of quiescence (Carskadon & Dement, 2011). Sleep in humans can be 
measured quantitatively using a gold standard objective measure, for example 
polysomnography (requiring an overnight sleep study) or actigraphy (usually a small 
portable actimetry sensor device worn on the wrist) (Kirsch, 2012; Mellor, 2014). 
However, the present study utilised a self-reported questionnaire: Pittsburgh Sleep 
Quality Index (PSQI); Section 4.3.1. The PSQI is a subjective measure of sleep 
(Kirsch, 2012) that has been validated and assessed as reliable in a cohort of older 
women (Beaudreau et al., 2012) and older men (Spira et al., 2011). 
 
2.4.1 Normal function of sleep 
Normal sleep for one person would not be the same for another due to large inter-
individual variability, but generally it is considered to extend for about 6–8 hours 
(Carskadon & Dement, 2011). Specifically, sleep is a reversible process (people go 
from wakefulness to sleep and vice versa) that oscillates over a 24-hour period, 
known as the circadian rhythm, that operates from a complex internal pace-maker 
associated with fluctuating body temperature, the endogenous hormone melatonin 
(produced by the pineal gland in the brain), and homeostatic sleep pressure (Schmidt, 
Collette, Cajochen, & Peigneux, 2007). Accordingly, when an individual begins to 
feel sleepy (that is, homeostatic sleep pressure rises) their core body temperature will 
decline as they are falling asleep, with a corresponding increase in plasma melatonin 
levels. Thus, the converse is true when cycling to a period of wakefulness, with 
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decreasing melatonin levels and an increase in core body temperature (Landry & Liu-
Ambrose, 2014; Monk, 2005; Schmidt et al., 2007). 
There is not one stage of sleep but several (referred to as sleep architecture) which 
are neuroanatomically, neurophysiologically, and behaviourally distinct. In humans, 
sleep is characterised by two prominent stages: rapid eye movement (REM) and non-
rapid eye movement (NREM) sleep. NREM is further subdivided into three stages—
N1, N2 and N3 (Berry et al., 2015). These NREM divisions are described in relation 
to the waveforms they produce on an electroencephalogram (EEG) and include: N1, 
a transition from wakefulness to light sleep (in conjunction with a reduction in brain 
wave activity); N2, with reductions in heart rate as well as body temperature, 
relaxation of muscles and EEG readouts featuring K-complexes plus sleep spindles. 
N3 is also known as slow wave sleep (SWS) or delta sleep and is considered the 
deepest, most restorative phase of sleep which is characterised by brain waves that 
display a low frequency and high voltage (Berry et al., 2015; Wolkove, Elkholy, 
Baltzan, & Palayew, 2007). Furthermore, humans cycle through sleep stages from 
N1, through N2, into N3 (N1 corresponds with easy arousal to wakefulness, and the 
opposite for N3) then into REM approximately every 90 minutes. Of interest, 
dreaming occurs during REM: where the eyes move rapidly in bursts of activity 
behind an individual’s closed lids, motor activity is actively suppressed, and 
increases in breathing, heart and brain rates are noted (Berry et al., 2015; Carskadon 
& Dement, 2011). 
 
2.4.2 Sleep and AD 
In general, older adults have lower tolerance to changes of their circadian rhythm, 
and their sleep patterns may change to going to sleep at an earlier time and waking at 
an earlier time (known as phase shift); which is pronounced more so in AD 
(Auerbach, 2014). Furthermore, it has been estimated that dysfunctional sleep may 
be present in up to 45% of people with AD, which is distressing because disturbed 
sleep has been listed as a possible factor that accelerates the institutionalisation of 
these people (Peter-Derex, Yammine, Bastuji, & Croisile, 2015). With this in mind, 
Mander, Winer, Jagust, and Walker (2016) highlight that sleep disturbance (amid 
others) is one of the first observable symptoms of AD, possibly presenting before a 
diagnosis of AD or even MCI. 
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Common sleep dysfunctions that are experienced by persons with AD include: 
frequent awakenings that occur late at night or early in the morning, referred to as 
sleep fragmentation; increased time to fall asleep (known as, sleep latency); and poor 
maintenance of sleep (Wolkove et al., 2007). Of note however, accumulating 
evidence suggests that rather than simply manifesting as a comorbidity of AD, 
dysfunctional sleep likely contributes to AD risk and severity. Indeed, a prospective 
cohort study by Lim, Kowgier, Yu, Buchman and Bennett (2013), suggests that 
greater sleep fragmentation contributes to the aetiology of AD by increasing the 
associated risk of developing AD and also accelerating the rate at which cognition 
declines. 
 
2.4.3 Sleep and AD pathology 
As mentioned in the previous section, a bi-directional relationship of sleep and AD 
phenotypes has been hypothesised (Holth et al., 2017; Ju, Lucey, & Holtzman, 
2014). This posits that the AD phenotype might be causal in sleep dysfunction, and 
alternatively, it is also quite possible that dysfunctional sleeping behaviour could 
contribute to the AD phenotype (Mander et al., 2016). Moreover, a recent review 
authored by B. M. Brown, Rainey-Smith, Bucks, Weinborn, and Martins (2016) 
summarises this bi-directional relationship. 
It has been noted in a study of live mice by Xie et al. (2013) that quality sleep 
enhances Aβ clearance from the brain. Correspondingly, Mander et al. (2015) 
suggest that human NREM (SWS) is impaired by brain Aβ burden which in turn 
disrupts memory consolidation. This association between dysfunctional sleep and Aβ 
burden in the brain is further supported by Branger et al. (2016) in their investigation 
of healthy adults’ sleep behaviour. Further, a recent cross-sectional human study 
suggests that a greater Aβ burden is associated with increased time to fall asleep 
(sleep latency period) (B. M. Brown, Rainey-Smith, Villemagne, et al., 2016). 
Coupled with these findings, Kang et al. (2009) reported an increase in tissue fluid 
Aβ levels during acute sleep deprivation in two AD mouse models, whilst chronic 
sleep deprivation was shown to accelerate Aβ deposition in the brain. Furthermore, 
pharmacologically enhanced sleep (that is, sleep manipulated by the administration 
of drugs) decreased Aβ plaque deposition in these animals. 
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Lim et al. (2013) specify that sleep may prove to be a valuable target for AD 
intervention; possibly slowing the progress of AD pathology, that consequently 
might improve cognition. As such, many investigators also suggest that further study, 
particularly optimising sleep as a clinical target, is warranted as it could have 
positive benefits through the diminished aggregation of Aβ (Branger et al., 2016; B. 
M. Brown, Rainey-Smith, Villemagne, et al., 2016; Kang et al., 2009). The 
biological mechanism postulated to underpin Aβ clearance during sleep is a 
lymphatic–like clearance system, termed the glymphatic system. 
 
2.5 Glymphatic system 
Kress and colleagues (2014), describe that the brain has a special type of lymphatic–
like clearance system that operates (parallel to the human lymphatic system) through 
the employment of a network of paravascular clearing mechanisms. This system has 
been designated as the glymphatic system. The term glymphatic is appropriate as it 
acknowledges the critical role that the glia or supporting cells of the brain perform, in 
particular astrocytes (the most common glial cell type) (see Figure 4) (Xiao & Hu, 
2014). Moreover, of upmost importance is that the clearance mechanism of the 
glymphatic system is postulated to function almost entirely during sleep and is 
mostly suppressed diurnally (Lundgaard et al., 2016). 
Astrocytes in human brains are essential to the formation of the blood brain barrier 
(BBB) which serves to create a tight knit barrier against large molecules (including 
many drugs), infectious particles (that is, viruses, fungi and bacteria) and inversely 
operates with the glymphatic system to clear toxins (Ballabh, Braun, & Nedergaard, 
2004; Potokar, Jorgačevski, & Zorec, 2016; C. Yang et al., 2016). Furthermore, 
astrocytes are involved in maintaining brain plasticity and serve to maintain ion, 
osmotic, neurotransmitter and metabolite homeostasis (see Figure 4) (Sajja et al., 
2016; Xiao & Hu, 2014). 
Also crucial to the glymphatic system is cerebrospinal fluid (CSF). CSF is a clear 
fluid that is perfused in the CNS, in particular within the sub-arachnoid space of the 
spinal cord and the ventricles of the brain (Simon & Iliff, 2016). CSF is produced by 
the choroid plexus and secreted into the brain’s ventricles (see Figure 5) (Damkier, 
Brown, & Praetorius, 2013). It has recently been hypothesised that CSF is not in 
circulation, but instead is regularly exchanged with brain extracellular fluid 
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providing a mechanism for the brain’s toxins to exit the CNS (via transport in the 
CSF) (Orešković & Klarica, 2014). Interestingly, Lee et al. (2015) in an investigation 
of rodent sleeping posture, suggests sleep posture also influences the effectiveness of 
the clearance of Aβ from the CNS. In this study, glymphatic clearance was 
hypothesised to be more efficient in the lateral (lying on your side) position, than the 
supine (lying on your back) position, and much less effective in the prone position. 
Whilst the present study did not investigate sleep posture, it may prove prudent to do 
so in future investigations of glymphatic clearance and sleep. 
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Figure 4: Glymphatic system: Schematic representation of the brain’s fluid 
compartments and barriers showing the location of aquaporin 4 (AQP4) in 
astrocytic endfeet. 
The fluid compartments in the brain consist of intracellular fluid (ICF; 60–68 %), 
interstitial fluid (ISF) or extracellular fluid (12–20 %), blood (10 %), and cerebrospinal 
fluid (CSF; 10 %) (Johanson, 2008; Thrane, Thrane, & Nedergaard, 2014). The brain 
accumulates toxins during wakefulness and during sleep it clears these toxins 
(including amyloid-beta; Aβ). The ‘system’ of clearance has been named the 
glymphatic system. A major protein channel in the glymphatic system is AQP4—
illustrated by an arrow and red circle. AQP4 allows for fluid to transfer between 
astrocytic endfeet: enabling an influx swell and an efflux deflation. Adapted from 
Jessen, Munk, Lundgaard, and Nedergaard (2015). 
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2.5.1 Glymphatic system’s role in AD 
The human brain has a high metabolic rate thereby producing many waste products 
including Aβ, which, as stated earlier, is prone to accumulation (Jessen et al., 2015): 
a process which is even more pronounced in the aged (R. Ellis, Croteau, & Hong, 
2014). Further, senescent brains (including AD phenotypes) are proposed to 
demonstrate impairment of glymphatic clearance mechanisms (Kress et al., 2014), 
thereby exacerbating Aβ accumulation. Animal studies, using in vivo imaging, 
support this notion of an impaired glymphatic clearance (Iliff et al., 2012). 
Consequently, toxic levels of Aβ are hypothesised to build up thus burdening the 
brain and exacerbating AD progression (Gallina, Scollato, Conti, Di Lorenzo, & 
Porfirio, 2015).  
However, there remains a paucity of literature examining glymphatic clearance in 
humans. As such, this Honours research has endeavoured to address an element of 
this knowledge gap by taking a novel approach investigating a potential mechanism 
that plausibly impacts glymphatic function that, in turn, may modify the relationship 
between sleep parameters and AD pathognomonic features. This approach was the 
investigation of the role of genetic variation in Aquaporins—specifically Aquaporin 
1 (AQP1) and Aquaporin 4 (AQP4)—which are discussed in detail in the next 
section.    
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Figure 5: Schematic representation of ion composition and transport across the 
choroid plexus epithelial cells: With aquaporin 1’s (AQP1) location indicated by 
red circles. 
Within the brain, AQP1 (illustrated by red circles with arrow) is expressed primarily 
in the choroid plexus epithelial cells and is involved in transfer of cerebrospinal fluid 
(CSF). AQP1 is also an intricate part of the brain’s waste clearance mechanism; 
designated the glymphatic system. Adapted from Jessen et al. (2015). 
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2.5.2 Aquaporins 
Water channel proteins are trans-membrane proteins that serve to transport water in 
and out of cells, and are also known as aquaporins (AQP) (Nagelhus & Ottersen, 
2013; Sorani, Manley, & Giacomini, 2008). Aquaporin water channel proteins are 
expressed throughout the mammalian body (King, Yasui, & Agre, 2000; Potokar et 
al., 2016). Of particular relevance to the current study, there are many isoforms of the 
aquaporin water channels found in the CNS, that is: AQP1, 2, 3, 4, 5, 7, 8, 9, and 11, 
however AQP4’s expression is the more pronounced (Benga & Huber, 2012; Suzuki 
et al., 2013). Both AQP1 and AQP4 are proposed to play integral roles in the 
glymphatic system, as illustrated in Figures 4 and 5. Aquaporin 1, also known as 
channel-like integral membrane protein, 28-kDa (CHIP28), was the first water 
channel protein to be discovered and is encoded by the AQP1 gene at cytogenetic 
location 7p14.3 (King et al., 2000; OMIM, 2016). In the CNS, AQP1’s function is 
proposed to relate to the production and movement of CSF (Benga & Huber, 2012). 
Furthermore, an animal study of rats’ brains treated with a neurotoxin, demonstrated 
via immunohistochemical and immunofluorescence techniques that AQP1 is 
upregulated. This suggests that AQP1 involvement in rat brain damage is central to 
glymphatic clearance (Hoshi et al., 2016). However, Igarashi, Tsujita, Kwee, and 
Nakada’s (2014)  magnetic resonance imaging study (MRI) of AQP1 and AQP4 
knockout mice suggests that AQP1’s function is secondary to AQP4. 
Aquaporin 4, also known as human mercurial insensitive water channel (MIWC), is 
encoded by the AQP4 gene at cytogenetic location 18q11.2 (Lu et al., 1996; B. Yang, 
Ma, & Verkman, 1995). AQP4 is, as mentioned above, the most common water 
channel in the CNS (Papadopoulos & Verkman, 2013), is located primarily in the 
subpial and perivascular endfeet of astrocytic processes and via the glymphatic 
system is postulated to be involved in Aβ clearance (Xiao & Hu, 2014). Furthermore, 
a study of autopsied human brains suggests that Aquaporin expression is distributed 
in a manner similar to neuritic plaques (Moftakhar, Lynch, Pomakian, & Vinters, 
2010): which by inference suggests that AQP1 and AQP4s’ expression in the brain is 
involved (either by a failure to clear, or some other mechanism) in plaque deposition 
(Hoshi et al., 2012). Similarly, a recent perivascular AQP4 localization investigation 
of autopsied human brains (25 cognitively intact individuals < 60 years old, 33 
cognitively intact individuals > 60 years, and 21 individuals with AD > 60 years old) 
conducted by Zeppenfeld et al. (2017), adds weight to the argument of a glymphatic 
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clearance dysfunction. The authors reported a decreased localization of AQP4 in the 
perivascular region of AD brains and this was associated, after controlling for age, 
with increased AD pathognomonic features (that is, NFTs and Aβ burden). By 
contrast, the cognitively intact (all ages) specimens had no observable loss of AQP4 
perivascular localization. Taken together, these findings suggest that the glymphatic 
system is an important biological mechanism underpinning the clearance of brain 
Aβ. Further, a decrease in AQP4 expression—or mislocalization—could be involved 
with a lack of Aβ clearance. 
A human PET imaging study by Suzuki et al. (2015) , demonstrated that aquaporin 
mediated (AQP4) water influx to the CSF, and interstitial (extracellular space; ECS) 
flow, is reduced in humans with AD: thereby, negatively affecting the clearance rate 
of Aβ. These findings are also supported by Conn (2017). Furthermore, Bakker et al. 
(2016) discuss that the mechanism of Aβ clearance from the human brain is 
multifactorial and the exact pathways involved are yet to be deduced. However, these 
authors do report that evidence from animal models is suggestive of a perivascular 
and paravascular clearing mechanism that involves the bulk flow of interstitial fluid, 
likely involving AQP4. W. Yang et al.’s (2012)  AQP4 deficient mouse study, also 
supports the notion that the functionality of this water channel (AQP4) is related to 
the efficacy of Aβ clearance. Moreover, other mouse model studies have suggested 
that pericapillary (Virchow-Robin) space water homeostasis is regulated by AQP4 
and is a harbinger for the clearing of Aβ by astrocytes and the glymphatic system 
(Igarashi, Suzuki, Kwee, & Nakada, 2014). 
A review by Sorani et al. (2008) highlighted that some genetic variants of AQP1 and 
AQP4 have been elucidated which generally affect the water channels’ ability to 
transfer water by a partial loss of function. Yet, the authors conclude that more 
investigation into the genetic polymorphisms is warranted. Furthermore, there 
remains a paucity of human literature relating to the role of Aquaporins in AD, sleep 
and the glymphatic system. Hence, this Honours research investigated the role of 
sleep, aquaporin polymorphisms and the AD pathological hallmark of Aβ. 
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3.0 Theoretical Framework 
Aβ accumulates in the brains of individuals who have a propensity towards AD 
(through genetic and/or lifestyle determinants) (Selkoe & Hardy, 2016). The 
accumulation of Aβ is thought to begin about 20 years before the onset of AD 
symptomology and is problematic due to the formation of insoluble aggregates or 
amyloid plaques which are neurotoxic (Villemagne et al., 2013). Numerous human 
and animal studies (B. M. Brown, Rainey-Smith, Bucks, et al., 2016; Ju et al., 2014) 
have suggested that sleep is a potentially useful lifestyle target whereby early 
intervention could be implemented to induce a lower Aβ burden. Moreover, sleep 
interventions could potentially prove to be important in improving the quality of life 
of individuals with AD. 
Recently discovered (and relevant to AD research), is a lymphatic–like system in the 
CNS, termed the glymphatic system, that has been postulated to be implicit in the 
clearance of Aβ from the brain (Iliff et al., 2012; Jessen et al., 2015). The glymphatic 
system has been hypothesised to primarily elicit Aβ clearance whilst one is asleep 
(Xie et al., 2013)—making sleep an important consideration in the investigation of 
ageing and AD. Furthermore, water channel proteins, namely Aquaporin 1 and 4, 
have been suggested to be pivotal in the function of glymphatic clearance of Aβ from 
the human brain. 
The motivating research question that provided guidance for the design of the present 
study was: are genetic variants in AQP1 and/or AQP4 associated with AD 
phenotypes or sleep? To address this research question, I utilised observational data 
and undertook the investigation within a cross-sectional retrospective study design. 
 
3.1 Hypotheses and aims 
The overall aim of the present study was to investigate whether genetic variation 
(single nucleotide polymorphisms, SNPs) within the genes encoding water channel 
proteins expressed in the brain, specifically Aquaporin 1 (AQP1) and Aquaporin 4 
(AQP4), are associated with AD risk and brain Aβ burden and, further, whether they 
moderate the relationship between PSQI sleep parameters and brain Aβ burden. 
SNPs of interest in AQP1 and AQP4 were investigated with regard to consequences 
of the clearing mechanisms of the glymphatic system—that is, brain Aβ burden. It is 
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important to realize that the glymphatic system is postulated to only function as an 
Aβ clearing mechanism during sleep, and glymphatic clearance during dysfunctional 
sleep is proposed to be sub-optimal and result in a higher Aβ burden. Thus, the study 
hypotheses are in part formed on the premise that good sleep quality will elicit 
greater clearance of Aβ (that is, reduced brain Aβ burden) and that the functional 
implication of genetic variation would manifest through an impact on brain Aβ 
burden. Therefore, the specific hypotheses of the present study were: 
Hypothesis 1 (H1): Genetic variation in AQP1/AQP4 is associated with differences 
in: i) AD risk, and/or ii) brain Aβ burden. 
Hypothesis 2 (H2): Genetic variation in AQP1/AQP4 is associated with differences 
in PSQI sleep parameters (including sleep quality/quantity). 
Hypothesis 3 (H3): Genetic variation in AQP1/AQP4 moderates the relationship 
between PSQI sleep parameters and brain Aβ burden. 
Considering these hypotheses, this Honours investigation was undertaken with the 
following 3 aims that provided guidance for the research: 
Aim 1: To determine whether genetic polymorphisms in AQP1 and AQP4 genes are 
associated with: i) the clinical classification of AD, and/or ii) levels of brain Aβ 
burden. 
Aim 2: To test whether polymorphisms of AQP1 and AQP4 are associated with 
differences in PSQI-determined sleep parameters. 
Aim3: Use moderated regression analyses to test whether genetic variants in AQP1 
and AQP4 moderate the relationship between PSQI sleep parameters (“sleep 
quality/quantity”) and brain Aβ burden. 
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4.0 Materials and Methods 
4.1 Research design 
This investigation utilised a cross-sectional study design that incorporated previously 
collected data from the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study. 
Briefly, initial participant inclusion/ exclusion criteria (outlined in Section 4.2.1) 
selected: those samples to be included in the first phase of the study that addressed 
Aims 1 and 2, and a secondary dataset that was incorporated into the second phase of 
the study, which addressed Aim 3. 
 
4.2 Participants 
This investigation accessed the data of participants already enrolled in the AIBL 
Study, a prospective longitudinal study of ageing launched in 2006. A paper authored 
by K. A. Ellis et al. (2009) specifies the AIBL Study’s design, including participants’ 
enrolment process, neuropsychological assessments, plus, exclusion and diagnostic 
criteria. In brief, AIBL participants are males and females over the age of 60 at 
enrolment who are either cognitively normal healthy controls (HC) or have been 
classified into an MCI or AD grouping. Approval of the AIBL Study has been 
granted by each of the ethics committees of each of the member institutions; Austin 
Health, St Vincent’s Health, Hollywood Private Hospital, and Edith Cowan 
University (ECU), and informed written consent was given by all volunteers. Further 
ethical considerations are outlined in Appendix 1. 
 
4.2.1 Study specific inclusion criteria 
Whilst having access to the complete AIBL cohort, only those individuals with 
genetic data (outlined in 4.3.2 below) were included in the study. Further, specific 
inclusion criteria were then applied for each aim of the study.  
Within the context of Aim 1 a ‘clean’ sample of HCs was defined by the inclusion of 
only those participants with a stable clinical diagnosis of ‘cognitively healthy’ across 
the duration of the 72-months of follow-up time-points and, where assessed, were 
required to have a low brain amyloid-beta (Aβ) burden through positron emission 
tomography (PET) imaging (outlined in Section 4.3.3 below). Specifically, to be 
classified as a HC the participant, if scanned, was required to have a 11C-Pittsburgh 
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compound B PET (PiB-PET) like standardised uptake value ratio (SUVR) of < 1.4 
(as calculated using the Before the Centiloid Kernel Transformation (BeCKeT) scale) 
for all scans. For the classification of AD, the following criteria were applied: the 
clinical diagnosis of AD or the combination of the clinical diagnosis of amnestic-
mild cognitive impairment (aMCI) and a high brain Aβ burden (BeCKeT of ≥ 1.4), 
the combination of which has been shown in the AIBL cohort to be an extremely 
accurate predictor of AD development within 3-years (Rowe et al., 2013). From 
these participants, only those with imaging data were included in the second part of 
Aim 1. 
In the context of Aim 2 only participants with genetic and sleep (Section 4.3.2) data 
were included. Whilst for Aim 3 a further criterion was that imaging data must also 
be available at the same time point at which the sleep data were aquired. 
 
4.3 Data accessed 
4.3.1 Sleep data 
A subset of AIBL participants completed, at the 72-month follow-up time point, the 
Pittsburgh Sleep Quality Index (PSQI) (Buysse, Reynolds, Monk, Berman, & 
Kupfer, 1989): a 19-item, self-report measure assessing sleep quality and 
disturbances over the previous month. The PSQI provides the following factor 
scores: sleep quality, sleep latency, sleep duration, sleep efficiency, sleep 
disturbances, sleep medication use, and daytime dysfunction, as well as a global 
score (known as PSQI total). A PSQI total score > 5 indicates poor sleep. In the 
present study, the relationship between genetic variants in AQP1 and AQP4, brain 
Aβ burden, and the following sleep parameters was assessed: PSQI total, sleep 
latency (reported in minutes), sleep duration (reported in hours), and PSQI-derived 
parameters of sleep disturbance, sleep efficiency, and daytime dysfunction. 
 
4.3.2 Genetic data 
Genetic data accessed in this study were derived from a genome-wide single 
nucleotide polymorphism (SNP) array on 1358 AIBL participants. Briefly, genome 
wide analysis of 976,713 SNPs (including 273,000 exome variants and an additional 
13,000 custom content SNPs) on the Illumina OmniExpressHumanExome+ 
BeadChip was undertaken by the Australian Genome Research Facility (Melbourne, 
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Victoria). Genetic markers were subsequently mapped to human genome reference 
hg19 with only 67 markers being unmappable. Quality control was undertaken at 
both marker and sample levels. At the marker level 25083 duplicated markers 
(identical genomic location but different marker identifications), 2925 markers with 
< 95% call rate and 67 unmappable markers were removed. At the sample level, 9 
samples with call rate < 98%, 1 sample with a mismatch gender between reported 
and calculated based on genotyping data, 32 samples with high heterozygosity rate 
(defined as more than 3 standard deviations from the cohort mean) were removed. 
Overall, 948,720 markers and 1316 samples were in the final data set for imputation. 
Imputation was undertaken using impute2 ver2.3 using 1000 genome reference panel 
(2015 release). 
In addition to the Aquaporin genetic data, the present study also included APOE 
genotype data as a covariate (specifically the presence/absence of the ε4 allele). 
These data were previously determined through TaqMan® genotyping assays (Life 
Technologies, USA) for rs7412 (Assay ID: C____904973_10) and rs429358 (Assay 
ID: C___3084793_20) that were carried out on a QuantStudio 12K Flex real-time 
PCR system (Applied Biosystems, USA). 
 
4.3.2.1 Aquaporin SNP selection and quality control procedures 
The GWAS dataset was analysed within the protocol of assembly 37, annotation 
release 105 (GRCh37.p13). Initially all SNP genomic regions of interest were 
extracted from the GWAS dataset for each gene (AQP1: GRCh37.p13: 
Chr.7:30,949,615–30,965,615 base pairs (bp), and AQP4: GRCh37.p13: 
Chr18:24,430–24,450 kilobase pairs (kb), see Appendices 2 and 3), which included a 
flanking region of 10 kb up- and downstream of the gene. The SNP data from these 
regions were uploaded separately (by gene) into Golden Helix SNP and Variation 
Suite (SVS version 8.7.0) and all genetic variants were then subjected to the quality 
control criteria. Specifically, i) all monomorphic (i.e. those with only one reported 
allele) SNPs were removed, ii) all SNPs with a successful genotype in < 95% of 
cases were removed, iii) all SNPs with an observed minor allele frequency of < 5% 
were removed, and finally iv) all SNPs that departed from Hardy-Weinberg 
Equilibrium (that is, p < 0.05 from that expected) were removed (Hardy–Weinberg 
equilibrium theorem states that allele and genotype frequencies in a population will 
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remain constant from generation to generation in the absence of other evolutionary 
influences). 
Subsequently, each SNP dataset underwent Linkage Disequilibrium (LD) pruning as 
implemented within SVS using the following settings: LD threshold r2 > 0.8, window 
size 10, and increment 5. LD pruning is a method that inactivates (“prunes”) SNPs 
that are in high LD with other SNPs such that analyses are only undertaken using 
SNPs that are not in LD with each other. This approach reduced the number of SNPs 
being analysed but still maintained maximum coverage of genetic variation across 
the gene of interest. Genetic information for SNPs selected after LD pruning were 
extracted for all participants selected for inclusion in this study. 
 
4.3.3 Brain imaging data 
A subset of participants included in the present study have undergone PET using one 
of the following radiolabelled Αβ tracers, either; 11C-Pittsburgh Compound B (PiB), 
18F-florbetapir or 18F-flutemetamol, as previously described (Clark et al., 2011; Rowe 
et al., 2010; Vandenberghe et al., 2010). Images were analysed using CapAIBL, a 
web-based freely availably MR-less methodology to generate PET standardized 
uptake value ratios (SUVR) for all tracers (Bourgeat et al., 2015). Briefly, SUVs 
were summed and normalized to either the cerebellar cortex SUV (PiB), whole 
cerebellum SUV (florbetapir) or pons SUV (flutemetamol), to yield the target-region 
to reference-region SUVR. To allow for the analysis of these different tracers as a 
single continuous variable, a linear regression transformation has already been 
applied to generate PiB-like SUVR units termed the “Before the Centiloid Kernel 
Transformation” (BeCKeT) scale (Villemagne et al., 2014). These BeCKeT values 
were utilised in this cross-sectional study. 
 
4.3.4 Demographic data 
Participants provided demographic data and medical history via the completion of a 
questionnaire at their AIBL study assessment closest to their PET scan. At the study 
visit, participants also undertook a comprehensive neuropsychological assessment, 
completed lifestyle questionnaires and provided a fasted blood sample. All 
participants completed the short-form Geriatric Depression Scale (GDS) (Almeida & 
Almeida, 1999). Specifically for this study, age, sex, calculated body mass index 
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(BMI), GDS score and information regarding a medical history of cardiovascular 
disease (CVD), as well as APOE genotype data (specifically the presence/absence of 
the ε4 allele) was extracted from the AIBL Integrated Dataset (IDS version 6.0.0). 
 
4.4 Data analyses 
Statistical techniques and inferences were carried out with the aid of Golden Helix 
(Inc.) SVS (version 8.7.0) (Golden Helix, 2016), for logistic and linear regression 
analyses in Aim 1 and 2 (Section 4.4.2), and IBM SPSS Statistics, Version 24.0 
(Armonk, NY: IBM Corp.) for moderation analyses in Aim 3 (Section 4.4.3). For all 
Aims, the procedure for regression analyses performed was ordinary least squares 
(OLS) (Cohen, Cohen, West, & Aiken, 2003; Hayes, 2013). 
 
4.4.1 Genetic Models 
In all analyses the AQP1 and AQP4 SNPs were grouped using at least two of the 
below three genetic models:  
1. Additive model (Aim 1 and Aim 2): the associations of the minor allele (M) are 
cumulative, that is, where having two minor alleles (MM) as opposed to having 
no minor alleles (mm) is two times more likely to affect the outcome in a 
certain direction as is having just one minor allele (Mm) as opposed to no 
minor alleles (mm); where major allele is m. 
2. Dominant model (all Aims): tests the association of having at the minimum one 
minor allele M (either Mm or MM) versus not having any minor alleles (mm). 
3. Recessive model (all Aims): tests the association of having the minor allele M 
as both alleles (MM) versus at the minimum one major allele m (Mm or mm). 
 
4.4.2 Risk and linear regression analyses (Aim 1/Aim 2) 
Logistic regression analysis was performed with the binary dependent (outcome) 
variable of clinical classification, as defined in 4.2.1. Covariates included were 
APOE ε4 allele carriage (binary, presence/absence of 4 allele), sex and age. 
Linear regression was performed with the quantitative trait dependent (outcome) 
variables of brain Αβ burden (in BeCKeTs; Section 4.3.3) or the respective PSQI 
sleep parameters (Section 4.3.1) for Aim 1 and Aim 2, respectively. AQP1 and AQP4 
individual SNPs were entered as independent (predictor) variables. Covariates 
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included were APOE ε4 allele carriage (binary, presence/absence of 4 allele), sex 
and age—due to these variables being potential confounders. Similarly, covariates 
for Aim 2 included body mass index (BMI), geriatric depression scale (GDS), a 
medical history of CVD, sex and age (these potential confounders were also 
controlled for by B. M. Brown, Rainey-Smith, Villemagne, et al. (2016)). 
For both, nominal significance (uncorrected) was reported at p < 0.05. However, 
final levels of significance was ascertained after correction for the False Discovery 
Rate (FDR)—designated as q-value with significance threshold set at q < 0.05—
(Benjamini & Hochberg, 1995; Benjamini & Yekutieli, 2001) as applied in SVS 
(version 8.7.0). 
 
4.4.3 Moderation analyses (Aim 3) 
The moderation analysis was undertaken in SPSS and significance was also met if 
the p-value was < 0.05. A custom dialog box, called PROCESS (release 2.16.3) 
(Hayes, 2013), was installed into SPSS and utilised for the moderation analysis. 
Within Hayes (2013) PROCESS command (in SPSS) moderation model one was 
selected (see Figure 6), and bootstrapping (5000 bootstrap samples) was additionally 
chosen. 
The equation used for the undertaken moderation (interaction) analysis was: 𝑌 =
𝑖𝑌 + 𝑏1𝑋 + 𝑏2𝑊 + 𝑏3𝑋𝑊. Where: Y = outcome, iY = Y intercept, b1 = coefficient 
of the predictor, X = predictor, b2 = coefficient of the moderating variable, W = 
moderator, b3 = coefficient of the interaction, XW = interaction of the predictor * 
moderator. 
To visualise the moderation of the effect of X on Y by the moderating variable (W) it 
was necessary to probe the significant interactions with a post hoc analysis. Simple 
slopes analysis was used, where the mean of W and 1 standard deviation above and 
below that was plotted (Aiken & West, 1993; Hayes & Rockwood, 2016). AQP1 and 
AQP4 SNPs were included as a moderator variable (W) in the models established by 
B. M. Brown, Rainey-Smith, Villemagne, et al. (2016)—to ascertain whether they 
modify the relationship between sleep parameters and brain Αβ burden. 
To facilitate the interpretation of the post hoc probing, the interactions were analysed 
with respect to the dominant and recessive genetic models only (Section 4.4.1). Brain 
Αβ burden (in BeCKeTs) was entered as the outcome variable (Y) with each of the 
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six PSQI sleep parameters entered individually as the independent variable (X). 
Finally, SNPs in AQP1 and AQP4 (interaction of PSQI sleep parameter * AQP1/4 
SNP) was the moderator (W) variable. Moderation analyses covaried for age, BMI, 
medical history of CVD, GDS and APOE ε4 allele carriage.    
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Figure 6: a) Simple conceptual moderation model, b) diagram of the statistical 
moderation model. 
a) X refers to the independent or predictor variable, Y refers to outcome or response 
variable, and W refers to the moderator variable. Adapted from Hayes (2013, p. 209). 
b) X refers to the independent or predictor variable, Y refers to outcome or response 
variable, W refers to the moderator variable, XW is the interaction (that is, the 
predictor variable multiplied by the moderator variable); b1 is the regression 
coefficient of the predictor (X), b2 is the regression coefficient of the moderator, b3 
is the regression coefficient of the interaction, and ey1 is the residual. Adapted from 
Hayes (2013, p. 215). 
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5.0 Results 
5.1 SNP selection and quality control 
Previously accrued Genome-wide Association Study (GWAS) data from the AIBL 
study cohort (Section 4.3.2) were leveraged in this study for the selection of single 
nucleotide polymorphisms (SNPs) within, and 10 kilobase pairs (kb), up- and 
downstream of the Aquaporin 1 (AQP1) and Aquaporin 4 (AQP4) genes (as 
described in Section 4.3.2.1). This resulted in the initial identification of 525 AQP1 
and 538 AQP4 SNPs. Quality control (QC) exclusion criteria, outlined in Section 
4.3.2.1, were then applied to filter the list of SNPs to take forward for analysis in the 
subsequent sections of this thesis. These QC measures resulted in a step-wise 
reduction in SNPs (Figure 7) and retained a final total of 18 and 32 SNPs for AQP1 
and AQP4, respectively. A list of these SNPs including minor allele frequency and 
Hardy-Weinberg equilibrium p-values are presented in Appendix 4. 
To remove SNP redundancy and therefore reduce total SNP number for analysis, 
linkage disequilibrium (LD) pruning, as described in Section 4.3.2.1, was 
undertaken. By eliminating a high degree of correlation (r2 value of > 0.8), the total 
SNP numbers were reduced to 8 (from 18) and 13 (from 32) for AQP1 and AQP4, 
respectively. The minor allele frequencies and Hardy-Weinberg equilibrium p-values 
for the specific SNPs selected for analysis are presented in Table 1. This reduction in 
SNP content was made without compromising SNP coverage of the AQP1 and AQP4 
genes. A visual depiction of the LD prune, both pre- and post-pruning, can be found 
in Figures 8 and 9 for AQP1 and AQP4, respectively. 
 
5.2 Demographics of the cohort 
This cross-sectional project’s study cohort demographic information and data 
(including brain imaging, genetic and sleep data) were extracted from the larger 
prospective Australian Imaging, Biomarker and Lifestyle (AIBL) study of ageing 
cohort. As sample sizes within each aim changed due to availability of the data to be 
analysed, the demographic characteristics are presented Aim-by-Aim in Table 2. The 
study specific inclusion criteria for defining groups to be analysed with specific aims 
are described in Section 4.2.1. 
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Figure 7: Flow diagram of genetic data quality control and SNP selection for 
AQP1 and AQP4. 
Chromosomal region of AQP1 (cytogenetic location, 7p14.3) selected from 30,951–
30,965 kilobases (kb) and AQP4 (cytogenetic location, 18q11.2) selected from 
24,432–24,446kb. Prior to SNP data quality control there were n = 525 AQP1 SNPs 
and n = 538 AQP4 SNPs. Exclusion criteria applied were: i) removal of monomorphic 
SNPs (n = 417 AQP1 and n = 403 AQP4), ii) removal of SNPs that had a call rate of 
< 0.05, iii) removal of those SNPs that had a minor allele frequency (MAF) < 0.05, 
and iv) removal of those SNPs that deviated from Hardy-Weinberg equilibrium 
(HWE; p < 0.05 constituted removal). Application of excluding criteria (i-iv) left n = 
18 AQP1 and n = 32 AQP4 SNPs. Finally, linkage disequilibrium (LD) pruning was 
undertaken (r2 cut-off of 0.8, window size 10, increment 5) leaving n = 8 AQP1 and 
n = 13 AQP4 SNPs to take forward for analyses. 
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Table 1: AQP1 and AQP4 SNPs Obtained Post Linkage Disequilibrium Pruning. 
SNP Ref Major Allele   Call Rate   Minor Allele   MAF HWE-p 
AQP1          
rs2075574 C   1.00   T   0.36   0.64 
rs1859838 A   1.00   G   0.17   0.06 
rs4419722 T   1.00   G   0.12   0.64 
rs1004317 A   1.00   G   0.39   0.79 
rs62449133 A   0.97   G   0.22   0.16 
rs2299905 A   0.96   T   0.28   0.29 
rs28362727 A   0.97   C   0.27   0.47 
rs11537660 T   1.00   C   0.07   0.72 
AQP4                   
rs11661081 C   1.00   A   0.09   0.89 
rs9951307 A   1.00   G   0.36   0.65 
rs7240333 C   0.99   T   0.11   0.41 
rs68006382 A   0.98   G   0.18   0.62 
rs71353406 C   0.98   A   0.30   0.45 
rs12968026 T   0.97   C   0.12   0.48 
rs3875089 T   1.00   C   0.16   0.84 
rs162007 G   1.00   A   0.20   0.80 
rs162003 C   1.00   T   0.08   0.86 
rs151245 T   1.00   G   0.40   0.22 
rs151246 G   0.99   T   0.20   0.11 
rs2339214 G   0.98   A   0.48   0.63 
rs491148 A   1.00   G   0.17   0.11 
Final curated list of Aquaporin 1 (AQP1) and Aquaporin 4 (AQP4) single nucleotide 
polymorphisms (SNPs) selected for analysis in subsequent Aims. SNP Ref, the 
reference single nucleotide polymorphism (SNP) marker (rs). Nucleotides: guanine 
(G), cytosine (C), adenine (A), thymine (T). Exclusion criteria: Call rate < 95%; 
MAF, minor allele frequency < 5%; HWE-p, Hardy-Weinberg equilibrium p-value < 
0.05. 
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Figure 8: Linkage disequilibrium (LD) structures for AQP1 
LD structures are presented (a) pre, and (b) post LD pruning of AQP1 SNPs. LD 
pruning was undertaken in Golden Helix SVS (v8.7.0) using criteria of: r2 > 0.8, 
window size 10, increment 5. a) Prior to LD pruning AQP1 SNPs n = 18, b) after LD 
pruning AQP1 SNPs n = 8. Vertical lines above the diamond graph indicate SNPs. 
Diamond graph: deep red indicates high r2 value, whilst deep blue indicates a lower r2 
value.  
a 
b 
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Figure 9: Linkage disequilibrium (LD) structures for AQP4 
LD structures are presented (a) pre, and (b) post LD pruning of AQP4 SNPs. LD 
pruning was undertaken in Golden Helix SVS (v8.7.0) using criteria of: r2 > 0.8, 
window size 10, increment 5. a) Prior to LD pruning AQP4 SNPs n = 32, b) after LD 
pruning AQP4 SNPs n = 13. Vertical lines above the diamond graph indicate SNPs. 
Diamond graph: deep red indicates high r2 value, whilst deep blue indicates a lower r2 
value. 
  
a 
b 
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Table 2: Demographic Characteristics of the Cohort Studied (per Aim). 
Cohort Descriptive 
Statistics  
  Aim1 Aim 2 Aim 3 
  HC   AD         
 n =   528   402   462   222 
Age   69.7 ± 6.5   75.8 ± 7.3   75.0 ± 6.0   75.2 ± 6.1 
Sex (% F)   64.4   52.3   58.1   57.2 
APOE (% ε4)   19.7   65.4   22.7   23.0 
Aβ: BeCKeT*   1.21 ± 0.09†   2.12 ± 0.5‡      1.38 ± 0.38 
BMI         26.5 ± 4.3   26.4 ± 4.2 
GDS         1.4 ± 1.7   1.3 ± 1.6 
% Good sleepers (n)         50.9 (235)   55.9 (124) 
PSQI total         6.2 ± 1.2   5.6 ± 3.2 
Sleep latency (minutes)         19.9 ± 19.4   17.0 ± 16.6 
Sleep duration (hours)         6.8 ± 1.2   7.0 ± 1.2 
All values represented as mean ± standard deviation, unless otherwise indicated. Data 
are only presented for where data were available for all participants included in the 
respective study aim analyses. HC, Healthy control; AD, Alzheimer’s disease; APOE, 
apolipoprotein E ε4 allele carriage; Aβ, amyloid-beta; BMI, Body Mass Index; GDS, 
Geriatric Depression Scale; PSQI, Pittsburgh Sleep Quality Index. *11C-Pittsburgh 
compound B PET (PiB-PET) like standardised uptake value ratio (SUVR) generated 
using the Before the Centiloid Kernel Transformation (BeCKeT) scale, † n = 376, ‡ 
n = 288. 
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Briefly, within the first part of Aim 1, associations of AQP1 and AQP4 SNPs with 
AD risk analysis were assessed in healthy controls (HC; n = 528) and AD cases (n = 
402). Where HCs were defined as having a stable clinical classification across all 
time points and a low brain Amyloid-beta (Aβ; PiB-PET-like SUVR < 1.4), whilst 
the classification of AD required either a clinical diagnosis of AD or the combination 
of a clinical diagnosis of amnestic-mild cognitive impairment (aMCI) and a high 
brain Aβ burden (SUVR ≥ 1.4). From these, only those individuals with available 
brain imaging data (HC, n = 376; AD, n = 288) were included in the second part of 
Aim 1, where analyses were performed to ascertain if AQP1 and AQP4 SNPs were 
associated with brain Aβ burden. The impact of AQP1 and AQP4 SNPs on Pittsburgh 
Sleep Quality Index (PSQI) sleep parameters (Aim 2) was investigated in those 
individuals with both PSQI and genetic data (n = 462). Finally, the moderating 
effects of AQP1/AQP4 SNPs on the relationship between sleep parameters and brain 
Aβ burden (Aim 3) was investigated in individuals for whom there were available 
genetic data, PSQI data and imaging data. The PSQI and imaging data were required 
to be available from the same 72-month follow-up time-point of the AIBL study (n = 
222). 
 
5.3 Analysis of association between AQP1/AQP4 SNPs and AD risk 
A risk analysis was undertaken to ascertain whether there were differences in 
genotype and allelic frequencies of AQP1 and AQP4 SNPs between the HC (n = 
528) and AD (n = 402) groups (Table 3). No significant associations of AQP1 SNPs 
with AD risk were observed across the three genetic models used: additive, dominant 
and recessive (described in Section 4.4). Nominal significance (that is, uncorrected p-
value) was observed in two AQP4 SNPs; rs7240333 (additive genetic model p = 
0.04, and dominant genetic model p = 0.03), and rs68006382 (recessive genetic 
model p = 0.04). However, these associations did not remain significant after False 
Discovery Rate (FDR) correction. 
 
5.4 Association of AQP1 and AQP4 SNPs with brain Aβ burden 
To determine if any statistical association between AQP1 and AQP4 SNPs and brain 
Aβ was evident a linear regression analysis was performed. Table 4 shows the 
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nominal (uncorrected) p-values, across the three genetic models (additive, dominant, 
and recessive) performed in the absence (base model) or presence (adjusted model) 
of the covariates of age, sex, APOE ε4 allele and clinical classification (HC or AD). 
No significant associations were detected for AQP1 SNPs in the adjusted models, 
though nominal significance was observed in the base model for rs4419722 (p = 
0.025) and rs11537660 (p = 0.036). Conversely, no significant associations of AQP4 
variants were observed in the base models, however two AQP4 variants, rs162007 
(additive model, p = 0.044 [β = 0.057]; recessive model, p = 0.047, [β = 0.162]); and 
rs162003 (dominant model, p = 0.047 [β = 0.086]) presented with nominally 
significant associations with brain Aβ burden in the adjusted models. Whilst 
nominally significant associations with brain Aβ burden were observed, they did not 
survive FDR correction. A complete list of p-values from all models for all SNPs is 
provided in Appendix 5.  
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Table 3: AQP1 and AQP4 Genotype and Allele Frequencies and association with 
AD risk.  
SNP Ref MAF MM Mm mm p-value† 
 AD HC AD HC AD HC AD HC Add* Rec* Dom* 
AQP1            
rs2075574 0.35 0.34 0.12 0.12 0.45 0.44 0.42 0.44 0.37 0.61 0.16 
rs1859838 0.17 0.16 0.04 0.04 0.26 0.25 0.70 0.72 0.94 0.74 0.85 
rs4419722 0.12 0.12 0.02 0.01 0.21 0.22 0.77 0.77 0.18 0.10 0.25 
rs1004317 0.38 0.39 0.14 0.15 0.47 0.48 0.39 0.37 0.73 0.90 0.48 
rs62449133 0.22 0.22 0.06 0.06 0.32 0.32 0.62 0.63 0.88 0.79 0.63 
rs2299905 0.27 0.28 0.08 0.08 0.38 0.40 0.55 0.52 0.83 0.65 0.80 
rs28362727 0.26 0.27 0.07 0.08 0.39 0.37 0.54 0.55 0.86 0.75 0.60 
rs11537660 0.06 0.07 <.01 <.01 0.12 0.13 0.88 0.86 0.26 0.10 0.95 
AQP4                       
rs11661081 0.09 0.10 0.01 0.01 0.17 0.18 0.82 0.82 0.86 0.70 0.78 
rs9951307 0.37 0.34 0.13 0.12 0.48 0.45 0.39 0.43 0.46 0.73 0.21 
rs7240333 0.13 0.11 0.01 0.02 0.24 0.18 0.75 0.80 0.04 0.42 0.03 
rs68006382 0.16 0.19 0.02 0.04 0.29 0.31 0.70 0.65 0.08 0.04 0.14 
rs71353406 0.30 0.30 0.08 0.09 0.43 0.44 0.49 0.48 0.92 0.75 0.72 
rs12968026 0.13 0.12 0.02 0.02 0.23 0.20 0.76 0.78 0.69 0.87 0.44 
rs3875089 0.17 0.16 0.03 0.03 0.28 0.26 0.69 0.71 0.86 0.90 0.58 
rs162007 0.17 0.20 0.03 0.04 0.27 0.32 0.70 0.64 0.16 0.38 0.06 
rs162003 0.07 0.09 <.01 0.01 0.13 0.16 0.87 0.82 0.07 0.06 0.07 
rs151245 0.41 0.41 0.13 0.17 0.54 0.47 0.32 0.36 0.07 0.13 0.25 
rs151246 0.21 0.20 0.05 0.06 0.32 0.29 0.64 0.66 0.63 0.59 0.55 
rs2339214 0.48 0.46 0.21 0.22 0.53 0.49 0.26 0.29 0.52 0.92 0.29 
rs491148 0.18 0.18 0.03 0.05 0.31 0.26 0.66 0.69 0.18 0.17 0.42 
AQP1, Aquaporin 1; AQP4, Aquaporin 4; SNP Ref, reference single nucleotide 
polymorphism marker (rs); HC, Healthy control; AD, Alzheimer’s disease; MAF, 
Minor Allele Frequency; M, Minor allele; m, major allele; MM, homozygote for the 
minor allele; Mm, heterozygote for the minor allele; mm, homozygote for the major 
allele. *Genetic models: Add, additive (homozygote for the minor allele (MM) vs 
heterozygote for the minor allele (Mm) vs homozygote for the major allele (mm)); 
Rec, recessive (homozygote for the minor allele (MM) vs heterozygote/homozygote 
for the major allele (Mm/mm)); Dom, dominant (heterozygote/homozygote for the 
minor allele (Mm or MM) vs homozygote for the major allele (mm)). †Nominally 
significant (p < 0.05; uncorrected) p-values bolded.   
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Table 4: Association of AQP1 and AQP4 genetic variants with brain Aβ burden.  
SNP Ref Additive† Dominant† Recessive† 
 Base* Adj* Base* Adj* Base* Adj* 
AQP1       
rs4419722 0.108 0.457 0.242 0.658 0.025 0.781 
rs11537660 0.586 0.313 0.920 0.528 0.036 0.312 
AQP4             
rs3875089 0.059 0.504 0.056 0.563 0.488 0.596 
rs162007 0.714 0.044 0.999 0.100 0.260 0.047 
rs162003 0.586 0.061 0.751 0.047 0.218 0.977 
SNP Ref, reference single nucleotide polymorphism marker (rs); AQP1, Aquaporin 
1; AQP4, Aquaporin 4. †Genetic models: Additive (homozygote for the minor allele 
(MM) vs heterozygote for the minor allele (Mm) vs homozygote for the minor allele 
(Mm)); Recessive (homozygote for the minor allele (MM) vs 
heterozygote/homozygote for the major allele (Mm/mm)); Dominant 
(heterozygote/homozygote for the minor allele (Mm or MM) vs homozygote for the 
major allele (mm)). *Statistical models: Base, base statistical model that is, no 
covariates; Adj, Adjusted statistical model (covaries for: age, sex, Apolipoprotein E 
status (ε4-carrier/non-carrier) and clinical classification (Healthy 
control/Alzheimer’s disease). Nominally significant (p < 0.05; uncorrected) p-values 
bolded. 
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5.5 Association of AQP1 and AQP4 SNPs with PSQI sleep parameters 
Linear regression analysis was also performed to determine if AQP1/AQP4 SNPs 
were associated with PSQI sleep parameters, specifically: PSQI total, sleep latency 
(minutes), sleep duration (hours), sleep disturbances, sleep efficiency and daytime 
dysfunction. As per Section 5.4, both a base statistical model (no covariates) and an 
adjusted statistical model, covarying for age, sex, APOE ε4 allele and clinical 
classification (HC or AD), were used. Table 5 summarises those AQP1 and AQP4 
SNPs for which a nominal significance was observed in one or both statistical 
models for a respective PSQI sleep parameter. A complete list of p-values derived 
from these analyses is provided in Appendix 6. 
For AQP1 nominally (uncorrected) significant associations were observed for several 
SNPs across multiple sleep parameters. AQP1 rs1004317 (additive model, p = 0.041; 
dominant model, p = 0.025), rs2299905 (additive model, p = 0.012; dominant genetic 
model, p = 0.019) and rs28362727 (additive model, p = 0.045) were associated in the 
base model with PSQI total. However, only rs1004317 (dominant model, p = 0.047) 
and rs2299905 (additive model, p = 0.015; dominant genetic model, p = 0.033) were 
significant in the adjusted model, though they did not survive FDR correction. Two 
of these SNPs, rs2299905 (additive model, p = 0.045) and rs28362727 (additive 
model, p = 0.037) in addition to rs1859838 (recessive model, p = 0.043) were 
associated in the base model with sleep duration. However, only rs1859838 
(recessive model, p = 0.031) was significant after adjusting for covariates, though 
again failed to survive FDR correction.  
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Table 5: Association of AQP1 and AQP4 SNPs with Pittsburgh Sleep Quality 
Index Sleep Parameters. 
PSQI Sleep Parameter SNP Ref Additive† Dominant† Recessive† 
   Base* Adj* Base* Adj* Base* Adj* 
 AQP1       
PSQI total 
rs1004317 0.041 0.052 0.025 0.047 0.364 0.289 
rs2299905 0.012 0.015 0.019 0.033 0.095 0.067 
rs28362727 0.045 0.062 0.088 0.111 0.110 0.135 
Sleep duration (hours) 
rs1859838 0.065 0.088 0.166 0.238 0.043 0.031 
rs2299905 0.045 0.057 0.093 0.136 0.110 0.081 
rs28362727 0.037 0.061 0.094 0.162 0.064 0.064 
Sleep disturbances rs1859838 0.357 0.596 0.841 0.889 0.015 0.037 
  AQP4             
PSQI total 
rs71353406 0.130 0.100 0.042 0.045 0.856 0.871 
rs12968026 0.593 0.836 0.647 0.466 0.0006‡ 0.002‡ 
rs3875089 0.494 0.442 0.940 0.931 0.012 0.021 
Sleep disturbances rs68006382 0.097 0.146 0.034 0.077 0.062 0.902 
Daytime dysfunction 
rs12968026 0.446 0.855 0.981 0.381 0.005 0.032 
rs3875089 0.556 0.364 0.151 0.096 0.024 0.066 
rs162007 0.271 0.116 0.139 0.044 0.477 0.476 
PSQI, Pittsburgh Sleep Quality Index Sleep Parameters: PSQI total, sleep latency 
(Latency, in minutes), sleep duration (Duration, in hours), sleep disturbances 
(Disturbances), Daytime dysfunction. SNP Ref, reference single nucleotide 
polymorphism marker (rs); AQP1, Aquaporin 1; AQP4, Aquaporin 4. †Genetic 
models: Additive (homozygote for the minor allele (MM) vs heterozygote for the 
minor allele (Mm) vs homozygote for the major allele (mm)); Recessive (homozygote 
for the minor allele (MM) vs heterozygote/homozygote for the major allele 
(Mm/mm)); Dominant (heterozygote/homozygote for the minor allele (Mm or MM) 
vs homozygote for the major allele (mm)). *Statistical models: Base, base statistical 
model that is, no covariates; Adj, Adjusted statistical model (covaries for: age, sex, 
body mass index (BMI), geriatric depression scale (GDS) and a medical history of 
CVD). ‡Values significant after False Discovery Rate correction (q < 0.05). Values 
that reached nominal significance (p < 0.05, uncorrected) are bolded.   
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AQP1 rs1859838 was also observed to have a nominally significant association with 
sleep disturbances in both the base (recessive model, p = 0.015) and adjusted 
(recessive model, p = 0.037) models. However, this association likewise was not 
significant after FDR correction. 
Several AQP4 SNPs also demonstrated nominally (uncorrected) significant 
associations with multiple sleep parameters. Significant associations with PSQI total 
were observed for AQP4 SNPs in the base (rs71353406, dominant model, p = 0.042; 
rs12968026, recessive model, p < 0.001; rs3875089, recessive model, p = 0.012) and 
adjusted models (rs71353406, dominant model, p = 0.045; rs12968026, recessive 
model, p = 0.002; rs3875089, recessive model, p = 0.021). The observed associations 
for rs12968026 (unadjusted, β = 4.74 [SE: 1.37]; adjusted, β = 4.15 [SE: 1.34]) 
remained significant after FDR correction for both the base (q = 0.008) and adjusted 
(q = 0.028) statistical models. Both rs12968026 (recessive model, p = 0.005) and 
rs3875089 (recessive model, p = 0.024) were associated with daytime dysfunction in 
the base model. However, only rs12968026 (recessive model, p = 0.032), in addition 
to rs162007 (dominant model, p = 0.044) were significant after adjusting for 
covariates, though neither was significant after FDR correction. Finally, a nominally 
significant association of rs68006382 (dominant model, p = 0.034) with sleep 
disturbances was observed for the base model, which neither survived adjustment for 
covariates or correction for the FDR. 
 
5.6 Moderating effect of AQP1 and AQP4 SNPs on the relationship between PSQI 
sleep parameters and brain Aβ burden 
Linear regression analysis confirmed the association of sleep latency (minutes) with 
Aβ burden (β = 0.004, t (215) = 2.66; 95% CI, 0.001–0.007; p = 0.008) in this subset 
of the AIBL cohort, independent of AQP1 and AQP4 SNPs. No other PSQI sleep 
parameter was observed to be associated with brain Aβ burden in these analyses, 
which covaried for age, sex, body mass index (BMI), geriatric depression scale 
(GDS), a medical history of cardiovascular disease (CVD) and APOE ε4 allele status 
(see Appendix 7).  
To determine if AQP1 or AQP4 SNPs moderated the relationship between PSQI 
sleep parameters and brain Aβ burden, multivariate linear regression analyses were 
performed within the moderation model (SPSS, PROCESS see Section 4.4.3) and 
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covaried for age, sex, BMI, GDS, a medical history of CVD and APOE ε4 allele 
status. Sixteen of these statistical models revealed significant moderation effects for 
either AQP1 or AQP4 SNPs on the PSQI sleep parameters of sleep latency, sleep 
duration and daytime dysfunction and are presented in Tables 6–8. Additionally, 
visual representation of the conditional effects (that is, simple slopes analyses, as 
described in Section 4.4.2) of those models is depicted in Figures 10–15. A complete 
list of all AQP1 and AQP4 moderation analyses, including those that did not reach 
significance, are presented in the respective appendices (PSQI Total, Appendix 8; 
Sleep Latency, Appendix 9; Sleep Duration, Appendix 10; Sleep Disturbances, 
Appendix 11; Sleep Efficiency, Appendix 12; Daytime Dysfunction, Appendix 13). 
The relationship between PSQI-determined sleep latency (in minutes) and brain Aβ 
burden was observed to be significantly moderated by the largest number of AQP1 or 
AQP4 SNPs (six in total; Table 6). With respect to AQP1, the interaction of 
rs28362727 and sleep latency was significant for both the dominant (R2-change 
(ΔR2) = 0.018; p = 0.034) and recessive (ΔR2 = 0.035; p = 0.003) genetic models. 
Visual representation of these conditional effects of AQP1 rs28362727 for both the 
dominant and recessive genetic models is presented in Figure 10. A total of five 
AQP4 SNPs were also found to significantly moderate the impact of sleep on brain 
Aβ burden. The interaction of the AQP4 SNPs rs491148 and sleep latency was 
statistically significant for both dominant (ΔR2 = 0.017; p = 0.036) and recessive 
(ΔR2 = 0.020; p = 0.022) genetic models (simple slopes analysis, Figure 11). Whilst 
rs9951307 (ΔR2 = 0.015; p = 0.048), rs71353406 (ΔR2 = 0.019; p = 0.030), 
rs3875089 (ΔR2 = 0.019; p = 0.028) and rs151246 (R2-change, 0.039; p = 0.002) 
were significant in the dominant genetic model only (simple slopes analyses, Figure 
12). 
The interaction of AQP1 or AQP4 SNPs with PSQI-determined sleep duration (in 
hours) was only observed to have a significant moderation effect on brain Aβ burden 
for three AQP4 SNPs: rs12968026, rs2339214 and rs491148 (Table 7). For 
rs12968026 (ΔR2 = 0.019; p = 0.034) and rs491148 (ΔR2 = 0.016; p = 0.045) the 
association was observed only in the dominant genetic model. Whilst for rs2339214 
(ΔR2 = 0.041; p = 0.002), the strongest significant moderation of sleep duration on 
brain Aβ burden was observed in the recessive model. A visual representation of the 
conditional effects of those models is presented in Figure 13. 
47 
 
The relationship between PSQI-determined daytime dysfunction and brain Aβ 
burden was observed to be significantly moderated by several AQP1 or AQP4 SNPs 
(Table 8). The interaction with daytime dysfunction of the AQP1 SNPs, rs1004317 
(ΔR2 = 0.024; p = 0.015), rs62449133 (ΔR2 = 0.047; p = 0.001), rs2299905 (ΔR2 = 
0.034; p = 0.002) was observed to be significant in the recessive genetic model. 
Visual representation of these conditional effects of AQP1 rs1004317, rs62449133, 
and rs2299905 for the recessive genetic model is presented in Figure 14. Two AQP4 
SNPs were also found to significantly moderate the relationship of daytime 
dysfunction with brain Aβ burden (Table 8). The interaction of the AQP4 SNP 
rs9951307 (ΔR2 = 0.021; p = 0.023) and daytime dysfunction was statistically 
significant for the dominant model. Whereas a statistically significant interaction of 
rs491148 (ΔR2 = 0.022; p = 0.0206) and daytime dysfunction was observed in the 
recessive genetic model. Visual representation, of both conditional effects, is 
presented in Figure 15. 
Finally, Table 9 provides a summary of the 16 significant moderation results from 
the interaction analyses: Revealing those AQP1/4 SNPs which had a moderating 
influence (conditional effect) on the outcome measured—brain Aβ burden. 
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Table 6: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Latency. 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1                           
Model summary: rs28362727   0.167 <0.001           0.184 <0.001   
Age 0.011 0.004 0.006         0.011 0.004 0.011       
BMI 0.006 0.006 0.326         0.003 0.006 0.661       
CVD risk -0.004 0.039 0.915         <0.001 0.039 0.995       
GDS -0.005 0.015 0.716         -0.005 0.015 0.751       
APOE ε4 0.300 0.057 <0.001         0.306 0.057 <0.001       
rs28362727 -0.127 0.069 0.068         -0.298 0.122 0.015       
Latency -0.001 0.002 0.754         0.002 0.002 0.170       
INT 0.006 0.003 0.034     0.018  0.017 0.006 0.003     0.035 
AQP4                           
Model summary: rs9951307   0.186 <0.001           0.166 <0.001   
Age 0.010 0.004 0.019         0.010 0.004 0.013       
BMI 0.003 0.006 0.607         0.004 0.006 0.752       
CVD risk -0.013 0.039 0.741         -0.012 0.039 0.752       
GDS -0.007 0.015 0.658         -0.010 0.015 0.485       
APOE ε4 0.312 0.056 <0.001         0.309 0.057 <0.001       
rs9951307 0.015 0.070 0.831         0.025 0.123 0.837       
Latency 0.008 0.002 0.001         0.004 0.002 0.006       
INT -0.006 0.003 0.048     0.015  -0.005 0.006 0.347     0.004 
Model summary: rs71353406   0.180 <0.001           0.163 <0.001   
Age 0.010 0.004 0.023         0.010 0.004 0.018       
BMI 0.004 0.006 0.556         0.005 0.006 0.401       
CVD risk -0.008 0.039 0.833         -0.012 0.040 0.769       
GDS -0.006 0.015 0.692         -0.009 0.015 0.552       
APOE ε4 0.298 0.058 <0.001         0.307 0.058 <0.001       
rs71353406 -0.063 0.069 0.362         0.050 0.158 0.754       
Latency 0.001 0.002 0.688         0.004 0.002 0.022       
INT 0.006 0.003 0.030     0.019  0.003 0.006 0.675     0.001 
Model summary: rs3875089  0.184 <0.001      0.165 <0.001  
Age 0.010 0.004 0.019         0.011 0.004 0.010       
BMI 0.005 0.006 0.400         0.004 0.006 0.458       
CVD risk -0.016 0.039 0.683         -0.017 0.040 0.660       
GDS -0.010 0.015 0.501         -0.012 0.015 0.426       
APOE ε4 0.310 0.057 <0.001         0.313 0.058 <0.001       
rs3875089 -0.050 0.074 0.497         -0.005 0.416 0.990       
Latency 0.002 0.002 0.248         0.004 0.002 0.008       
INT 0.007 0.003 0.028     0.019  0.010 0.027 0.706     0.001 
 
(continued over) 
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Table 6 (cont.): Moderation Analysis for AQP1 and AQP4 SNPs on Sleep 
Latency. 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 (cont.)                         
Model summary: rs151246   0.201 <0.001           0.165 <0.001   
Age 0.009 0.004 0.023         0.011 0.004 0.012       
BMI 0.004 0.006 0.525         0.005 0.006 0.448       
CVD risk -0.015 0.038 0.699         -0.014 0.039 0.731       
GDS -0.007 0.015 0.654         -0.011 0.015 0.469       
APOE ε4 0.303 0.056 <0.001         0.310 0.057 <0.001       
rs151246 0.117 0.070 0.096         0.064 0.175 0.716       
Latency 0.009 0.002 <0.001         0.004 0.002 0.006       
INT -0.009 0.003 0.002     0.039  -0.008 0.007 0.294     0.004 
Model summary: rs491148   0.185 <0.001           0.193 <0.001   
Age 0.010 0.004 0.016         0.012 0.004 0.005       
BMI 0.005 0.006 0.360         0.005 0.006 0.393       
CVD risk -0.018 0.039 0.650         -0.017 0.039 0.657       
GDS -0.011 0.015 0.450         -0.011 0.015 0.459       
APOE ε4 0.316 0.057 <0.001         0.320 0.057 <0.001       
rs491148 -0.035 0.075 0.639         -0.333 0.271 0.220       
Latency 0.002 0.002 0.639         0.004 0.001 0.014       
INT 0.007 0.003 0.036     0.017  0.035 0.015 0.022     0.020 
Model summary statistics for significant Aquaporin 1 (AQP1) and Aquaporin 4 
(AQP4) reference single nucleotide polymorphism (SNP) markers (rs). †Genetic 
models: Dominant (heterozygote/homozygote for the minor allele (Mm or MM) vs 
homozygote for the major allele (mm)), Recessive (homozygote for the minor allele 
(MM) vs heterozygote/homozygote for the major allele (Mm/mm)); β, Coefficient of 
predictors; SE, standard error; Sig, p-value; R2, coefficient of multiple determination; 
ΔR2, multiple correlation coefficient (R) squared change; BMI, Body Mass Index; 
CVD risk, cardiovascular disease risk; GDS, Geriatric Depression Scale; APOE, 
Apolipoprotein E ε4 allele carriage (presence/absence); INT, Interaction (Sleep 
latency * model summary SNP). Models where the interaction term (INT) resulted in 
a statistically significant R2-change (p < 0.05) are indicated (bolded).   
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Figure 10: Conditional effects of AQP1 SNPs on the relationship between sleep 
latency and brain Aβ burden. 
Moderating effects of Aquaporin 1 (AQP1) rs28362727, for both the a) dominant and 
b) recessive genetic models, on the relationship between sleep latency (minutes) and 
brain Aβ burden. W, moderator variable; M, Minor allele; m, major allele. a) Dominant 
genetic model: W = 0 (homozygote for the major allele (mm)) compared to W = 1 
(heterozygote/homozygote for the minor allele (mM or MM)). b) Recessive genetic 
model: W = 0 (homozygote/ heterozygote for the major allele (mm or mM)) compared 
to W = 1 (homozygote for the minor allele (MM)). Brain Aβ burden is presented as  
11C-Pittsburgh compound B (PiB) positron emission tomography (PET) like 
standardised uptake value ratio (SUVR) using the Before the Centiloid Kernel 
Transformation (BeCKeT) scale.  
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Figure 11: Conditional effects of AQP4 rs491148 on the relationship between 
sleep latency and brain Aβ burden 
Moderating effects of the Aquaporin 4 (AQP4) rs491148, for both the a) dominant and 
b) recessive genetic models, on the relationship between sleep latency (minutes) and 
brain Aβ burden. W, moderator variable; M, Minor allele; m, major allele. a) Dominant 
genetic model: W = 0 (homozygote for the major allele (mm)) compared to W = 1 
(heterozygote/homozygote for the minor allele (mM or MM)). b) Recessive genetic 
model: W = 0 (homozygote/ heterozygote for the major allele (mm or mM)) compared 
to W = 1 (homozygote for the minor allele (MM)). Brain Aβ burden is presented as 
11C-Pittsburgh compound B (PiB) positron emission tomography (PET) like 
standardised uptake value ratio (SUVR) using the Before the Centiloid Kernel 
Transformation (BeCKeT) scale.  
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Figure 12: Further conditional effects of AQP4 SNPs on the relationship between 
sleep latency and brain Aβ burden. 
Moderating effects, in the dominant genetic model, for Aquaporin 4 (AQP4) single 
nucleotide polymorphisms (SNPs) a) rs9951307, b) rs7135406, c) rs3875089 and d) 
rs151246 on the relationship between sleep latency (minutes) and brain Aβ burden. W, 
moderator variable; M, Minor allele; m, major allele. Dominant genetic model: W = 0 
(homozygote for the major allele (mm)) compared to W = 1 (heterozygote/homozygote 
for the minor allele (mM or MM)). Brain Aβ burden is presented as 11C-Pittsburgh 
compound B (PiB) positron emission tomography (PET) like standardised uptake 
value ratio (SUVR) using the Before the Centiloid Kernel Transformation (BeCKeT) 
scale.  
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Table 7: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Duration. 
   Dominant†             Recessive†   
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4              
Model summary: rs12968026  0.149 <0.001           0.126 <0.001   
Age 0.012 0.004 0.005         0.011 0.004 0.010       
BMI 0.005 0.006 0.370         0.004 0.006 0.520       
CVD risk -0.023 0.040 0.565         -0.009 0.040 0.816       
GDS -0.007 0.015 0.662         -0.003 0.015 0.838       
APOE ε4 0.289 0.058 <0.001         0.283 0.059 <0.001       
rs12968026 0.807 0.352 0.023         0.065 0.715 0.928       
Duration 0.026 0.023 0.251         0.005 0.021 0.817       
INT -0.104 0.049 0.034     0.019   -0.010 0.105 0.923     <0.001 
Model summary: rs2339214   0.132 <0.001           0.174 <0.001   
Age 0.010 0.004 0.018         0.011 0.004 0.009       
BMI 0.005 0.006 0.403         0.004 0.006 0.507       
CVD risk -0.011 0.041 0.796         -0.009 0.040 0.819       
GDS -0.005 0.016 0.774         -0.008 0.015 0.595       
APOE ε4 0.302 0.059 <0.001         0.307 0.058 <0.001       
rs2339214 0.056 0.324 0.864         -0.993 0.329 0.003       
Duration 0.014 0.038 0.714         -0.031 0.024 0.197       
INT -0.009 0.045 0.850     <0.001  0.149 0.047 0.002     0.041 
Model Summary: rs491148   0.156 <0.001           0.146 <0.001   
Age 0.011 0.004 0.007         0.012 0.004 0.005       
BMI 0.005 0.006 0.377         0.004 0.006 0.736       
CVD risk -0.023 0.040 0.565         -0.016 0.040 0.684       
GDS -0.012 0.015 0.419         -0.008 0.015 0.574       
APOE ε4 0.317 0.058 <0.001         0.316 0.059 <0.001       
rs491148 0.707 0.320 0.028         -0.135 0.662 0.839       
Duration 0.030 0.024 0.202         0.005 0.021 0.819       
INT -0.090 0.045 0.045     0.016   0.053 0.097 0.584     0.001 
Model summary statistics for significant Aquaporin 4 (AQP4) reference single 
nucleotide polymorphism (SNP) markers (rs)—no Aquaporin 1 (AQP1) SNPs were 
significant. †Genetic models: Dominant (heterozygote/homozygote for the minor allele 
(Mm or MM) vs homozygote for the major allele (mm)), Recessive (homozygote for 
the minor allele (MM) vs heterozygote/homozygote for the major allele (Mm/mm)); 
β, Coefficient of predictors; SE, standard error; Sig, p-value; R2, coefficient of multiple 
determination; ΔR2, multiple correlation coefficient (R) squared change; BMI, Body 
Mass Index; CVD risk, cardiovascular disease risk; GDS, Geriatric Depression Scale; 
APOE, Apolipoprotein E ε4 allele carriage (presence/absence); INT, Interaction (Sleep 
duration * model summary SNP). Models where the interaction term (INT) resulted in 
a statistically significant R2-change (p < 0.05) are indicated (bolded).   
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Figure 13: Conditional effects of AQP4 SNPs on the relationship between sleep 
duration and brain Aβ burden 
Moderating effects of Aquaporin 4 (AQP4) single nucleotide polymorphisms (SNPs) 
a) rs12968026 (dominant model), b) rs491148 (dominant model), and c) rs2339214 
(recessive model) on the relationship between sleep duration (hours) and brain Aβ 
burden. W, moderator variable; M, Minor allele; m, major allele. Dominant genetic 
model: W = 0 (homozygote for the major allele (mm)) compared to W = 1 
(heterozygote/homozygote for the minor allele (mM or MM)). Recessive genetic 
model: W = 0 (homozygote/heterozygote for the major allele (mm or mM)) compared 
to W = 1 (homozygote for the minor allele (MM)). Brain Aβ burden is presented as 
11C-Pittsburgh compound B (PiB) positron emission tomography (PET) like 
standardised uptake value ratio (SUVR) using the Before the Centiloid Kernel 
Transformation (BeCKeT) scale.  
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Table 8: Moderation Analysis for AQP1 and AQP4 SNPs on Daytime Dysfunction. 
   Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1                           
Model summary: rs1004317   0.144 <0.001           0.160 <0.001   
Age 0.010 0.004 0.017         0.009 0.004 0.046       
BMI 0.004 0.006 0.557         0.004 0.006 0.465       
CVD risk -0.013 0.040 0.739         -0.004 0.040 0.922       
GDS -0.012 0.016 0.458         -0.013 0.016 0.429       
APOE ε4 0.306 0.058 <0.001         0.307 0.057 <0.001       
rs1004317 -0.029 0.067 0.575         -0.268 0.119 0.025       
Daytime dysfunction -0.029 0.067 0.668         -0.002 0.043 0.973       
INT 0.090 0.078 0.246     0.005   0.260 0.106 0.015     0.024 
Model summary: rs62449133   0.141 <0.001           0.191 <0.001   
Age 0.010 0.004 0.018         0.009 0.004 0.037       
BMI 0.003 0.006 0.578         0.002 0.006 0.786       
CVD risk -0.002 0.040 0.955         0.014 0.039 0.714       
GDS -0.009 0.017 0.600         -0.007 0.016 0.647       
APOE ε4 0.314 0.059 <0.001         0.345 0.058 <0.001       
rs62449133 -0.006 0.076 0.936         -0.494 0.151 0.001       
Daytime dysfunction -0.002 0.055 0.965         -0.034 0.042 0.429       
INT 0.022 0.073 0.766     <0.001  0.411 0.119 0.001     0.047 
Model summary: rs2299905   0.146 <0.001           0.181 <0.001   
Age 0.010 0.004 0.025         0.009 0.004 0.045       
BMI 0.003 0.006 0.578         0.002 0.006 0.786       
CVD risk -0.003 0.040 0.944         0.012 0.040 0.765       
GDS -0.009 0.017 0.593         -0.008 0.016 0.607       
APOE ε4 0.318 0.059 <0.001         0.339 0.058 <0.001       
rs2299905 -0.087 0.074 0.245         -0.458 0.149 0.002       
Daytime dysfunction -0.022 0.058 0.709         -0.027 0.043 0.534       
INT 0.057 0.074 0.440     0.003   0.336 0.115 0.002     0.034 
 
(continued over) 
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Table 8 (cont.): Moderation Analysis for AQP1 and AQP4 SNPs on Daytime 
Dysfunction. 
   Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4                           
Model summary: rs9951307   0.165 <0.001           0.143 <0.001   
Age 0.010 0.004 0.013         0.010 0.004 0.014       
BMI 0.005 0.006 0.405         0.006 0.006 0.340       
CVD risk -0.012 0.040 0.740         -0.011 0.040 0.788       
GDS -0.009 0.016 0.593         -0.014 0.017 0.410       
APOE ε4 0.302 0.057 <0.001         0.296 0.058 <0.001       
rs9951307 -0.201 0.074 0.007         -0.179 0.124 0.152       
Daytime dysfunction -0.067 0.058 0.245         0.018 0.042 0.667       
INT 0.165 0.072 0.023     0.021  0.126 0.111 0.256     0.005 
Model summary: rs491148   0.143 <0.001           0.168 <0.001   
Age 0.010 0.004 0.020         0.010 0.004 0.015       
BMI 0.005 0.006 0.394         0.005 0.006 0.384       
CVD risk -0.012 0.041 0.760         -0.007 0.040 0.866       
GDS -0.016 0.017 0.351         -0.008 0.016 0.623       
APOE ε4 0.302 0.058 <0.001         0.312 0.058 <0.001       
rs491148 0.101 0.082 0.221         0.568 0.197 0.004       
Daytime dysfunction 0.046 0.047 0.337         0.043 0.041 0.300       
INT -0.034 0.082 0.337     0.001  -0.339 0.144 0.020     0.022 
Model summary statistics for significant Aquaporin 1 (AQP1) and Aquaporin 4 
(AQP4) reference single nucleotide polymorphism (SNP) markers (rs). †Genetic 
models: Dominant (heterozygote/homozygote for the minor allele (Mm or MM) vs 
homozygote for the major allele (mm)), Recessive (homozygote for the minor allele 
(MM) vs heterozygote/homozygote for the major allele (Mm/mm)); β, Coefficient of 
predictors; SE, standard error; Sig, p-value; R2, coefficient of multiple 
determination,;ΔR2, multiple correlation coefficient (R) squared change; BMI, Body 
Mass Index; CVD risk, cardiovascular disease risk; GDS, Geriatric Depression Scale; 
APOE, Apolipoprotein E ε4 allele carriage (presence/absence); INT, Interaction 
(Daytime dysfunction * model summary SNP). Models where the interaction term 
(INT) resulted in a statistically significant R2-change (p < 0.05) are indicated (bolded). 
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Figure 14: Conditional effects of AQP1 SNPs on the relationship between daytime 
dysfunction and brain Aβ burden 
Moderating effects, in the recessive genetic model, for Aquaporin 1 (AQP1) single 
nucleotide polymorphisms (SNPs) a) rs1004317, b) rs62449133, and c) rs2299905 on 
the relationship between daytime dysfunction and brain Aβ burden. W, moderator 
variable; M, Minor allele; m, major allele. Recessive genetic model: W = 0 
(homozygote/heterozygote for the major allele (mm or mM)) compared to W = 1 
(homozygote for the minor allele (MM)). Brain Aβ burden is presented as 11C-
Pittsburgh compound B (PiB) positron emission tomography (PET) like standardised 
uptake value ratio (SUVR) using the Before the Centiloid Kernel Transformation 
(BeCKeT) scale.  
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Figure 15: Conditional effects of AQP4 SNPs on the relationship between daytime 
dysfunction and brain Aβ burden 
Moderating effects of Aquaporin 4 (AQP4) single nucleotide polymorphisms (SNPs) 
a) rs9951307 (dominant model), and b) rs491148 (recessive model) on the relationship 
between daytime dysfunction and brain Aβ burden. W, moderator variable; M, Minor 
allele; m, major allele.  Dominant genetic model: W = 0 (homozygote for the major 
allele (mm)), and W = 1 (heterozygote or homozygote for the minor allele (mM or 
MM)). Recessive genetic model: W = 0 (heterozygote or homozygote for the major 
allele (mM or mm)), and W = 1 (homozygote for the minor allele (MM)). Brain Aβ 
burden is presented as 11C-Pittsburgh compound B (PiB): positron emission 
tomography (PET) tracer, standardised uptake value ratio (SUVR), Before the 
Centiloid Kernel Transformation (BeCKeT) scale.  
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Table 9: Summary of Significant Interactions in the Moderation Analyses of 
AQP1 and AQP4 SNPs on PSQI sleep parameters on brain Aβ burden. 
PSQI  SNP Ref 
Genetic 
Model† 
β SE 
95% CI (BCa)  
[LLCI, ULCI] 
p-value f2 
 Sleep latency (minutes)           
AQP1               
    rs28362727 dominant 0.006 0.003 [0.001, 0.012] 0.034 0.20 
    rs28362727 recessive 0.017 0.006 [0.006, 0.028] 0.003 0.23 
AQP4               
    rs9951307 dominant -0.006 0.003 [-0.012, -0.001] 0.048 0.23 
    rs7135406 dominant 0.006 0.003 [0.001, 0.012] 0.030 0.22 
    rs3875089 dominant 0.007 0.003 [0.001, 0.013] 0.028 0.23 
    rs151246 dominant -0.009 0.003 [-0.015, -0.004] 0.002 0.25 
    rs491148 dominant 0.007 0.003 [0.001, 0.013] 0.036 0.23 
    rs491148 recessive 0.035 0.015 [0.005, 0.065] 0.022 0.24 
 Sleep duration (hours)           
AQP4               
    rs12968026 dominant -0.104 0.049 [-0.199, -0.008] 0.034 0.18 
    rs491148 dominant -0.090 0.045 [-0.178, -0.002] 0.045 0.18 
    rs2339214 recessive 0.149 0.047 [0.057, 0.240] 0.002 0.21 
 Daytime dysfunction           
AQP1               
    rs1004317 recessive 0.260 0.106 [0.052, 0.468] 0.015 0.19 
    rs62449133 recessive 0.411 0.119 [0.177, 0.645] 0.001 0.24 
    rs2299905 recessive 0.336 0.115 [0.109, 0.564] 0.002 0.22 
AQP4               
    rs9951307 dominant 0.165 0.072 [0.024, 0.307] 0.023 0.20 
    rs491148 recessive -0.339 0.144 [-0.623, -0.055] 0.020 0.20 
A summary of all Aquaporin 1 (AQP1) and Aquaporin 4 (AQP4) single nucleotide 
polymorphisms (SNPs) with significant (p < 0.05) moderation of the relationship 
between the listed Pittsburgh Sleep Quality Index (PSQI) sleep parameters and brain 
Aβ burden. SNP Ref, reference SNP marker (rs). †Genetic model: Recessive 
(homozygote for the minor allele (MM) vs heterozygote/homozygote for the major 
allele (Mm/mm)); Dominant (heterozygote/homozygote for the minor allele (Mm or 
MM) vs homozygote for the major allele (mm)). β, Coefficient of predictors; SE, 
standard error; 95% CI (BCa), 95% Confidence Interval (bias-corrected and 
accelerated; based on 5000 bootstrap samples) with lower (LLCI) and upper (ULCI) 
limits. Cohen’s f2 effect size (Cohen, 1988).  
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6.0 Discussion 
This study aimed to investigate whether genetic variation within the genes encoding 
water channel proteins expressed in the brain, specifically Aquaporin 1 (AQP1) and 
Aquaporin 4 (AQP4), were associated with; i) Alzheimer’s disease (AD) risk and 
brain β-amyloid (Aβ) burden, ii) self-reported sleep quality and quantity, and finally, 
iii) whether these genetic variations moderate the relationship between self-reported 
sleep parameters and brain Aβ burden. To achieve these aims, an observational and 
cross-sectional investigation was undertaken using genetic data extracted from a 
genome-wide association study (GWAS) in participants of the Australian Imaging, 
Biomarkers and Lifestyle (AIBL) study of ageing. These genetic data were combined 
with AIBL participant sleep assessment data, determined via the Pittsburgh Sleep 
Quality Index (PSQI), and brain Aβ burden data, from positron emission 
tomography. 
Overall, the study reports insufficient evidence to support the hypothesis that either 
AQP1 or AQP4 SNPs are associated with either an increased AD risk or differences 
in brain Aβ burden. However, there was sufficient evidence to suggest that genetic 
variation in AQP4, specifically rs12968026, is associated with altered, self-reported, 
“overall” sleep quality (PSQI total score). Nonetheless, the major finding from this 
study was that several AQP1 and AQP4 SNPs altered the relationship between PSQI-
determined sleep parameters and brain Aβ burden. This finding provides sufficient 
evidence to support the hypothesis that genetic variation in AQP1 and AQP4 
moderates the conditional effect that 3 PSQI-determined sleep parameters, namely, 
sleep latency (time taken to fall asleep, in minutes), sleep duration (length of sleep, in 
hours) and daytime dysfunction (disruption of daytime activities due to sleepiness), 
had on brain Aβ burden. 
 
6.1 Genetic variation within AQP1 and AQP4 is not associated with AD risk or brain 
Aβ burden 
Logistic regression risk analysis, based upon the frequency of the minor allele of 
each genetic variant in the healthy controls and AD cases revealed only a nominal 
level of significance for two AQP4 SNPs, rs7240333 and rs68006382 with altered 
AD risk (section 5.3, Table 3). However, to ensure the reduction of familywise or 
experimental error when conducting multiple analyses with the same data, it was 
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prudent to evaluate the findings using a correction for multiple testing. After 
correction for the False Discovery Rate (FDR), no SNPs across the 3 genetic models 
retained significance. Therefore, there were no genetic polymorphisms in either 
AQP1 or AQP4 that could be reported to be associated with an increase AD risk, in 
the AIBL cohort using the clinical grouping criteria outlined in Section 4.2.1. 
Likewise, results of the linear regression, to see if there was a relationship between 
AQP1 and AQP4 SNPs and brain Aβ burden (Section 5.4, Table 4), suggested only a 
nominal level of significance for two AQP4 SNPs (rs162007 and rs162003). 
However, as with the AD risk analysis, these associations were not significant after 
FDR correction.  
Whilst these results suggest that there is no direct link between AQP1 and AQP4 
genetic variation and either increased risk for AD or brain Aβ burden, the study of 
only common variants (minor allele frequency, MAF > 0.05) means that, even when 
considering the respective levels of gene coverage combined with the respective 
Linkage Disequilibrium (LD) structures, the possibility cannot be discounted that an 
untyped rare coding genetic variant may impart some functional impact on either 
AQP1 or AQP4 that could alter clearance of Aβ in the brain and subsequent AD risk. 
 
6.2 Genetic variation in AQP4, but not AQP1, is associated with overall sleep 
quality 
To ascertain if AQP1 and AQP4 SNPs were associated with any of the PSQI-
determined sleep parameters in this study, multiple linear regression was carried out. 
This analysis (Section 5.5, Table 5) indicates that one AQP4 SNP, rs12968026 
recessive genetic model, is significantly associated with self-reported overall sleep 
quality (PSQI total) after correction for multiple testing and adjusting for potential 
confounders. 
The regression coefficient for this significant finding (unadjusted β = 4.74 [SE: 
1.37]; adjusted β = 4.15 [SE: 1.34]) suggests a positive linear association or 
relationship between homozygotes for the minor allele, rs12968026-C, and worse 
overall sleep quality. A PSQI total score of > 5 indicates poor sleep and the higher 
the score the worse sleep an individual experiences (Buysse et al., 1989). Thus, this 
finding suggests that individuals homozygous for the AQP4 rs12968026-C allele 
have worse self-reported overall sleep compared to those with a different genotype. 
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A National Center for Biotechnology Information (NCBI) genomic reference dbSNP 
(Sherry et al., 2001) check revealed that rs12968026 is located at Chr18:24,444,150 
within the first intron of AQP4 (NCBI, 2017c). Upon, cross-check with the Ensembl 
database (Yates et al., 2016) the genetic variant effect predictor (McLaren et al., 
2016) confirmed that this SNP is intronic and appears to have no discernible 
functional implication for the AQP4 protein that would provide a basis for a 
mechanism by which it impacts overall sleep. An analysis of the LD structure of the 
AQP4 gene using the Ensembl database (Yates et al., 2016) with regards to potential 
linkage with functional AQP4 SNP variants suggests several variants of interest. 
Firstly, rs12968026 is in complete LD and thus tags a single coding variant in exon 
1, namely, rs35248760 (D’ 1.0, r2 1.0). However, this single coding variant was 
listed as a synonymous SNP thus creating only a subtle change in the transcribed 
codon but no change to the amino acid sequence (Hunt, Sauna, Ambudkar, 
Gottesman, & Kimchi-Sarfaty, 2012). Whilst rs35248760 does not appear to be a 
SNP that impacts functionality of the protein it encodes, it cannot be ruled out that 
rs12968026 and rs35248760 may be in linkage with an untyped rare non-
synonymous variant in exon 1 (Khoury et al., 2010), that does impact AQP4 
functionality. To ascertain whether such variants exist in our study cohort would 
require targeted resequencing of this region of the AQP4 gene which is beyond the 
scope of this Honours project. 
Secondly, rs12968026 was observed to tag two further variants, rs72878776 (D’ 1.0, 
r2 1.0) and rs1058427 (D’ 1.0, r2 1.0), within the 5-prime and 3-prime untranslated 
regions of the AQP4 gene, respectively (McLaren et al., 2016). Of the two variants, 
rs72878776 is possibly of most functional relevance through potentially influencing 
gene transcription, via modification (creation or deletion) of a transcription factor 
binding site (Frazer, Murray, Schork, & Topol, 2009). However, analysis of the 
implications of the base change (T to C) to the DNA sequence using an in-silico tool, 
PROMO (Farré et al., 2003), to interrogate the TRANSFAC database (Wingender, 
Dietze, Karas, & Knüppel, 1996) suggested that potential transcription factor binding 
sites were not influenced by this SNP. 
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6.3 Genetic variation within AQP1 and AQP4 moderates the effect of sleep latency 
on brain Aβ burden 
PSQI-determined sleep latency (time to fall asleep in minutes) was the only sleep 
parameter in this study to be associated with brain Aβ burden in cognitively healthy 
controls; confirming results previously reported using the AIBL cohort (B. M. 
Brown, Rainey-Smith, Villemagne, et al., 2016), among a subset (n = 184) of 
participants included in the current study (n = 222). One AQP1 SNP, rs28362727, in 
both the dominant and recessive models had a significant interaction with self-
reported sleep latency and the resultant effect on brain Aβ burden. In both genetic 
models, carriage of the minor allele (rs28362727-C) in combination with longer time 
to fall asleep was associated with an elevated PiB-like SUVR (> 1.4). This 
association was observably stronger in homozygotes, suggesting a potential gene-
dosage effect (Figure 10). Ensembl database and NCBI dbSNP check discerned that 
this AQP1 variant is intronic, it is however, in medium (D’ 0.65, r2 0.17) to strong 
(D’ 0.99, r2 0.06) LD with two genetic variants, rs10046506 and rs10046532, 
respectively, which are located within a regulatory region (open chromatin region) 
approximately 12kb upstream. It is conceivable that these two variants have a 
regulatory effect on AQP1, which may subsequently affect cerebrospinal fluid 
formation or movement (Xie et al., 2013). However, a comprehensive study of AQP1 
knockout animal models would be required to confirm such a conclusion. 
Five AQP4 SNPs (rs9951307, rs7135406, rs3875089, rs151246, and rs491148) in the 
dominant models, had significant interactions with self-reported sleep latency and the 
resultant effect on brain Aβ burden (Figures 11 and 12). Of these five SNPs, 
rs491148 also had an observably stronger effect in the recessive model (Figure 12), 
again suggestive of a gene-dosage effect for the minor allele (rs491148-G). 
Specifically, carriage of at least one copy of the rs491148-G allele was associated 
with a PiB-like SUVR approaching 1.6, whilst homozygosity of the G-allele was 
associated with a PiB-like SUVR approaching 2.3—a level usually associated with a 
clinical diagnosis of AD. Of note, three of these AQP4 variants; rs9951307 (D’ 0.99, 
r2 0.07), rs3875089 (D’ 1.00, r2 0.64) and rs491148 (D’ 0.93, r2 0.46), are in strong 
LD with the same AQP4 synonymous coding variant in exon 1 (rs35248760) which 
was previously linked to self-reported overall sleep quality (Section 6.2). This 
accumulation of evidence of linkage with exon 1 of AQP4 suggests sequencing of 
this exon for rare coding (functional) genetic variants may be warranted. 
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Previous studies have reported an association of sleep latency with brain Aβ 
(Branger et al., 2016; B. M. Brown, Rainey-Smith, Villemagne, et al., 2016). The 
current study supports this association as AQP4 is ubiquitously expressed in 
astrocytic end-feet in the brain and is proposed to be implicit in glymphatic clearance 
of Aβ during sleep (Mander et al., 2016). Accordingly, those AQP4 SNPs that had a 
moderating effect on the relationship between sleep latency and Aβ may predispose 
those individuals to suboptimal sleep parameters due to the Aβ burden within the 
brain. Alternatively, as a bi-directional relationship between sleep and Aβ has been 
postulated (B. M. Brown, Rainey-Smith, Bucks, et al., 2016; Ju et al., 2014) it is 
conceivable that the suboptimal sleep parameters (driven by genetic differences) 
instead contribute to brain Aβ burden. 
 
6.4 Genetic variation in AQP4, but not AQP1, moderates the effect of sleep duration 
on brain Aβ burden  
This study found three AQP4 SNPs, rs12968026, rs491148 and rs2339214, 
interacting with sleep duration to have a moderating effect on levels of Aβ in the 
brain. Of these three SNPs, rs12968026 was previously associated with overall sleep 
quality in this study (Section 6.2), whilst rs491148 was shown to interact with sleep 
latency to moderate brain Aβ burden (Section 6.3). For both rs12968026 and 
rs491148, the nature of the relationship between sleep duration and brain Aβ was 
similar, in that carriage of the minor allele of the respective variants was associated 
with elevated PiB-like SUVR (> 1.4) when self-reported sleep duration was ‘short’ 
(approximately 6-hours or less; Figure 13). 
The final variant, rs2339214 presents with a potential bi-directional moderation of 
the relationship between sleep duration and brain Aβ burden. Specifically, 
homozygosity of the minor allele, rs2339214-A, is suggestive of protecting against 
the hypothesised negative impact of reduced sleep duration on brain Aβ burden (PiB-
like SUVR < 1.3, at 6-hours or less sleep duration) yet is associated with elevated 
brain Aβ when sleep duration is ‘long’ (PiB-like SUVR ~ 1.6, > 8-hours sleep 
duration). To this researcher’s knowledge there has been no previous report of a bi-
modal relationship between sleep duration and brain Aβ burden. However, there is 
evidence in the literature that such a bi-modal relationship exists between sleep 
duration and cognition. Specifically, both short and long sleep duration is purported 
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to contribute to poorer cognitive function and increased risk of cognitive impairment 
and AD compared to intermediate sleep duration (Potvin et al., 2012; Schmutte et al., 
2007; Xu et al., 2011). It remains to be determined whether this could be a 
consequence of a bi-modal relationship between sleep duration and Aβ.  
The concurrent associations of rs491148 with a moderating effect on the relationship 
of both sleep latency and duration with brain Aβ provides further evidence to support 
the role of genetic variation in AQP4 in brain health. Specifically, the longer one 
takes to fall asleep (latency) conceivably plays a role in the quantity of sleep 
(duration), which in turn potentially has an impact on the postulated glymphatic 
system’s clearance of neurotoxins, in this case Aβ—manifesting as a higher brain Aβ 
burden. Thus, one sleep parameter in isolation may not be detrimental, particularly 
with respect to clearance mechanisms, but rather sleep dysfunction as a concert of 
multiple suboptimal sleep parameters negatively impacts brain health (Villa, Ferini-
Strambi, & Combi, 2015): This may be particularly apparent when genetic factors, 
such as those studied herein, are taken into account. 
 
6.5 Genetic variation within AQP1 and AQP4 moderates the relationship of Daytime 
Dysfunction with brain Aβ burden 
Daytime dysfunction, that is, actual disruption of daytime activities due to sleepiness, 
is highly likely to be significantly impacted by sleep latency and sleep duration, such 
that poor sleep quality or short duration would likely manifest as poor diurnal 
functioning (Sprecher et al., 2015). Thus, a relationship between daytime dysfunction 
and brain Aβ burden is likely not direct but rather a consequence of factors, that is, 
sleep quality/quantity, that influence it. The association of two AQP4 SNPs, 
previously associated with sleep latency (Section 6.3), with a moderating effect on 
daytime dysfunction’s relationship with brain Aβ burden is suggestive of supporting 
this notion of an indirect relationship between daytime dysfunction and Aβ. 
However, the implications of this moderation are counterintuitive. Specifically, 
homozygosity of the rs491148-G allele, in the presence of increased sleep latency, 
was associated with increased brain Aβ burden, yet this genotype is associated with 
elevated brain Aβ burden in concert with decreased daytime dysfunction. Similarly, 
carriage of the minor allele of rs9951307 was suggestive of reducing the impact of 
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increasing sleep latency on brain Aβ, whereas it is associated with increasing the 
impact of daytime dysfunction. 
Three AQP1 SNPs (rs1004317, rs62449133 and rs2299905) in the recessive models, 
demonstrated significant interactions with daytime dysfunction and its relationship 
with brain Aβ burden (Figure 14). In all cases, homozygosity of the minor allele was 
associated with an observably higher level of brain Aβ burden, compared to non-
homozygotes, when higher levels of daytime dysfunction were reported. Conversely, 
in the absence of daytime dysfunction, homozygote individuals had observably lower 
brain Aβ burden. Two of these SNPs, rs1004317 (PSQI total) and rs2299905 (PSQI 
total and duration) only had nominal significance with sleep parameters, however all 
three variants were in medium LD (D’ 0.52–0.692, r2 0.16–0.34) with rs10046506 
and high LD (D’ 0.75–0.99, r2 0.06–0.11) with rs10046532.rs10046506 and 
rs10046532 are the same two genetic variants, located within a regulatory region 
upstream of AQP1, discovered to be in LD with AQP1 rs28362727, which was found 
to moderate the relationship between sleep latency and brain Aβ burden (Section 
6.3).  
It is worthy of consideration however, that suboptimal sleep parameters may also be 
affecting the ability of an individual to perceive any daytime dysfunction, which 
would suggest that the relationship between daytime dysfunction and brain Aβ 
should be interpreted with caution regardless of genotype. 
 
6.6 Limitations and Strengths of the study 
Whilst the findings of this study are novel and suggest that genetic variation of AQP1 
and AQP4 can moderate the relationship between sleep parameters and brain Aβ 
burden, there are some limitations that need to be considered. First, this study was 
observational and utilised a cross sectional retrospective design; consequently, no 
conclusions regarding temporal or causal relationships can be drawn (Bonita, 
Beaglehole, & Kjellström, 2006). Second, a subjective sleep measure was utilised 
which relies on the accuracy and fidelity of the respondents. Indeed, utilisation of an 
objective measure of sleep such as actigraphy or polysomnography would 
circumvent the limitation of self-report. Moreover, use of polysomnography, the 
‘gold standard’ in differentiating sleep from wake, and in identifying sleep stages, 
would provide detail regarding the association of sleep architecture with brain Aβ. 
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Notwithstanding, the subjective assessment of sleep using the PSQI was appropriate 
and justified in this study due to its cost effectiveness and ease of administration to a 
large cohort (the AIBL cohort from which the current study drew data). Further, the 
PSQI has demonstrated internal reliability and construct validity (see Mollayeva et 
al. (2016) for a systematic review and meta-analysis). Third, the brain imaging and 
PSQI administration were completed on separate days; however, Aβ deposition is a 
relatively slow process, occurring over many years (Villemagne et al., 2013), and 
sleep habits are usually chronic, particularly in the age group studied. Finally, this 
study did not include a measure of glymphatic clearance thus, any inference of 
potential mechanisms underpinning the association of aquaporin genetic variation 
with a functional impact on Aβ clearance from the brain is speculative and would 
require further functional studies to elucidate. 
Many aspects of this study however, provide confidence in the findings. A well-
characterised cohort was utilised, thereby increasing the internal validity of the 
results. The sample size was large (over 200) and by means of the central limit 
theorem the statistical assumptions (for example, assumption of normally distributed 
data) were not violated (Hayes, 2005). Additionally, the statistically robust measure 
of bootstrapping was utilised; thereby maintaining precision and helping to keep the 
results reliable (Wilcox, 2012; Wright, London, & Field, 2011). Furthermore, the 
calculated effect size for the moderation analyses (Cohen's f-squared) ranged from 
0.18–0.25, representing a moderate effect (Aiken & West, 1993; Cohen, 1992) of the 
interactions of AQP1 and AQP4 SNPs with Aβ levels and the sleep parameters of 
latency, duration, and daytime dysfunction. Plausibly, these data herein could be 
used as a generalizable measure for other studies that assess similar subjective sleep 
parameters and their interaction with genetic variants. 
 
6.7 Future implications 
This study adds weight to the argument that the brain’s paravascular clearance 
mechanism, the proposed glymphatic system, is the biological mechanism 
underpinning Aβ clearance from the brain (Iliff et al., 2012). However, further study 
is warranted, in the context of neurodegenerative disease research, that builds upon 
the utilisation of AQP1/4 (for instance, knockout or transgenic) mouse models (for 
example, Peng et al. (2016) AQP4 deficient murine study of glymphatic system). 
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Conceivably, such work may further implicate (or refute) the hypothesized 
glymphatic clearance mechanism as the biological mechanism underpinning Aβ 
efflux from the brain, and could provide a platform to investigate the functional 
implications of aquaporin variants reported in this study. In this respect, the linkage 
of associated SNPs in this study with genetic regions with potential functional 
relevance (upstream regulatory region from AQP1 and exon 1 of AQP4) warrants 
follow-up genetic (for example, sequencing) and functional studies, as described 
above. 
Prospectively, the results of this study engender a greater understanding of what 
factors may moderate a sleep-AD phenotype relationship, and suggest that 
establishing interventions targeted at improving sleep parameters may be beneficial 
for positively modulating cerebral Aβ levels and, thus, potentially delaying AD 
onset. Indeed, findings from this study could be used to both stratify retrospective 
analysis of existing datasets, or perhaps more importantly, to derive tailored AD 
intervention strategies based on the genetics of the individual. For example, a sleep-
specific intervention targeted at reducing sleep latency may be most beneficial to 
individuals who are genetically predisposed to a heightened impact of latency on 
pathological or clinical outcomes. 
Overall, the data from this study have provided proof of concept that genetic 
variation, at least in genes encoding cerebrally expressed water-channel proteins 
Aquaporin 1 and Aquaporin 4, likely moderate the relationship between sleep 
parameters and AD-related imaging, and perhaps, clinical phenotypes. Whether other 
genetic factors may likewise moderate the relationship between sleep parameters and 
AD characteristics remains to be determined, however, the current study provides 
evidence to support future investigation of such interactions. 
 
 
 
 
 
  
69 
 
7.0 Conclusion 
In summary, this thesis presents significant evidence that genetic variation within the 
genes encoding the central nervous system expressed water channel proteins, 
Aquaporin 1 and 4 (AQP1 and AQP4, respectively) moderate the relationship 
between self-reported sleep parameters and brain Aβ burden. These findings 
specifically found that three PSQI-determined sleep parameters: sleep latency 
(minutes), sleep duration (hours) and daytime dysfunction (disruption of daytime 
activities due to sleepiness), when interacting with AQP1/AQP4 genetic variants 
influenced brain Aβ. However, the study was cross-sectional and observational, so 
no conclusions can be drawn regarding temporal causal relationships. Nonetheless, 
the results further support a role for the hypothesised glymphatic system in the 
clearance of Aβ during sleep. Future studies assessing the functional impact of 
genetic variation in AQP1/AQP4 on these processes would greatly assist in furthering 
our understanding of the contribution of sleep to AD pathogenesis. 
This study further highlights that a multitude of factors need to be considered when 
investigating a complex neurodegenerative condition, such as, Alzheimer’s disease. 
Moreover, the findings of the present study suggest that sleep is intricately 
influenced by genetic variation: Thereby, providing a rationale for the utilisation of 
genetics in combination with interventions aimed at improving suboptimal sleep 
parameters to target those individuals who would benefit the most. Finally, the 
results reported in this thesis support the notion that further investigation of the 
interaction of genetic variation with other lifestyle factors may prove advantageous 
in the quest to develop strategies aimed at preventing or delaying AD onset. 
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9.0 Appendices 
 
Appendix 1: Ethical considerations. 
Approval of the AIBL Study has been granted by the respective ethics committees of 
each of the member institutions: Austin Health, St Vincent’s Health (HREC-A 
081/07), Hollywood Private Hospital (HPH215), and ECU (ECU-1878-MARTINS); 
and informed written consent was given by all volunteers. Further, the present study 
had been granted ethical clearance from ECU Human Research Ethics Committee: 
ECU-17156-MAZZUCCHELLI. In-line with the National Health and Medical 
Research Council, Australian Research Council, and Australian Vice-Chancellors’ 
Committee (2015) statement, all secondary data was de-identified and as such 
ensured participants’ anonymity. Also, electronically stored data was secured by 
password and only accessible by authorised persons. 
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Appendix 4: Complete SNP list for AQP1 and AQP4 prior to LD pruning. 
SNP Ref Major Allele Call Rate Minor Allele MAF HWE-p 
AQP1      
rs2075574 C 1.00 T 0.36 0.64 
rs1859838 A 1.00 G 0.17 0.06 
rs4419722 T 1.00 G 0.12 0.64 
rs28362709 G 0.97 T 0.21 0.18 
rs10236571 A 0.97 G 0.22 0.17 
rs2267719 C 1.00 T 0.06 0.85 
rs10276670 A 0.97 G 0.22 0.20 
rs1004317 A 1.00 G 0.39 0.79 
rs62449133 A 0.97 G 0.22 0.16 
rs2299905 A 0.96 T 0.28 0.29 
rs2299906 C 1.00 T 0.06 0.40 
rs1004318 C 1.00 T 0.06 0.54 
rs10255904 C 1.00 T 0.06 0.77 
rs17159702 T 1.00 C 0.28 0.16 
rs28362727 A 0.97 C 0.27 0.47 
rs765840 T 0.99 A 0.06 0.90 
rs765839 C 0.99 G 0.06 0.92 
rs11537660 T 1.00 C 0.07 0.72 
AQP4           
rs11661081 C 1.00 A 0.09 0.89 
rs9951307 A 1.00 G 0.36 0.65 
rs12455617 C 1.00 A 0.12 0.41 
rs16942851 T 0.99 G 0.19 0.98 
rs7240333 C 0.99 T 0.11 0.41 
rs1058427 G 0.98 T 0.12 0.55 
rs14393 G 0.98 T 0.30 0.38 
rs1058424 A 0.98 T 0.18 0.59 
rs335929 A 1.00 C 0.19 0.98 
rs3763043 C 1.00 T 0.31 0.44 
rs68006382 A 0.98 G 0.18 0.62 
rs335930 A 0.98 C 0.21 0.49 
rs11661256 T 0.98 A 0.12 0.49 
rs71353406 C 0.98 A 0.30 0.45 
rs335931 A 0.98 G 0.19 0.97 
rs67207056 G 0.97 A 0.12 0.51 
rs55875625 T 0.97 C 0.12 0.49 
rs455671 A 0.97 G 0.19 1.00 
rs35248760 C 0.97 A 0.12 0.49 
rs72878776 G 0.97 A 0.12 0.49 
rs63514 C 0.98 T 0.19 0.70 
rs12968026 T 0.97 C 0.12 0.48 
rs3875089 T 1.00 C 0.16 0.84 
rs162008 C 0.99 T 0.19 0.93 
rs162007 G 1.00 A 0.20 0.80 
rs162003 C 1.00 T 0.08 0.86 
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Complete SNP list for AQP1 and AQP4 prior to LD pruning (cont.). 
SNP Ref Major Allele Call Rate Minor Allele MAF HWE-p 
AQP4 cont.           
rs3834826 - 0.99 C 0.40 0.29 
rs11662318 C 0.98 T 0.16 0.67 
rs151245 T 1.00 G 0.40 0.22 
rs151246 G 0.99 T 0.20 0.11 
rs2339214 G 0.98 A 0.48 0.63 
rs491148 A 1.00 G 0.17 0.11 
Final, post quality control, list of Aquaporin 1 (AQP1) and Aquaporin 4 (AQP4) 
single nucleotide polymorphisms (SNPs) selected for prior to Linkage 
Disequilibrium (LD) pruning. Nucleotides: guanine (G), cytosine (C), adenine (A), 
thymine (T). SNP Ref, the reference single nucleotide polymorphism (SNP) marker 
(rs). Exclusion criteria: Call rate < 95%; MAF, minor allele frequency < 5%; HWE-
p, Hardy-Weinberg equilibrium p-value < 0.05. 
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Appendix 5: Full results from linear regression analysis for the association of 
AQP1 and AQP4 genetic variants with brain Aβ burden. 
SNP Ref Additive† Dominant† Recessive† 
 Base* Adj* Base* Adj* Base* Adj* 
AQP1       
rs2075574 0.467 0.551 0.805 0.394 0.272 0.991 
rs1859838 0.256 0.561 0.156 0.712 0.868 0.441 
rs4419722 0.108 0.457 0.242 0.658 0.025 0.781 
rs1004317 0.794 0.422 0.741 0.770 0.346 0.255 
rs62449133 0.286 0.344 0.262 0.269 0.690 0.884 
rs2299905 0.495 0.286 0.327 0.260 0.858 0.652 
rs28362727 0.849 0.461 0.516 0.578 0.443 0.477 
rs11537660 0.586 0.313 0.920 0.528 0.036 0.312 
AQP4             
rs11661081 0.117 0.180 0.103 0.142 0.853 0.892 
rs9951307 0.113 0.169 0.134 0.095 0.327 0.751 
rs7240333 0.392 0.370 0.394 0.464 0.432 0.386 
rs68006382 0.502 0.378 0.505 0.251 0.773 0.690 
rs71353406 0.934 0.986 0.926 0.644 0.712 0.358 
rs12968026 0.146 0.636 0.129 0.637 0.737 0.840 
rs3875089 0.059 0.504 0.056 0.563 0.488 0.596 
rs162007 0.714 0.044 0.999 0.100 0.260 0.047 
rs162003 0.586 0.061 0.751 0.047 0.218 0.977 
rs151245 0.828 0.402 0.833 0.656 0.471 0.307 
rs151246 0.261 0.086 0.324 0.139 0.408 0.183 
rs2339214 0.576 0.988 0.539 0.769 0.768 0.743 
rs491148 0.430 0.453 0.235 0.585 0.473 0.393 
SNP Ref, reference single nucleotide polymorphism marker (rs); AQP1, Aquaporin 1; 
AQP4, Aquaporin 4; MAF, Minor allele frequency; M, Minor allele; m, major allele; 
MM, homozygote for the minor allele; Mm, heterozygote for the minor allele; mm, 
homozygote for the major allele. †Genetic models: Additive (homozygote for the 
minor allele (MM) vs heterozygote for the minor allele (Mm) vs homozygote for the 
major allele (mm)); Recessive (homozygote for the minor allele (MM) vs 
heterozygote/homozygote for the major allele (Mm/mm)); Dominant 
(heterozygote/homozygote for the minor allele (Mm or MM) vs homozygote for the 
major allele (mm)). *Statistical models: Base, base statistical model that is no 
covariates; Adj, Adjusted statistical model (covaries for: age, sex, Apolipoprotein E 
status (ε4-carrier/non-carrier) and clinical classification (Healthy control/Alzheimer’s 
disease). Nominally significant (p < 0.05; uncorrected) p-values bolded.  
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Appendix 6: Full results from linear regression analysis for the association of 
AQP1 and AQP4 genetic variants with PSQI Sleep Parameters. 
PSQI Sleep Parameter SNP Ref Additive† Dominant† Recessive† 
   Base* Adj* Base* Adj* Base* Adj* 
 AQP1       
PSQI total rs2075574 0.306 0.628 0.763 0.994 0.102 0.317 
 rs1859838 0.162 0.111 0.100 0.087 0.908 0.747 
 rs4419722 0.745 0.655 0.680 0.576 0.759 0.701 
 rs1004317 0.041 0.052 0.025 0.047 0.364 0.289 
 rs62449133 0.058 0.087 0.054 0.104 0.403 0.316 
 rs2299905 0.012 0.015 0.019 0.033 0.095 0.067 
 rs28362727 0.045 0.062 0.088 0.111 0.110 0.135 
 rs11537660 0.220 0.279 0.218 0.263 0.788 0.938 
Sleep Latency (mins) rs2075574 0.957 0.926 0.567 0.643 0.454 0.613 
 rs1859838 0.678 0.794 0.695 0.883 0.818 0.672 
 rs4419722 0.553 0.476 0.534 0.434 0.969 0.904 
 rs1004317 0.236 0.304 0.284 0.426 0.408 0.372 
 rs62449133 0.336 0.447 0.371 0.559 0.547 0.459 
 rs2299905 0.072 0.107 0.080 0.148 0.297 0.249 
 rs28362727 0.391 0.588 0.513 0.776 0.410 0.451 
 rs11537660 0.627 0.771 0.710 0.835 0.472 0.615 
Sleep Duration (hours) rs2075574 0.287 0.365 0.510 0.507 0.237 0.396 
 rs1859838 0.065 0.088 0.166 0.238 0.043 0.031 
 rs4419722 0.188 0.175 0.189 0.185 0.716 0.612 
 rs1004317 0.550 0.634 0.513 0.634 0.789 0.794 
 rs62449133 0.074 0.082 0.142 0.179 0.126 0.091 
 rs2299905 0.045 0.057 0.093 0.136 0.110 0.081 
 rs28362727 0.037 0.061 0.094 0.162 0.064 0.064 
 rs11537660 0.999 0.890 0.939 0.968 0.688 0.587 
Sleep Disturbances rs2075574 0.260 0.629 0.388 0.716 0.317 0.661 
 rs1859838 0.357 0.596 0.841 0.889 0.015 0.037 
 rs4419722 0.232 0.174 0.256 0.187 0.562 0.581 
 rs1004317 0.926 0.772 0.899 0.628 0.730 0.926 
 rs62449133 0.689 0.817 0.727 0.624 0.070 0.097 
 rs2299905 0.616 0.912 0.715 0.994 0.610 0.788 
 rs28362727 0.662 0.902 0.890 0.824 0.438 0.489 
 rs11537660 0.904 0.764 0.939 0.905 0.291 0.308 
Sleep Efficiency rs2075574 0.799 0.928 0.730 0.688 0.301 0.431 
 rs1859838 0.478 0.554 0.309 0.350 0.566 0.476 
 rs4419722 0.848 0.616 0.654 0.443 0.264 0.290 
 rs1004317 0.488 0.665 0.287 0.499 0.917 0.942 
 rs62449133 0.730 0.771 0.916 0.953 0.496 0.521 
 rs2299905 0.868 0.777 0.671 0.807 0.254 0.275 
 rs28362727 0.729 0.794 0.342 0.398 0.364 0.358 
 rs11537660 0.573 0.719 0.535 0.651 0.880 0.692 
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Appendix 6: Full results from linear regression analysis for the association of 
AQP1 and AQP4 genetic variants with PSQI Sleep Parameters (cont.). 
PSQI Sleep Parameter SNP Ref Additive† Dominant† Recessive† 
   Base* Adj* Base* Adj* Base* Adj* 
 AQP1 (cont.)       
Daytime Dysfunction rs2075574 0.200 0.826 0.352 0.986 0.223 0.672 
 rs1859838 0.597 0.977 0.929 0.810 0.149 0.448 
 rs4419722 0.464 0.678 0.441 0.665 0.981 0.974 
 rs1004317 0.894 0.824 0.971 0.656 0.838 0.866 
 rs62449133 0.948 0.748 0.987 0.661 0.890 0.926 
 rs2299905 0.812 0.530 0.683 0.404 0.859 0.974 
 rs28362727 0.796 0.535 0.938 0.847 0.643 0.268 
 rs11537660 0.655 0.968 0.565 0.828 0.576 0.362 
  AQP4             
PSQI Total rs11661081 0.443 0.465 0.412 0.407 0.947 0.770 
 rs9951307 0.730 0.794 0.836 0.627 0.297 0.189 
 rs7240333 0.539 0.323 0.387 0.205 0.593 0.636 
 rs68006382 0.284 0.360 0.251 0.348 0.779 0.722 
 rs71353406 0.130 0.100 0.042 0.045 0.856 0.871 
 rs12968026 0.593 0.836 0.647 0.466 .0006‡ 0.002‡ 
 rs3875089 0.494 0.442 0.940 0.931 0.012 0.021 
 rs162007 0.761 0.545 0.968 0.723 0.374 0.338 
 rs162003 0.926 0.802 0.747 0.999 0.307 0.226 
 rs151245 0.698 0.697 0.928 0.787 0.396 0.277 
 rs151246 0.572 0.636 0.407 0.366 0.715 0.424 
 rs2339214 0.775 0.788 0.554 0.416 0.867 0.656 
 rs491148 0.550 0.732 0.770 0.973 0.287 0.259 
Sleep Latency (minutes) rs11661081 0.664 0.676 0.562 0.568 0.544 0.526 
 rs9951307 0.777 0.756 0.883 0.984 0.721 0.536 
 rs7240333 0.787 0.822 0.848 0.713 0.728 0.724 
 rs68006382 0.171 0.170 0.189 0.182 0.456 0.470 
 rs71353406 0.384 0.604 0.863 0.908 0.084 0.314 
 rs12968026 0.283 0.340 0.277 0.372 0.708 0.571 
 rs3875089 0.123 0.195 0.098 0.187 0.770 0.648 
 rs162007 0.568 0.400 0.656 0.460 0.562 0.545 
 rs162003 0.989 0.754 0.951 0.708 0.832 0.857 
 rs151245 0.935 0.973 0.843 0.925 0.913 0.852 
 rs151246 0.744 0.797 0.756 0.853 0.854 0.776 
 rs2339214 0.876 0.630 0.925 0.744 0.868 0.636 
 rs491148 0.484 0.583 0.594 0.732 0.457 0.438 
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Appendix 6: Full results from linear regression analysis for the association of 
AQP1 and AQP4 genetic variants with PSQI Sleep Parameters (cont.). 
PSQI Sleep Parameter SNP Ref Additive† Dominant† Recessive† 
   Base* Adj* Base* Adj* Base* Adj* 
  AQP4 cont.             
Sleep Duration (hours) rs11661081 0.471 0.523 0.506 0.564 0.648 0.641 
 rs9951307 0.722 0.551 0.555 0.695 0.096 0.062 
 rs7240333 0.588 0.406 0.410 0.242 0.507 0.469 
 rs68006382 0.991 0.750 0.824 0.867 0.546 0.601 
 rs71353406 0.730 0.428 0.488 0.315 0.642 0.993 
 rs12968026 0.411 0.482 0.163 0.204 0.124 0.126 
 rs3875089 0.771 0.658 0.996 0.860 0.341 0.339 
 rs162007 0.590 0.689 0.301 0.381 0.205 0.213 
 rs162003 0.842 0.979 0.598 0.729 0.149 0.152 
 rs151245 0.854 0.891 0.650 0.822 0.798 0.580 
 rs151246 0.626 0.751 0.575 0.597 0.967 0.719 
 rs2339214 0.769 0.693 0.795 0.726 0.827 0.767 
 rs491148 0.510 0.623 0.530 0.662 0.713 0.720 
Sleep Disturbances rs11661081 0.343 0.333 0.405 0.397 0.411 0.400 
 rs9951307 0.563 0.418 0.627 0.653 0.660 0.326 
 rs7240333 0.939 0.812 0.859 0.996 0.410 0.398 
 rs68006382 0.097 0.146 0.034 0.077 0.672 0.902 
 rs71353406 0.165 0.181 0.112 0.137 0.733 0.684 
 rs12968026 0.886 0.548 0.848 0.576 0.919 0.716 
 rs3875089 0.904 0.979 0.968 0.996 0.774 0.920 
 rs162007 0.674 0.748 0.382 0.429 0.236 0.209 
 rs162003 0.727 0.643 0.849 0.791 0.411 0.304 
 rs151245 0.368 0.361 0.159 0.181 0.861 0.958 
 rs151246 0.466 0.708 0.442 0.554 0.818 0.726 
 rs2339214 0.140 0.093 0.287 0.126 0.171 0.226 
 rs491148 0.076 0.188 0.084 0.206 0.382 0.483 
Sleep Efficiency rs11661081 0.511 0.591 0.732 0.830 0.083 0.084 
 rs9951307 0.308 0.325 0.272 0.289 0.693 0.708 
 rs7240333 0.621 0.511 0.726 0.637 0.521 0.406 
 rs68006382 0.275 0.268 0.186 0.207 0.917 0.907 
 rs71353406 0.557 0.608 0.414 0.480 0.903 0.923 
 rs12968026 0.708 0.519 0.799 0.637 0.593 0.421 
 rs3875089 0.660 0.632 0.863 0.886 0.336 0.242 
 rs162007 0.704 0.742 0.461 0.492 0.360 0.354 
 rs162003 0.562 0.591 0.510 0.499 0.842 0.643 
 rs151245 0.832 0.873 0.761 0.830 0.996 0.986 
 rs151246 0.783 0.869 0.760 0.790 0.957 0.867 
 rs2339214 0.906 0.946 0.827 0.946 0.968 0.845 
 rs491148 0.663 0.887 0.510 0.701 0.687 0.571 
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Appendix 6: Full results from linear regression analysis for the association of 
AQP1 and AQP4 genetic variants with PSQI Sleep Parameters (cont.). 
PSQI Sleep Parameter SNP Ref Additive† Dominant† Recessive† 
   Base* Adj* Base* Adj* Base* Adj* 
  AQP4 cont.             
Daytime Dysfunction rs11661081 0.971 0.832 0.920 0.996 0.493 0.263 
 rs9951307 0.682 0.503 0.931 0.514 0.474 0.715 
 rs7240333 0.974 0.545 0.962 0.538 0.974 0.838 
 rs68006382 0.726 0.628 0.482 0.711 0.454 0.612 
 rs71353406 0.754 0.991 0.635 0.945 0.889 0.878 
 rs12968026 0.446 0.855 0.989 0.381 0.005 0.032 
 rs3875089 0.556 0.364 0.151 0.096 0.024 0.066 
 rs162007 0.271 0.116 0.139 0.044 0.477 0.476 
 rs162003 0.831 0.684 0.855 0.679 0.840 0.931 
 rs151245 0.531 0.247 0.920 0.442 0.296 0.246 
 rs151246 0.521 0.580 0.596 0.575 0.587 0.819 
 rs2339214 0.154 0.110 0.113 0.140 0.486 0.259 
 rs491148 0.801 0.489 0.843 0.369 0.801 0.816 
PSQI, Pittsburgh Sleep Quality Index Sleep Parameters: PSQI total, Sleep Latency 
(minutes), Sleep Duration (hours), Sleep Disturbances, Sleep Efficiency and Daytime 
Dysfunction. SNP Ref, reference single nucleotide polymorphism marker (rs); AQP1, 
Aquaporin 1; AQP4, Aquaporin 4. †Genetic models: Additive (homozygote for the 
minor allele (MM) vs heterozygote for the minor allele (Mm) vs homozygote for the 
major allele (Mm)); Recessive (homozygote for the minor allele (MM) vs 
heterozygote/homozygote for the major allele (Mm/mm)); Dominant 
(heterozygote/homozygote for the minor allele (Mm or MM) vs homozygote for the 
major allele (mm)). *Statistical models: Base, base statistical model that is no 
covariates; Adj, Adjusted statistical model (covaries for: age, sex, body mass index 
(BMI), geriatric depression scale (GDS) and a medical history of CVD). ‡Values 
significant after False Discovery Rate correction (q < 0.05). Values that reached 
nominal significance (p < 0.05, uncorrected) are bolded. 
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Appendix 7: Linear regression analyses for the association of PSQI Sleep 
parameters with brain Aβ burden. 
PSQI parameter               
Covariates β SE t Sig. R2 F Sig. 
Model summary (PSQI Total)       0.134 5.526 <0.001 
PSQI total 0.004 0.008 0.547 0.585       
Age 0.011 0.004 2.513 0.013       
BMI 0.004 0.006 0.730 0.466       
CVD risk -0.011 0.040 -0.269 0.788       
GDS -0.010 0.016 -0.617 0.538       
APOE ε4 0.305 0.058 5.265 <0.001       
Model summary (Sleep Latency)       0.160 6.824 <0.001 
Sleep latency 0.004 0.001 2.656 0.008       
Age 0.010 0.004 2.499 0.013       
BMI 0.004 0.006 0.741 0.459       
CVD risk -0.012 0.039 -0.314 0.754       
GDS -0.010 0.015 -0.684 0.495       
APOE ε4 0.306 0.057 5.375 <0.001       
Model summary (Sleep Duration)     0.133 5.483 <0.001 
Sleep duration 0.006 0.020 0.276 0.783       
Age 0.011 0.004 2.560 0.011       
BMI 0.004 0.006 0.718 0.473       
CVD risk -0.011 0.040 -0.279 0.781       
GDS -0.007 0.015 -0.448 0.654       
APOE ε4 0.302 0.058 5.197 <0.001       
Model summary (Sleep Disturbances)     0.136 5.656 <0.001 
Sleep disturbances -0.047 0.047 -0.988 0.325       
Age 0.010 0.004 2.520 0.012       
BMI 0.004 0.006 0.631 0.528       
CVD risk -0.004 0.040 -0.091 0.927       
GDS -0.005 0.015 -0.333 0.740       
APOE ε4 0.304 0.058 5.254 <0.001       
Model summary (Sleep Efficiency)     0.135 5.599 <0.001 
Sleep efficiency -0.027 0.033 -0.822 0.412       
Age 0.011 0.004 2.543 0.012       
BMI 0.004 0.006 0.041 0.534       
CVD risk -0.007 0.040 -0.177 0.859       
GDS -0.005 0.015 -0.351 0.726       
APOE ε4 0.303 0.058 5.249 <0.001       
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Appendix 7: Linear regression analyses for the association of PSQI Sleep 
parameters with brain Aβ burden (cont.). 
PSQI                
Covariates β SE t Sig. R2 F Sig. 
Model summary (Daytime Dysfunction)     0.111 5.584 <0.001 
Daytime dysfunction 0.031 0.040 0.776 0.439       
Age 0.010 0.004 2.446 0.015       
BMI 0.004 0.006 0.730 0.466       
CVD risk -0.014 0.040 -0.345 0.731       
GDS -0.012 0.016 -0.742 0.459       
APOE ε4 0.304 0.058 5.250 <0.001       
PSQI, Pittsburgh Sleep Quality Index; β, coefficient of predictors; SE, standard error; 
t, Student’s t distribution test statistic; F, Fisher’s F ratio/ distribution; Sig, 
Significance (p-value); R2, coefficient of multiple determination; BMI, Body Mass 
Index; GDS, Geriatric Depression Scale; CVD risk, cardiovascular disease risk; 
APOE ε4, Apolipoprotein E ε4 allele carriage (presence/absence). 
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Appendix 8: Moderation Analysis for AQP1 and AQP4 SNPs on PSQI total. 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1                           
Model summary: rs2075574   0.135 <0.001           0.136 <0.001   
Age 0.010 0.004 0.014         0.011 0.004 0.012       
BMI 0.005 0.006 0.441         0.005 0.006 0.419       
CVD risk -0.001 0.040 0.783         -0.008 0.040 0.837       
GDS -0.010 0.016 0.559         -0.010 0.016 0.537       
APOE ε4 0.308 0.059 <0.001         0.307 0.058 <0.001       
rs2075574 -0.014 0.100 0.888         -0.010 0.148 0.944       
PSQI total 0.001 0.012 0.936         0.003 0.009 0.701       
INT 0.006 0.015 0.711     0.001  0.011 0.024 0.652     0.001 
Model summary: rs1859838   0.137 <0.001           0.139 <0.001   
Age 0.011 0.004 0.011         0.011 0.004 0.012       
BMI 0.005 0.006 0.426         0.003 0.006 0.609       
CVD risk -0.012 0.040 0.762         -0.011 0.040 0.785       
GDS -0.010 0.016 0.551         -0.009 0.016 0.557       
APOE ε4 0.310 0.059 <0.001         0.310 0.058 <0.001       
rs1859838 -0.076 0.105 0.469         -0.144 0.216 0.504       
PSQI total -0.001 0.010 0.962         0.004 0.008 0.659       
INT 0.014 0.016 0.400     0.003  0.004 0.037 0.916     <0.001 
Model summary: rs4419722   0.134 <0.001           0.162 <0.001   
Age 0.011 0.004 0.013         0.011 0.004 0.012       
BMI 0.004 0.006 0.477         0.004 0.006 0.517       
CVD risk -0.011 0.040 0.788         -0.001 0.039 0.974       
GDS -0.010 0.016 0.548         -0.016 0.016 0.314       
APOE ε4 0.304 0.058 <0.001         0.289 0.058 <0.001       
rs4419722 0.025 0.126 0.820         0.040 0.524 0.939       
PSQI total 0.006 0.009 0.528         0.005 0.008 0.510       
INT -0.007 0.020 0.727     0.001  0.126 0.102 0.218     0.006 
Model summary: rs1004317   0.139 <0.001           0.137 <0.001   
Age 0.011 0.004 0.011         0.011 0.004 0.013       
BMI 0.004 0.006 0.515         0.004 0.006 0.542       
CVD risk -0.011 0.040 0.784         -0.010 0.040 0.807       
GDS -0.010 0.016 0.565         -0.010 0.016 0.538       
APOE ε4 0.307 0.058 <0.001         0.309 0.058 <0.001       
rs1004317 0.011 0.108 0.919         -0.126 0.149 0.398       
PSQI total 0.012 0.014 0.415         0.002 0.009 0.795       
INT -0.011 0.017 0.529     0.002  0.018 0.024 0.456     0.002 
Model summary: rs62449133   0.142 <0.001           0.149 <0.001   
Age 0.010 0.004 0.016         0.010 0.004 0.015       
BMI 0.004 0.006 0.490         0.003 0.006 0.643       
CVD risk -0.002 0.040 0.957         0.001 0.040 0.999       
GDS -0.009 0.016 0.560         -0.010 0.016 0.511       
APOE ε4 0.318 0.059 <0.001         0.328 0.060 <0.001       
rs62449133 -0.028 0.100 0.782         -0.226 0.188 0.233       
PSQI total -0.001 0.011 0.991         0.001 0.008 0.870       
INT 0.007 0.015 0.648     0.001  0.025 0.029 0.388     0.003 
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Appendix 8: Moderation Analysis for AQP1 and AQP4 SNPs on PSQI total 
(cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1 cont.                           
Model summary: rs2299905   0.144 <0.001           0.152 <0.001   
Age 0.010 0.004 0.021         0.011 0.004 0.014       
BMI 0.004 0.006 0.544         0.002 0.006 0.735       
CVD risk -0.004 0.040 0.930         -0.003 0.040 0.946       
GDS -0.009 0.016 0.561         -0.010 0.016 0.551       
APOE ε4 0.320 0.059 <0.001         0.337 0.060 <0.001       
rs2299905 -0.030 0.101 0.766         -0.290 0.181 0.110       
PSQI total 0.005 0.012 0.712         0.001 0.008 0.983       
INT -0.002 0.016 0.884     <0.001  0.032 0.028 0.250     0.006 
Model summary: rs28362727   0.134 <0.001           0.129 <0.001   
Age 0.011 0.004 0.009         0.011 0.004 0.009       
BMI 0.006 0.006 0.353         0.005 0.006 0.407       
CVD risk -0.001 0.040 0.998         -0.001 0.040 0.984       
GDS -0.004 0.016 0.804         -0.004 0.016 0.792       
APOE ε4 0.289 0.058 <0.001         0.288 0.059 <0.001       
rs28362727 -0.110 0.097 0.262         -0.048 0.170 0.778       
PSQI total -0.007 0.012 0.573         0.002 0.008 0.816       
INT 0.016 0.015 0.277     0.005   0.001 0.032 0.966     <0.001 
Model summary: rs11537660   0.147 <0.001           N/A     
Age 0.011 0.004 0.010                     
BMI 0.005 0.006 0.438                     
CVD risk -0.015 0.040 0.700                     
GDS -0.010 0.016 0.519                     
APOE ε4 0.305 0.058 <0.001                     
rs11537660 -0.091 0.143 0.526                     
PSQI total 0.006 0.009 0.505                     
INT -0.006 0.022 0.782     <0.001              
AQP4                           
Model summary: rs11661081   0.136 <0.001           0.135 <0.001   
Age 0.011 0.004 0.013         0.010 0.004 0.014       
BMI 0.004 0.006 0.496         0.004 0.006 0.469       
CVD risk -0.009 0.040 0.820         -0.007 0.040 0.866       
GDS -0.010 0.016 0.526         -0.010 0.016 0.524       
APOE ε4 0.305 0.058 <0.001         0.303 0.058 <0.001       
rs11661081 0.084 0.142 0.554         -0.691 1.820 0.704       
PSQI total 0.007 0.009 0.449         0.005 0.008 0.579       
INT -0.017 0.023 0.465     0.002   0.082 0.257 0.750     <0.001 
Model summary rs9951307  0.151 <0.001           0.142 <0.001   
Age 0.010 0.004 0.015         0.011 0.004 0.011       
BMI 0.005 0.006 0.423         0.006 0.006 0.362       
CVD risk -0.009 0.039 0.818         -0.007 0.040 0.863       
GDS -0.008 0.016 0.636         -0.011 0.016 0.490       
APOE ε4 0.306 0.058 <0.001         0.301 0.058 <0.001       
rs9951307 -0.200 0.101 0.049         -0.241 0.177 0.174       
PSQI total -0.010 0.013 0.480         0.002 0.009 0.780       
INT 0.022 0.016 0.172     0.008   0.025 0.024 0.286     0.005 
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Appendix 8: Moderation Analysis for AQP1 and AQP4 SNPs on PSQI total 
(cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs7240333   0.151 <0.001           0.152 <0.001   
Age 0.010 0.004 0.016         0.011 0.004 0.011       
BMI 0.004 0.006 0.518         0.004 0.006 0.528       
CVD risk -0.004 0.040 0.915         -0.003 0.040 0.947       
GDS -0.012 0.016 0.441         -0.014 0.016 0.376       
APOE ε4 0.329 0.059 <0.001         0.320 0.058 <0.001       
rs7240333 0.025 0.125 0.842         0.252 0.351 0.473       
PSQI total 0.005 0.009 0.562         0.007 0.008 0.390       
INT 0.005 0.020 0.823     <0.001  -0.050 0.053 0.348     0.004 
Model summary: rs68006382   0.140 <0.001           0.148 <0.001   
Age 0.011 0.004 0.012         0.010 0.004 0.019       
BMI 0.006 0.006 0.340         0.005 0.006 0.409       
CVD risk -0.005 0.040 0.903         -0.009 0.040 0.823       
GDS -0.009 0.016 0.574         -0.008 0.016 0.624       
APOE ε4 0.302 0.059 <0.001         0.307 0.059 <0.001       
rs68006382 0.040 0.113 0.725         0.475 0.304 0.119       
PSQI total 0.006 0.009 0.528         0.007 0.008 0.396       
INT 0.001 0.019 0.978     <0.001  -0.082 0.061 0.179     0.008 
Model summary: rs71353406   0.136 <0.001           0.150 <0.001   
Age 0.010 0.004 0.017         0.010 0.004 0.023       
BMI 0.005 0.006 0.397         0.005 0.006 0.398       
CVD risk -0.010 0.040 0.796         -0.014 0.040 0.727       
GDS -0.009 0.016 0.601         -0.011 0.016 0.512       
APOE ε4 0.303 0.059 <0.001         0.303 0.059 <0.001       
rs71353406 0.026 0.101 0.796         0.450 0.212 0.035       
PSQI total 0.004 0.011 0.682         0.009 0.008 0.294       
INT 0.004 0.016 0.822     <0.001  -0.065 0.036 0.073     0.013 
Model summary: rs12968026   0.136 <0.001           0.128 <0.001   
Age 0.011 0.004 0.008         0.011 0.004 0.013       
BMI 0.005 0.006 0.419         0.004 0.006 0.511       
CVD risk -0.016 0.041 0.699         -0.009 0.040 0.827       
GDS -0.009 0.016 0.584         -0.007 0.016 0.650       
APOE ε4 0.283 0.058 <0.001         0.284 0.059 <0.001       
rs12968026 -0.003 0.116 0.981         -0.112 0.464 0.810       
PSQI total 0.003 0.009 0.738         0.006 0.008 0.453       
INT 0.013 0.018 0.452     0.002   0.009 0.045 0.846     <0.001 
Model summary: rs3875089   0.138 <0.001           0.142 <0.001   
Age 0.011 0.004 0.013         0.011 0.004 0.013       
BMI 0.005 0.006 0.445         0.005 0.006 0.440       
CVD risk -0.010 0.040 0.812         -0.010 0.040 0.805       
GDS -0.010 0.016 0.527         -0.009 0.016 0.591       
APOE ε4 0.300 0.058 <0.001         0.309 0.058 <0.001       
rs3875089 0.044 0.104 0.673         0.457 0.317 0.151       
PSQI total 0.004 0.010 0.678         0.005 0.008 0.518       
INT 0.002 0.016 0.893     <0.001  -0.041 0.035 0.235     0.006 
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Appendix 8: Moderation Analysis for AQP1 and AQP4 SNPs on PSQI total 
(cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs162007   0.134 <0.001           0.135 <0.001   
Age 0.010 0.004 0.014         0.010 0.004 0.016       
BMI 0.004 0.006 0.480         0.004 0.006 0.473       
CVD risk -0.010 0.040 0.807         -0.011 0.040 0.790       
GDS -0.010 0.016 0.543         -0.011 0.016 0.511       
APOE ε4 0.305 0.058 <0.001         0.306 0.058 <0.001       
rs162007 -0.020 0.105 0.847         -0.264 0.608 0.665       
PSQI total 0.003 0.010 0.737         0.005 0.008 0.574       
INT 0.004 0.017 0.819     <0.001  0.027 0.089 0.762     <0.001 
Model summary: rs162003   0.138 <0.001           N/A     
Age 0.010 0.004 0.015                     
BMI 0.004 0.006 0.555                     
CVD risk -0.009 0.040 0.821                     
GDS -0.010 0.016 0.544                     
APOE ε4 0.303 0.058 <0.001                     
rs162003 -0.122 0.137 0.374                     
PSQI total 0.002 0.009 0.783                     
INT 0.011 0.024 0.650     0.001               
Model summary: rs151245   0.134 <0.001           0.150 <0.001   
Age 0.011 0.004 0.014         0.010 0.004 0.017       
BMI 0.004 0.006 0.468         0.004 0.006 0.504       
CVD risk -0.011 0.040 0.791         -0.004 0.040 0.916       
GDS -0.010 0.016 0.541         -0.011 0.016 0.477       
APOE ε4 0.304 0.058 <0.001         0.310 0.058 <0.001       
rs151245 0.008 0.105 0.943         0.263 0.132 0.048       
PSQI total 0.005 0.014 0.713         0.011 0.009 0.212       
INT -0.001 0.017 0.944     <0.001  -0.035 0.019 0.070     0.013 
Model summary: rs151246   0.148 <0.001           0.141 <0.001   
Age 0.011 0.004 0.010         0.011 0.004 0.011       
BMI 0.005 0.006 0.369         0.004 0.006 0.465       
CVD risk -0.018 0.040 0.648         -0.012 0.040 0.767       
GDS -0.013 0.016 0.416         -0.010 0.016 0.525       
APOE ε4 0.305 0.058 <0.001         0.308 0.058 <0.001       
rs151246 0.124 0.102 0.224         0.223 0.269 0.408       
PSQI total 0.016 0.010 0.122         0.006 0.008 0.461       
INT -0.028 0.016 0.079     0.013   -0.050 0.041 0.226     0.006 
Model summary: rs2339214   0.140 <0.001           0.194 <0.001   
Age 0.010 0.004 0.028         0.010 0.004 0.019       
BMI 0.005 0.006 0.440         0.005 0.006 0.442       
CVD risk -0.007 0.040 0.854         -0.007 0.041 0.863       
GDS -0.008 0.016 0.633         -0.007 0.016 0.666       
APOE ε4 0.303 0.059 <0.001         0.303 0.059 <0.001       
rs2339214 -0.136 0.111 0.221         0.194 0.125 0.123       
PSQI total -0.012 0.014 0.395         0.009 0.009 0.344       
INT 0.023 0.017 0.170     0.008   -0.027 0.019 0.169     0.008 
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Appendix 8: Moderation Analysis for AQP1 and AQP4 SNPs on PSQI total 
(cont.). 
      Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs491148   0.144 <0.001           0.148 <0.001   
Age 0.011 0.004 0.009         0.012 0.004 0.008       
BMI 0.005 0.006 0.387         0.005 0.006 0.448       
CVD risk -0.020 0.041 0.624         -0.013 0.040 0.746       
GDS -0.014 0.016 0.396         -0.009 0.016 0.575       
APOE ε4 0.310 0.058 <0.001         0.316 0.058 <0.001       
rs491148 -0.010 0.108 0.926         0.417 0.279 0.137       
PSQI total 0.001 0.010 0.968         0.004 0.008 0.645       
INT 0.015 0.017 0.372     0.003   -0.027 0.033 0.415     0.003 
Model summary statistics for all Aquaporin 1 (AQP1) and Aquaporin 4 (AQP4) 
reference single nucleotide polymorphism (SNP) markers (rs). †Genetic models: 
Dominant (heterozygote/homozygote for the minor allele (Mm or MM) vs 
homozygote for the major allele (mm)), Recessive (homozygote for the minor allele 
(MM) vs heterozygote/homozygote for the major allele (Mm/mm)); β, Coefficient of 
predictors: SE, standard error; Sig, p-value; R2, coefficient of multiple determination, 
ΔR2, multiple correlation coefficient (R) squared change; BMI, Body Mass Index; 
CVD risk, cardiovascular disease risk; GDS, Geriatric Depression Scale; APOE, 
Apolipoprotein E ε4 allele carriage (presence/absence); INT, Interaction (PSQI total * 
model summary SNP). Models where the interaction term (INT) resulted in a 
statistically significant R2-change (p < 0.05) are indicated (bolded). If a model could 
not run due to that SNP variable being a constant then not applicable (N/A) is recorded 
for that model. 
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Appendix 9: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Latency. 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1                           
Model summary: rs2075574   0.161 <0.001           0.170 <0.001   
Age 0.010 0.004 0.014         0.011 0.004 0.012       
BMI 0.005 0.006 0.447         0.004 0.006 0.513       
CVD risk -0.013 0.040 0.744         -0.007 0.039 0.863       
GDS -0.001 0.015 0.551         -0.010 0.015 0.502       
APOE ε4 -0.009 0.059 <0.001         0.313 0.057 <0.001       
rs2075574 0.035 0.076 0.641         -0.064 0.107 0.552       
Latency 0.005 0.003 0.105         0.003 0.002 0.034       
INT -0.002 0.004 0.670     0.001   0.007 0.005 0.162     0.008 
Model summary: rs1859838   0.160 <0.001           0.163 <0.001   
Age 0.010 0.004 0.014         0.010 0.004 0.013       
BMI 0.004 0.006 0.463         0.003 0.006 0.572       
CVD risk -0.012 0.040 0.755         -0.013 0.039 0.744       
GDS -0.010 0.015 0.497         -0.010 0.015 0.506       
APOE ε4 0.307 0.058 <0.001         0.310 0.057 <0.001       
rs1859838 -0.009 0.074 0.904         -0.085 0.172 0.621       
Latency 0.004 0.002 0.067         0.004 0.002 0.011       
INT 0.001 0.003 0.930     <0.001  -0.002 0.012 0.892     <0.001 
Model summary: rs4419722   0.161 <0.001           0.188 <0.001   
Age 0.010 0.004 0.013         0.010 0.004 0.012       
BMI 0.004 0.006 0.454         0.004 0.006 0.513       
CVD risk -0.010 0.039 0.794         -0.003 0.039 0.940       
GDS -0.010 0.015 0.499         -0.016 0.015 0.286       
APOE ε4 0.306 0.057 <0.001         0.290 0.057 <0.001       
rs4419722 -0.051 0.010 0.603         -0.359 3.274 0.275       
Latency 0.004 0.002 0.020         0.004 0.001 0.007       
INT 0.003 0.005 0.553     0.001   0.258 0.201 0.201     0.006 
Model summary: rs1004317   0.163 <0.001           0.163 <0.001   
Age 0.010 0.004 0.013         0.010 0.004 0.016       
BMI 0.004 0.006 0.500         0.005 0.006 0.413       
CVD risk -0.012 0.040 0.755         -0.015 0.039 0.700       
GDS -0.010 0.015 0.508         -0.011 0.015 0.477       
APOE ε4 0.308 0.058 <0.001         0.306 0.057 <0.001       
rs1004317 -0.030 0.073 0.685         0.081 0.120 0.504       
Latency 0.004 0.002 0.067         0.004 0.002 0.007       
INT -0.001 0.003 0.802     <0.001  -0.007 0.008 0.359     0.003 
Model summary: rs62449133   0.162 <0.001           0.171 <0.001   
Age 0.010 0.004 0.019         0.010 0.004 0.019       
BMI 0.004 0.006 0.495         0.003 0.006 0.587       
CVD risk -0.002 0.039 0.965         -0.001 0.039 0.985       
GDS -0.010 0.015 0.498         -0.010 0.015 0.484       
APOE ε4 0.313 0.059 <0.001         0.322 0.059 <0.001       
rs62449133 0.025 0.071 0.726         0.102 0.149 0.493       
Latency 0.004 0.002 0.070         0.004 0.002 0.018       
INT -0.001 0.003 0.737     0.001   -0.016 0.011 0.145     0.009 
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Appendix 9: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Latency 
(cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1 cont.                           
Model summary: rs2299905   0.164 <0.001           0.171 <0.001   
Age 0.010 0.004 0.022         0.010 0.004 0.021       
BMI 0.004 0.006 0.551         0.003 0.006 0.648       
CVD risk -0.004 0.040 0.918         -0.004 0.039 0.915       
GDS -0.010 0.015 0.511         -0.009 0.015 0.562       
APOE ε4 0.319 0.058 <0.001         0.325 0.058 <0.001       
rs2299905 -0.032 0.381 0.648         0.061 0.148 0.683       
Latency 0.004 0.002 0.098         0.003 0.002 0.023       
INT -0.001 0.003 0.845     <0.001  -0.013 0.010 0.196     0.007 
Model summary: rs28362727   0.167 <0.001           0.184 <0.001   
Age 0.011 0.004 0.006         0.011 0.004 0.011       
BMI 0.006 0.006 0.326         0.003 0.006 0.661       
CVD risk -0.004 0.039 0.915         <0.001 0.039 0.995       
GDS -0.005 0.015 0.716         -0.005 0.015 0.751       
APOE ε4 0.300 0.057 <0.001         0.306 0.057 <0.001       
rs28362727 -0.127 0.069 0.068         -0.298 0.122 0.015       
Latency -0.001 0.002 0.754         0.002 0.002 0.170       
INT 0.006 0.003 0.034     0.018   0.017 0.006 0.003     0.035 
Model summary: rs11537660   0.178 <0.001           N/A     
Age 0.010 0.004 0.014                     
BMI 0.004 0.006 0.454                     
CVD risk -0.016 0.039 0.683                     
GDS -0.010 0.015 0.485                     
APOE ε4 0.308 0.057 <0.001                     
rs11537660 -0.240 0.122 0.050                     
Latency 0.003 0.002 0.023                     
INT 0.008 0.006 0.237     0.005               
AQP4                           
Model summary: rs11661081   0.169 <0.001           0.162 <0.001   
Age 0.010 0.004 0.019         0.010 0.004 0.015       
BMI 0.004 0.006 0.502         0.004 0.006 0.467       
CVD risk -0.011 0.039 0.785         -0.008 0.040 0.839       
GDS -0.010 0.015 0.504         -0.011 0.015 0.466       
APOE ε4 0.307 0.057 <0.001         0.304 0.057 <0.001       
rs11661081 0.111 0.099 0.262         -0.144 0.397 0.717       
Latency 0.005 0.002 0.003         0.004 0.002 0.008       
INT -0.007 0.005 0.132     0.009   -0.001 0.008 0.927     <0.001 
Model summary: rs9951307   0.186 <0.001           0.166 <0.001   
Age 0.010 0.004 0.019         0.010 0.004 0.013       
BMI 0.003 0.006 0.607         0.004 0.006 0.752       
CVD risk -0.013 0.039 0.741         -0.012 0.039 0.752       
GDS -0.007 0.015 0.658         -0.010 0.015 0.485       
APOE ε4 0.312 0.056 <0.001         0.309 0.057 <0.001       
rs9951307 0.015 0.070 0.831         0.025 0.123 0.837       
Latency 0.008 0.002 0.001         0.004 0.002 0.006       
INT -0.006 0.003 0.048     0.015   -0.005 0.006 0.347     0.004 
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Appendix 9: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Latency 
(cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs7240333   0.184 <0.001           0.182 <0.001   
Age 0.010 0.004 0.015         0.011 0.004 0.010       
BMI 0.004 0.006 0.554         0.004 0.006 0.518       
CVD risk -0.008 0.039 0.845         -0.004 0.039 0.921       
GDS -0.011 0.015 0.473         -0.013 0.015 0.378       
APOE ε4 0.328 0.058 <0.001         0.319 0.057 <0.001       
rs7240333 -0.027 0.081 0.736         0.251 0.297 0.398       
Latency 0.003 0.002 0.111         0.004 0.001 0.005       
INT 0.004 0.003 0.218     0.006   -0.016 0.013 0.225     0.006 
Model summary: rs68006382   0.174 <0.001           0.178 <0.001   
Age 0.011 0.004 0.012         0.010 0.004 0.017       
BMI 0.005 0.006 0.406         0.005 0.006 0.460       
CVD risk -0.001 0.040 0.980         -0.008 0.040 0.847       
GDS -0.008 0.015 0.582         -0.009 0.015 0.536       
APOE ε4 0.301 0.058 <0.001         0.309 0.058 <0.001       
rs68006382 -0.036 0.083 0.667         -0.113 0.203 0.578       
Latency 0.003 0.002 0.062         0.004 0.002 0.019       
INT 0.004 0.004 0.231     0.006   0.013 0.008 0.108     0.011 
Model summary: rs71353406   0.180 <0.001           0.163 <0.001   
Age 0.010 0.004 0.023         0.010 0.004 0.018       
BMI 0.004 0.006 0.556         0.005 0.006 0.401       
CVD risk -0.008 0.039 0.833         -0.012 0.040 0.769       
GDS -0.006 0.015 0.692         -0.009 0.015 0.552       
APOE ε4 0.298 0.058 <0.001         0.307 0.058 <0.001       
rs71353406 -0.063 0.069 0.362         0.050 0.158 0.754       
Latency 0.001 0.002 0.688         0.004 0.002 0.022       
INT 0.006 0.003 0.030     0.019   0.003 0.006 0.675     0.001 
Model summary: rs12968026   0.176 <0.001           0.157 <0.001   
Age 0.010 0.004 0.011         0.011 0.004 0.012       
BMI 0.005 0.006 0.414         0.004 0.006 0.515       
CVD risk -0.016 0.039 0.683         -0.009 0.039 0.816       
GDS -0.006 0.015 0.687         -0.007 0.015 0.647       
APOE ε4 0.287 0.057 <0.001         0.287 0.058 <0.001       
rs12968026 -0.041 0.083 0.620         -0.145 0.432 0.738       
Latency 0.002 0.002 0.145         0.004 0.001 0.007       
INT 0.006 0.003 0.056     0.015   0.012 0.029 0.687     0.001 
Model summary: rs3875089  0.184 <0.001      0.165 <0.001  
Age 0.010 0.004 0.019         0.011 0.004 0.010       
BMI 0.005 0.006 0.400         0.004 0.006 0.458       
CVD risk -0.016 0.039 0.683         -0.017 0.040 0.660       
GDS -0.010 0.015 0.501         -0.012 0.015 0.426       
APOE ε4 0.310 0.057 <0.001         0.313 0.058 <0.001       
rs3875089 -0.050 0.074 0.497         -0.005 0.416 0.990       
Latency 0.002 0.002 0.248         0.004 0.002 0.008       
INT 0.007 0.003 0.028     0.019   0.010 0.027 0.706     0.001 
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Appendix 9: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Latency 
(cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs162007   0.163 <0.001           0.161 <0.001   
Age 0.010 0.004 0.015         0.010 0.004 0.015       
BMI 0.004 0.006 0.481         0.004 0.006 0.464       
CVD risk -0.012 0.039 0.753         -0.013 0.039 0.745       
GDS -0.009 0.015 0.557         -0.010 0.015 0.498       
APOE ε4 0.307 0.057 <0.001         0.306 0.057 <0.001       
rs162007 0.041 0.071 0.564         -0.071 0.263 0.786       
Latency 0.005 0.002 0.010         0.004 0.002 0.010       
INT -0.003 0.003 0.364     0.003   0.001 0.018 0.963     <0.001 
Model summary: rs162003   0.168 <0.001           N/A     
Age 0.009 0.004 0.024                     
BMI 0.003 0.006 0.560                     
CVD risk -0.011 0.039 0.784                     
GDS -0.009 0.015 0.558                     
APOE ε4 0.302 0.057 <0.001                     
rs162003 -0.007 0.092 0.941                     
Latency 0.005 0.092 0.941                     
INT -0.004 0.004 0.286     0.005               
Model summary: rs151245   0.165 <0.001           0.163 <0.001   
Age 0.010 0.004 0.013         0.011 0.004 0.011       
BMI 0.004 0.006 0.498         0.004 0.006 0.504       
CVD risk -0.012 0.039 0.763         -0.012 0.039 0.754       
GDS -0.009 0.015 0.543         -0.012 0.015 0.439       
APOE ε4 0.300 0.057 <0.001         0.308 0.057 <0.001       
rs151245 0.065 0.079 0.414         0.069 0.107 0.524       
Latency 0.007 0.003 0.032         0.004 0.002 0.011       
INT -0.004 0.004 0.275     0.005   -0.001 0.005 0.928     <0.001 
Model summary: rs151246   0.201 <0.001           0.165 <0.001   
Age 0.009 0.004 0.023         0.011 0.004 0.012       
BMI 0.004 0.006 0.525         0.005 0.006 0.448       
CVD risk -0.015 0.038 0.699         -0.014 0.039 0.731       
GDS -0.007 0.015 0.654         -0.011 0.015 0.469       
APOE ε4 0.303 0.056 <0.001         0.310 0.057 <0.001       
rs151246 0.117 0.070 0.096         0.064 0.175 0.716       
Latency 0.009 0.002 <0.001         0.004 0.002 0.006       
INT -0.009 0.003 0.002     0.039   -0.008 0.007 0.294     0.004 
Model summary: rs2339214   0.164 <0.001           0.165 <0.001   
Age 0.010 0.004 0.024         0.010 0.004 0.023       
BMI 0.005 0.006 0.435         0.005 0.006 0.423       
CVD risk -0.012 0.040 0.768         -0.005 0.040 0.896       
GDS -0.007 0.015 0.638         -0.007 0.015 0.642       
APOE ε4 0.306 0.058 <0.001         0.301 0.058 <0.001       
rs2339214 -0.059 0.078 0.451         -0.029 0.092 0.758       
Latency 0.002 0.003 0.506         0.003 0.002 0.039       
INT 0.003 0.003 0.342     0.004   0.004 0.004 0.368     0.003 
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Appendix 9: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Latency 
(cont.) 
      Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs491148   0.185 <0.001           0.193 <0.001   
Age 0.010 0.004 0.016         0.012 0.004 0.005       
BMI 0.005 0.006 0.360         0.005 0.006 0.393       
CVD risk -0.018 0.039 0.650         -0.017 0.039 0.657       
GDS -0.011 0.015 0.450         -0.011 0.015 0.459       
APOE ε4 0.316 0.057 <0.001         0.320 0.057 <0.001       
rs491148 -0.035 0.075 0.639         -0.333 0.271 0.220       
Latency 0.002 0.002 0.639         0.004 0.001 0.014       
INT 0.007 0.003 0.036     0.017   0.035 0.015 0.022     0.020 
Model summary statistics for all Aquaporin 1 (AQP1) and Aquaporin 4 (AQP4) 
reference single nucleotide polymorphism (SNP) markers (rs). †Genetic models: 
Dominant (heterozygote/homozygote for the minor allele (Mm or MM) vs 
homozygote for the major allele (mm)), Recessive (homozygote for the minor allele 
(MM) vs heterozygote/homozygote for the major allele (Mm/mm)); β, Coefficient of 
predictors: SE, standard error; Sig, p-value; R2, coefficient of multiple determination, 
ΔR2, multiple correlation coefficient (R) squared change; BMI, Body Mass Index; 
CVD risk, cardiovascular disease risk; GDS, Geriatric Depression Scale; APOE, 
Apolipoprotein E ε4 allele carriage (presence/absence); INT, Interaction (Sleep 
latency * model summary SNP). Models where the interaction term (INT) resulted in 
a statistically significant R2-change (p < 0.05) are indicated (bolded). If a model could 
not run due to that SNP variable being a constant then not applicable (N/A) is recorded 
for that model. 
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Appendix 10: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Duration. 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1                           
Model summary: rs2075574   0.138 <0.001           0.135 <0.001   
Age 0.010 0.004 0.013         0.011 0.004 0.011       
BMI 0.005 0.006 0.402         0.005 0.006 0.442       
CVD risk -0.008 0.040 0.849         -0.009 0.040 0.831       
GDS -0.006 0.015 0.668         -0.007 0.015 0.654       
APOE ε4 0.300 0.059 <0.001         0.303 0.058 <0.001       
rs2075574 0.286 0.295 0.330         0.186 0.431 0.667       
Duration 0.028 0.032 0.385         0.007 0.022 0.749       
INT -0.039 0.042 0.356     0.003   -0.019 0.058 0.742     <0.001 
Model summary: rs1859838   0.134 <0.001           0.139 <0.001   
Age 0.011 0.004 0.011         0.011 0.004 0.012       
BMI 0.005 0.006 0.428         0.003 0.006 0.609       
CVD risk -0.011 0.040 0.782         -0.013 0.040 0.739       
GDS -0.007 0.015 0.647         -0.005 0.015 0.728       
APOE ε4 0.302 0.059 <0.001         0.308 0.058 <0.001       
rs1859838 0.165 0.307 0.591         -0.479 0.673 0.478       
Duration 0.014 0.026 0.581         0.004 0.021 0.835       
INT -0.024 0.043 0.583     0.001   0.047 0.090 0.601     0.001 
Model summary: rs4419722   0.133 <0.001           0.160 <0.001   
Age 0.011 0.004 0.011         0.011 0.004 0.010       
BMI 0.004 0.006 0.472         0.004 0.006 0.548       
CVD risk -0.011 0.040 0.775         0.001 0.039 0.995       
GDS -0.007 0.015 -0.037         -0.013 0.015 0.387       
APOE ε4 0.302 0.059 <0.001         0.290 0.058 <0.001       
rs4419722 -0.037 0.334 0.913         -1.977 2.010 0.327       
Duration 0.005 0.023 0.840         -0.008 0.021 0.706       
INT 0.003 0.047 0.947     <0.001  0.266 0.206 0.197     0.007 
Model summary: rs1004317   0.139 <0.001           0.134 <0.001   
Age 0.011 0.004 0.011         0.011 0.004 0.011       
BMI 0.004 0.006 0.547         0.004 0.006 0.520       
CVD risk -0.011 0.040 0.791         -0.010 0.040 0.799       
GDS -0.007 0.015 0.641         -0.007 0.015 0.646       
APOE ε4 0.307 0.058 <0.001         0.302 0.059 <0.001       
rs1004317 -0.276 0.316 0.383         0.086 0.453 0.850       
Duration -0.016 0.039 0.686         0.008 0.022 0.720       
INT 0.033 0.045 0.472     0.002   -0.017 0.063 0.791     <0.001 
Model summary: rs62449133   0.141 <0.001           0.144 <0.001   
Age 0.010 0.004 0.015         0.011 0.004 0.012       
BMI 0.004 0.006 0.486         0.003 0.006 0.615       
CVD risk -0.002 0.040 0.954         -0.002 0.040 0.966       
GDS -0.007 0.015 0.638         -0.008 0.015 0.620       
APOE ε4 0.313 0.060 <0.001         0.319 0.060 <0.001       
rs62449133 0.046 0.301 0.878         0.024 0.581 0.967       
Duration 0.010 0.027 0.711         0.010 0.021 0.651       
INT -0.005 0.042 0.902     <0.001  -0.016 0.081 0.845     <0.001 
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Appendix 10: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Duration 
(cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1 cont.                           
Model summary: rs2299905   0.145 <0.001           0.148 <0.001   
Age 0.010 0.004 0.019         0.011 0.004 0.013       
BMI 0.004 0.006 0.541         0.002 0.006 0.696       
CVD risk -0.005 0.040 0.901         -0.004 0.040 0.920       
GDS -0.007 0.015 0.650         -0.007 0.015 0.647       
APOE ε4 0.320 0.059 <0.001         0.325 0.059 <0.001       
rs2299905 -0.163 0.293 0.578         0.111 0.550 0.840       
Duration 0.001 0.031 0.982         0.011 0.021 0.611       
INT 0.017 0.042 0.682     0.001   -0.032 0.077 0.679     0.001 
Model summary: rs28362727   0.134 <0.001           0.129 <0.001   
Age 0.011 0.004 0.007         0.012 0.004 0.007       
BMI 0.006 0.006 0.326         0.005 0.006 0.407       
CVD risk -0.003 0.040 0.950         -0.001 0.040 0.975       
GDS -0.004 0.015 0.784         -0.003 0.015 0.843       
APOE ε4 0.277 0.058 <0.001         0.284 0.059 <0.001       
rs28362727 0.421 0.286 0.142         0.106 0.525 0.841       
Duration 0.046 0.030 0.127         0.015 0.022 0.494       
INT -0.063 0.040 0.121     0.010   -0.021 0.070 0.760     <0.001 
Model summary: rs11537660   0.061 <0.001           N/A     
Age 0.011 0.004 0.009                     
BMI 0.004 0.006 0.521                     
CVD risk -0.014 0.040 0.732                     
GDS -0.007 0.015 0.628                     
APOE ε4 0.301 0.058 <0.001                     
rs11537660 0.061 0.418 0.884                     
Duration 0.006 0.022 0.771                     
INT -0.027 0.061 0.655     0.001               
AQP4                           
Model summary: rs11661081   0.140 <0.001           0.134 <0.001   
Age 0.011 0.004 0.010         0.011 0.004 0.012       
BMI 0.004 0.006 0.500         0.004 0.006 0.477       
CVD risk -0.009 0.040 0.823         -0.007 0.041 0.856       
GDS -0.010 0.015 0.537         -0.007 0.015 0.640       
APOE ε4 0.304 0.058 <0.001         0.301 0.059 <0.001       
rs11661081 -0.526 0.405 0.196         -0.688 1.825 0.707       
Duration -0.006 0.022 0.801         0.005 0.020 0.806       
INT 0.074 0.057 0.199     0.007   0.083 0.258 0.748     <0.001 
Model summary rs9951307  0.143 <0.001           0.139 <0.001   
Age 0.011 0.004 0.009         0.011 0.004 0.009       
BMI 0.004 0.006 0.484         0.005 0.006 0.402       
CVD risk -0.011 0.040 0.782         -0.010 0.040 0.797       
GDS -0.005 0.015 0.725         -0.008 0.015 0.588       
APOE ε4 0.303 0.058 <0.001         0.303 0.058 <0.001       
rs9951307 -0.174 0.299 0.561         0.301 0.416 0.470       
Duration -0.003 0.034 0.920         0.011 0.022 0.622       
INT 0.014 0.042 0.744     <0.001   -0.055 0.061 0.372     0.003 
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Appendix 10: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Duration 
(cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs7240333   0.151 <0.001           0.147 <0.001   
Age 0.010 0.004 0.019         0.011 0.004 0.009       
BMI 0.004 0.006 0.505         0.004 0.006 0.548       
CVD risk -0.002 0.040 0.951         -0.003 0.040 0.942       
GDS -0.008 0.015 0.620         -0.009 0.015 0.545       
APOE ε4 0.322 0.059 <0.001         0.321 0.059 <0.001       
rs7240333 0.321 0.372 0.390         -0.462 1.035 0.656       
Duration 0.010 0.023 0.665         0.002 0.021 0.938       
INT -0.039 0.052 0.458     0.002   0.065 0.148 0.659     0.001 
Model summary: rs68006382   0.138 <0.001           0.142 <0.001   
Age 0.011 0.004 0.010         0.011 0.004 0.014       
BMI 0.006 0.006 0.350         0.006 0.006 0.368       
CVD risk -0.005 0.040 0.894         -0.007 0.040 0.871       
GDS -0.006 0.016 0.723         -0.007 0.015 0.670       
APOE ε4 0.302 0.059 <0.001         0.307 0.059 <0.001       
rs68006382 -0.021 0.348 0.951         -0.621 0.776 0.425       
Duration 0.002 0.024 0.923         -0.001 0.021 0.958       
INT 0.009 0.049 0.859     <0.001  0.099 0.103 0.340     0.004 
Model summary: rs71353406   0.135 <0.001           0.144 <0.001   
Age 0.190 0.004 0.017         0.010 0.004 0.016       
BMI 0.005 0.006 0.426         0.005 0.006 0.397       
CVD risk -0.009 0.041 0.823         -0.012 0.040 0.776       
GDS -0.004 0.016 0.793         -0.007 0.015 0.656       
APOE ε4 0.297 0.060 <0.001         0.307 0.059 <0.001       
rs71353406 0.190 0.305 0.535         -0.679 0.578 0.241       
Duration 0.013 0.028 0.634         -0.005 0.021 0.830       
INT -0.021 0.043 0.623     0.001   0.112 0.080 0.162     0.008 
Model summary: rs12968026   0.149 <0.001           0.126 <0.001   
Age 0.012 0.004 0.005         0.011 0.004 0.010       
BMI 0.005 0.006 0.370         0.004 0.006 0.520       
CVD risk -0.023 0.040 0.565         -0.009 0.040 0.816       
GDS -0.007 0.015 0.662         -0.003 0.015 0.838       
APOE ε4 0.289 0.058 <0.001         0.283 0.059 <0.001       
rs12968026 0.807 0.352 0.023         0.065 0.715 0.928       
Duration 0.026 0.023 0.251         0.005 0.021 0.817       
INT -0.104 0.049 0.034     0.019   -0.010 0.105 0.923     <0.001 
Model summary: rs3875089   0.143 <0.001           0.138 <0.001   
Age 0.011 0.004 0.008         0.011 0.004 0.008       
BMI 0.004 0.006 0.464         0.004 0.006 0.477       
CVD risk -0.016 0.400 0.694         -0.014 0.040 0.737       
GDS -0.008 0.015 0.588         -0.008 0.015 0.603       
APOE ε4 0.297 0.058 <0.001         0.309 0.059 <0.001       
rs3875089 0.448 0.311 0.151         -0.301 0.677 0.657       
Duration 0.023 0.025 0.343         0.003 0.021 0.876       
INT -0.056 0.044 0.200     0.007   0.064 0.098 0.515     0.002 
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Appendix 10: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Duration 
(cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs162007   0.133 <0.001           0.134 <0.001   
Age 0.011 0.004 0.012         0.011 0.004 0.014       
BMI 0.004 0.006 0.470         0.004 0.006 0.482       
CVD risk -0.012 0.040 0.767         -0.012 0.040 0.767       
GDS -0.007 0.015 0.652         -0.007 0.015 0.668       
APOE ε4 0.302 0.059 <0.001         0.302 0.059 <0.001       
rs162007 -0.051 0.309 0.870         -0.217 1.742 0.901       
Duration 0.003 0.025 0.900         0.005 0.020 0.820       
INT 0.007 0.043 0.872     <0.001  0.022 0.275 0.936     <0.001 
Model summary: rs162003   0.144 <0.001           N/A     
Age 0.011 0.004 0.011                     
BMI 0.004 0.006 0.554                     
CVD risk -0.007 0.040 0.866                     
GDS -0.007 0.015 0.620                     
APOE ε4 0.301 0.058 <0.001                     
rs162003 0.662 0.571 0.248                     
Duration 0.015 0.021 0.466                     
INT -0.100 0.077 0.194     0.007               
Model summary: rs151245   0.142 <0.001           0.137 <0.001   
Age 0.011 0.004 0.008         0.011 0.004 0.011       
BMI 0.004 0.006 0.505         0.004 0.006 0.518       
CVD risk -0.012 0.040 0.772         -0.010 0.040 0.808       
GDS -0.010 0.015 0.529         -0.008 0.015 0.599       
APOE ε4 0.309 0.058 <0.001         0.308 0.057 <0.001       
rs151245 0.437 0.298 0.144         -0.159 0.366 0.665       
Duration 0.043 0.033 0.184         -0.001 0.023 0.995       
INT -0.062 0.042 0.140     0.009   0.031 0.052 0.547     0.002 
Model summary: rs151246   0.135 <0.001           0.134 <0.001   
Age 0.011 0.004 0.012         0.011 0.004 0.010       
BMI 0.005 0.006 0.449         0.004 0.006 0.461       
CVD risk -0.013 0.040 0.749         -0.012 0.040 0.766       
GDS -0.007 0.015 0.645         -0.006 0.015 0.677       
APOE ε4 0.302 0.059 <0.001         0.303 0.059 <0.001       
rs151246 -0.208 0.308 0.500         0.050 0.626 0.937       
Duration -0.003 0.025 0.905         0.008 0.021 0.710       
INT 0.026 0.044 0.559     0.001   -0.016 0.082 0.843     <0.001 
Model summary: rs2339214   0.132 <0.001           0.174 <0.001   
Age 0.010 0.004 0.018         0.011 0.004 0.009       
BMI 0.005 0.006 0.403         0.004 0.006 0.507       
CVD risk -0.011 0.041 0.796         -0.009 0.040 0.819       
GDS -0.005 0.016 0.774         -0.008 0.015 0.595       
APOE ε4 0.302 0.059 <0.001         0.307 0.058 <0.001       
rs2339214 0.056 0.324 0.864         -0.993 0.329 0.003       
Duration 0.014 0.038 0.714         -0.031 0.024 0.197       
INT -0.009 0.045 0.850     <0.001  0.149 0.047 0.002     0.041 
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Appendix 10: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Duration 
(cont.). 
      Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model Summary: rs491148   0.156 <0.001           0.146 <0.001   
Age 0.011 0.004 0.007         0.012 0.004 0.005       
BMI 0.005 0.006 0.377         0.004 0.006 0.736       
CVD risk -0.023 0.040 0.565         -0.016 0.040 0.684       
GDS -0.012 0.015 0.419         -0.008 0.015 0.574       
APOE ε4 0.317 0.058 <0.001         0.316 0.059 <0.001       
rs491148 0.707 0.320 0.028         -0.135 0.662 0.839       
Duration 0.030 0.024 0.202         0.005 0.021 0.819       
INT -0.090 0.045 0.045     0.016   0.053 0.097 0.584     0.001 
Model summary statistics for all Aquaporin 1 (AQP1) and Aquaporin 4 (AQP4) 
reference single nucleotide polymorphism (SNP) markers (rs). †Genetic models: 
Dominant (heterozygote/homozygote for the minor allele (Mm or MM) vs 
homozygote for the major allele (mm)), Recessive (homozygote for the minor allele 
(MM) vs heterozygote/homozygote for the major allele (Mm/mm)); β, Coefficient of 
predictors: SE, standard error; Sig, p-value; R2, coefficient of multiple determination, 
ΔR2, multiple correlation coefficient (R) squared change; BMI, Body Mass Index; 
CVD risk, cardiovascular disease risk; GDS, Geriatric Depression Scale; APOE, 
Apolipoprotein E ε4 allele carriage (presence/absence); INT, Interaction (Sleep 
duration * model summary SNP). Models where the interaction term (INT) resulted in 
a statistically significant R2-change (p < 0.05) are indicated (bolded). If a model could 
not run due to that SNP variable being a constant then not applicable (N/A) is recorded 
for that model. 
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Appendix 11: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep 
Disturbances. 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1                           
Model summary: rs2075574   0.139 <0.001           0.141 <0.001   
Age 0.010 0.004 0.012         0.010 0.004 0.015       
BMI 0.004 0.006 0.509         0.004 0.006 0.517       
CVD risk -0.004 0.041 0.920         -0.002 0.040 0.958       
GDS -0.004 0.015 0.801         -0.004 0.015 0.818       
APOE ε4 0.305 0.058 <0.001         0.300 0.058 <0.001       
rs2075574 0.122 0.140 0.385         0.234 0.228 0.305       
Disturbances -0.009 0.066 0.896         -0.036 0.050 0.471       
INT -0.075 0.093 0.417     0.003   -0.120 0.144 0.407     0.003 
Model summary: rs1859838   0.137 <0.001           0.141 <0.001   
Age 0.011 0.004 0.013         0.011 0.004 0.012       
BMI 0.003 0.006 0.571         0.003 0.006 0.660       
CVD risk -0.001 0.041 0.973         -0.005 0.040 0.905       
GDS -0.005 0.015 0.746         -0.005 0.015 0.738       
APOE ε4 0.303 0.058 <0.001         0.308 0.058 <0.001       
rs1859838 0.053 0.159 0.737         -0.124 0.396 0.756       
Disturbances -0.037 0.054 0.495         -0.042 0.040 0.905       
INT -0.038 0.107 0.720     0.001   0.003 0.232 0.989     <0.001 
Model summary: rs4419722   0.137 <0.001           0.165 <0.001   
Age 0.011 0.004 0.012         0.011 0.004 0.011       
BMI 0.004 0.006 0.545         0.003 0.006 0.593       
CVD risk -0.004 0.040 0.916         0.007 0.040 0.865       
GDS -0.005 0.015 0.748         -0.011 0.015 0.484       
APOE ε4 0.302 0.058 <0.001         0.287 0.058 <0.001       
rs4419722 -0.037 0.170 0.830         -0.434 0.804 0.590       
Disturbances -0.050 0.054 0.355         -0.054 0.047 0.250       
INT 0.017 0.112 0.882     <0.001  0.692 0.512 0.177     0.007 
Model summary: rs1004317   0.139 <0.001           0.137 <0.001   
Age 0.011 0.004 0.011         0.011 0.004 0.012       
BMI 0.003 0.006 0.564         0.003 0.006 0.576       
CVD risk -0.005 0.040 0.898         -0.005 0.041 0.895       
GDS -0.005 0.015 0.739         -0.005 0.015 0.742       
APOE ε4 0.308 0.058 <0.001         0.306 0.058 <0.001       
rs1004317 -0.062 0.147 0.675         -0.093 0.229 0.686       
Disturbances -0.051 0.084 0.543         -0.051 0.052 0.326       
INT 0.012 0.101 0.902     <0.001  0.045 0.136 0.740     <0.001 
Model summary: rs62449133   0.143 <0.001           0.149 <0.001   
Age 0.010 0.004 0.018         0.010 0.004 0.016       
BMI 0.004 0.006 0.534         0.003 0.006 0.016       
CVD risk 0.004 0.040 0.922         0.006 0.040 0.880       
GDS -0.006 0.015 0.703         -0.005 0.015 0.742       
APOE ε4 0.315 0.059 <0.001         0.317 0.059 <0.001       
rs62449133 -0.015 0.142 0.916         0.212 0.326 0.517       
Disturbances -0.050 0.066 0.455         -0.022 0.049 0.648       
INT 0.022 0.094 0.815     <0.001  -0.184 0.195 0.349     0.004 
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Appendix 11: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep 
Disturbances (cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1 cont.                           
Model summary: rs2299905   0.146 <0.001           0.149 <0.001   
Age 0.010 0.004 0.021         0.010 0.004 0.017       
BMI 0.003 0.006 0.544         0.002 0.006 0.715       
CVD risk 0.006 0.040 0.988         0.001 0.040 0.974       
GDS -0.006 0.015 0.701         -0.005 0.015 0.757       
APOE ε4 0.321 0.059 <0.001         0.324 0.060 <0.001       
rs2299905 -0.087 0.141 0.536         0.022 0.308 0.943       
Disturbances -0.050 0.072 0.489         -0.024 0.049 0.635       
INT 0.034 0.095 0.719     0.001   -0.082 0.185 0.659     0.001 
Model summary: rs28362727   0.131 <0.001           0.135 <0.001   
Age 0.011 0.004 0.010         0.011 0.004 0.013       
BMI 0.005 0.006 0.406         0.004 0.006 0.488       
CVD risk 0.004 0.040 0.915         0.002 0.040 0.957       
GDS -0.002 0.015 0.921         -0.001 0.015 0.968       
APOE ε4 0.286 0.059 <0.001         0.284 0.058 <0.001       
rs28362727 -0.025 0.140 0.858         0.197 0.264 0.457       
Disturbances -0.041 0.062 0.506         -0.025 0.049 0.604       
INT 0.005 0.093 0.954     <0.001   -0.169 0.174 0.334     0.004 
Model summary: rs11537660   0.149 <0.001           N/A     
Age 0.011 0.004 0.010                     
BMI 0.004 0.006 0.525                     
CVD risk -0.006 0.040 0.875                     
GDS -0.005 0.015 0.740                     
APOE ε4 0.304 0.058 <0.001                     
rs11537660 -0.168 0.207 0.417                     
Disturbances -0.050 0.051 0.327                     
INT 0.032 0.139 0.819     <0.001               
AQP4                           
Model summary: rs11661081   0.137 <0.001           0.138 <0.001   
Age 0.011 0.004 0.013         0.010 0.004 0.014       
BMI 0.004 0.006 0.553         0.004 0.006 0.533       
CVD risk -0.004 0.040 0.931         0.001 0.041 0.987       
GDS -0.005 0.015 0.766         -0.005 0.015 0.732       
APOE ε4 0.304 0.058 <0.001         0.302 0.058 <0.001       
rs11661081 -0.046 0.178 0.796         -0.459 0.819 0.576       
Disturbances -0.052 0.054 0.332         -0.049 0.048 0.305       
INT 0.027 0.116 0.814     <0.001   0.233 0.515 0.652     0.001 
Model summary rs9951307  0.154 <0.001           0.140 <0.001   
Age 0.011 0.004 0.012         0.011 0.004 0.013       
BMI 0.003 0.006 0.584         0.005 0.006 0.446       
CVD risk -0.004 0.040 0.931         -0.004 0.040 0.925       
GDS -0.003 0.015 0.826         -0.005 0.015 0.765       
APOE ε4 0.311 0.058 <0.001         0.302 0.058 <0.001       
rs9951307 -0.276 0.143 0.055         -0.215 0.253 0.395       
Disturbances -0.140 0.081 0.085         -0.053 0.050 0.287       
INT 0.147 0.098 0.133     0.009   0.102 0.157 0.517     0.002 
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Appendix 11: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep 
Disturbances (cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs7240333   0.151 <0.001           0.151 <0.001   
Age 0.010 0.004 0.014         0.011 0.004 0.010       
BMI 0.003 0.006 0.580         0.003 0.006 0.590       
CVD risk 0.001 0.040 0.972         0.002 0.040 0.957       
GDS -0.007 0.015 0.634         -0.008 0.015 <0.001       
APOE ε4 0.326 0.059 <0.001         0.318 0.058 <0.001       
rs7240333 0.056 0.175 0.749         0.458 0.628 0.467       
Disturbances -0.036 0.053 0.500         -0.033 0.048 0.491       
INT -0.006 0.117 0.959     <0.001   -0.355 0.444 0.425     0.003 
Model summary: rs68006382   0.145 <0.001           0.142 <0.001   
Age 0.011 0.004 0.012         0.011 0.004 0.014       
BMI 0.005 0.006 0.414         0.005 0.006 0.399       
CVD risk 0.003 0.041 0.938         -0.002 0.041 0.970       
GDS -0.004 0.016 0.800         -0.006 0.016 0.712       
APOE ε4 0.304 0.059 <0.001         0.307 0.059 <0.001       
rs68006382 0.200 0.166 0.232         -0.150 0.452 0.740       
Disturbances -0.014 0.055 0.798         -0.047 0.050 0.347       
INT -0.127 0.119 0.289     0.005   0.190 0.319 0.552     0.002 
Model summary: rs71353406   0.139 <0.001           0.139 <0.001   
Age 0.011 0.004 0.013         0.010 0.004 0.016       
BMI 0.004 0.006 0.476         0.005 0.006 0.427       
CVD risk -0.006 0.041 0.892         -0.006 0.041 0.892       
GDS -0.004 0.016 0.775         -0.006 0.012 0.718       
APOE ε4 0.303 0.059 <0.001         0.305 0.059 <0.001       
rs71353406 0.146 0.141 0.302         0.234 0.325 0.472       
Disturbances -0.001 0.065 0.988         -0.034 0.050 0.489       
INT -0.079 0.096 0.410     0.003   -0.090 0.229 0.489     0.001 
Model summary: rs12968026   0.366 <0.001           0.129 <0.001   
Age 0.011 0.004 0.008         0.110 0.004 0.010       
BMI 0.004 0.006 0.497         0.003 0.006 0.582       
CVD risk -0.006 0.041 0.878         -0.004 0.041 0.918       
GDS -0.003 0.015 0.838         -0.003 0.015 0.870       
APOE ε4 0.280 0.059 <0.001         0.285 0.059 <0.001       
rs12968026 -0.012 0.178 0.946         -0.245 0.553 0.658       
Disturbances -0.041 0.052 0.361         -0.038 0.048 0.425       
INT 0.057 0.116 0.621     0.001   0.154 0.333 0.644     0.001 
Model summary: rs3875089   0.141 <0.001           0.141 <0.001   
Age 0.010 0.004 0.014         0.011 0.004 0.011       
BMI 0.004 0.006 0.538         0.004 0.006 0.519       
CVD risk -0.001 0.040 0.988         -0.006 0.041 0.879       
GDS -0.004 0.015 0.771         -0.006 0.015 0.704       
APOE ε4 0.303 0.058 <0.001         0.310 0.058 <0.001       
rs3875089 0.124 0.149 0.407         0.362 0.462 0.435       
Disturbances -0.032 0.057 0.584         -0.044 0.048 0.356       
INT -0.049 0.099 0.622     0.001   -0.149 0.284 0.602     0.001 
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Appendix 11: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep 
Disturbances (cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs162007   0.134 <0.001           0.135 <0.001   
Age 0.011 0.004 0.013         0.010 0.004 0.015       
BMI 0.004 0.006 0.528         0.004 0.006 0.539       
CVD risk -0.004 0.040 0.926         -0.003 0.040 0.938       
GDS -0.005 0.015 0.739         -0.006 0.015 0.695       
APOE ε4 0.304 0.058 <0.001         0.304 0.058 <0.001       
rs162007 0.015 0.144 0.919         -0.302 0.523 0.564       
Disturbances -0.043 0.058 0.467         -0.500 0.048 0.295       
INT -0.012 0.097 0.905     <0.001   0.177 0.413 0.668     0.001 
Model summary: rs162003   0.138 <0.001           N/A     
Age 0.010 0.004 0.019                     
BMI 0.003 0.006 0.659                     
CVD risk -0.001 0.040 0.978                     
GDS -0.005 0.015 0.720                     
APOE ε4 0.299 0.058 <0.001                     
rs162003 -0.189 0.220 0.391                     
Disturbances -0.058 0.050 0.245                     
INT 0.083 0.155 0.593     0.001               
Model summary: rs151245   0.134 <0.001           0.150 <0.001   
Age 0.010 0.004 0.014         0.010 0.004 0.016       
BMI 0.004 0.006 0.543         0.003 0.006 0.570       
CVD risk -0.004 0.041 0.931         0.003 0.041 0.950       
GDS -0.006 0.015 0.701         -0.008 0.015 0.599       
APOE ε4 0.304 0.058 <0.001         0.301 0.058 <0.001       
rs151245 0.085 0.153 0.580         0.261 0.206 0.206       
Disturbances -0.006 0.094 0.951         -0.028 0.051 0.586       
INT -0.056 0.108 0.602     0.001   -0.144 0.138 0.586     0.004 
Model summary: rs151246   0.148 <0.001           0.141 <0.001   
Age 0.011 0.004 0.011         0.011 0.004 0.012       
BMI 0.005 0.006 0.407         0.004 0.006 0.509       
CVD risk -0.008 0.040 0.844         -0.005 0.041 0.898       
GDS -0.009 0.015 0.547         -0.004 0.015 0.779       
APOE ε4 0.300 0.058 <0.001         0.306 0.059 <0.001       
rs151246 0.171 0.146 0.243         -0.124 0.392 0.753       
Disturbances 0.010 0.061 0.872         -0.048 0.048 0.318       
INT -0.143 0.098 0.144     0.009   0.039 0.256 0.880     <0.001 
Model summary: rs2339214   0.140 <0.001           0.136 <0.001   
Age 0.010 0.004 0.020         0.010 0.004 0.021       
BMI 0.005 0.006 0.472         0.004 0.006 0.472       
CVD risk 0.001 0.041 0.992         0.001 0.041 0.984       
GDS -0.005 0.016 0.749         -0.003 0.016 0.843       
APOE ε4 0.301 0.059 <0.001         0.300 0.059 <0.001       
rs2339214 -0.124 0.167 0.459         0.064 0.173 0.711       
Disturbances -0.101 0.091 0.270         -0.038 0.053 0.470      
INT 0.076 0.107 0.478     0.478   -0.020  0.123  0.869      <0.001  
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Appendix 11: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep 
Disturbances (cont.). 
      Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs491148   0.145 <0.001           0.151 <0.001   
Age 0.011 0.004 0.012         0.012 0.004 0.004       
BMI 0.004 0.006 0.473         0.004 0.006 0.506       
CVD risk -0.004 0.041 0.916         -0.013 0.040 0.744       
GDS -0.007 0.015 0.626         -0.008 0.015 0.590       
APOE ε4 0.305 0.058 <0.001         0.319 0.058 0.590       
rs491148 0.070 0.162 0.666         -0.050 0.401 0.901       
Disturbances -0.056 0.056 0.317         -0.055 0.048 0.248       
INT 0.006 0.104 0.955     <0.001   0.179 0.249 0.473     0.002 
Model summary statistics for all Aquaporin 1 (AQP1) and Aquaporin 4 (AQP4) 
reference single nucleotide polymorphism (SNP) markers (rs). †Genetic models: 
Dominant (heterozygote/homozygote for the minor allele (Mm or MM) vs 
homozygote for the major allele (mm)), Recessive (homozygote for the minor allele 
(MM) vs heterozygote/homozygote for the major allele (Mm/mm)); β, Coefficient of 
predictors: SE, standard error; Sig, p-value; R2, coefficient of multiple determination, 
ΔR2, multiple correlation coefficient (R) squared change; BMI, Body Mass Index; 
CVD risk, cardiovascular disease risk; GDS, Geriatric Depression Scale; APOE, 
Apolipoprotein E ε4 allele carriage (presence/absence); INT, Interaction (Sleep 
disturbances * model summary SNP). Models where the interaction term (INT) 
resulted in a statistically significant R2-change (p < 0.05) are indicated (bolded). If a 
model could not run due to that SNP variable being a constant then not applicable 
(N/A) is recorded for that model. 
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Appendix 12: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Efficiency.  
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1                           
Model summary: rs2075574   0.136 <0.001           0.137 <0.001   
Age 0.010 0.004 0.014         0.011 0.004 0.012       
BMI 0.004 0.006 0.523         0.004 0.006 0.497       
CVD risk -0.008 0.040 0.853         -0.005 0.040 0.894       
GDS -0.005 0.015 0.742         -0.006 0.015 0.722       
APOE ε4 0.305 0.058 <0.001         0.305 0.058 <0.001       
rs2075574 0.032 0.062 0.603         0.034 0.087 0.699       
Efficiency -0.012 0.052 0.813         -0.029 0.035 0.409       
INT -0.024 0.067 0.720     0.001  0.023 0.096 0.811     <0.001 
Model summary: rs1859838   0.137 <0.001           0.139 <0.001   
Age 0.010 0.004 0.020         0.011 0.004 0.012       
BMI 0.003 0.006 0.640         0.003 0.006 0.674       
CVD risk -0.001 0.040 0.979         -0.010 0.040 0.811       
GDS -0.005 0.015 0.755         -0.004 0.015 0.794       
APOE ε4 0.293 0.059 <0.001         0.308 0.058 <0.001       
rs1859838 0.050 0.067 0.453         -0.100 0.133 0.452       
Efficiency -0.003 0.037 0.936         -0.025 0.034 0.460       
INT -0.102 0.076 0.185     0.007   -0.072 0.145 0.623     0.001 
Model summary: rs4419722   0.139 <0.001           N/A     
Age 0.010 0.004 0.015                     
BMI 0.004 0.006 0.555                     
CVD risk -0.008 0.040 0.835                     
GDS -0.005 0.015 0.761                     
APOE ε4 0.301 0.058 <0.001                     
rs4419722 0.031 0.074 0.675                     
Efficiency -0.009 0.037 0.801                     
INT -0.074 0.076 0.335     0.004              
Model summary: rs1004317   0.152 <0.001           0.137 <0.001   
Age 0.010 0.004 0.015         0.010 0.004 0.014       
BMI 0.003 0.006 0.665         0.004 0.006 0.554       
CVD risk -0.005 0.040 0.910         -0.009 0.040 0.821       
GDS -0.001 0.015 0.968         -0.004 0.015 0.785       
APOE ε4 0.297 0.058 <0.001         0.303 0.058 <0.001       
rs1004317 0.019 0.065 0.769         -0.009 0.089 0.921       
Efficiency 0.042 0.051 0.414         -0.021 0.035 0.543       
INT -0.120 0.067 0.073     0.013  -0.054 0.102 0.593     0.001 
Model summary: rs62449133   0.146 <0.001           0.145 <0.001   
Age 0.010 0.004 0.025         0.011 0.004 0.014       
BMI 0.004 0.006 0.550         0.003 0.006 0.651       
CVD risk 0.004 0.040 0.922         -0.001 0.040 0.997       
GDS -0.005 0.015 0.760         -0.005 0.015 0.723       
APOE ε4 0.307 0.059 <0.001         0.321 0.059 <0.001       
rs62449133 0.050 0.062 0.422         -0.066 0.118 0.578       
Efficiency 0.008 0.040 0.838         -0.017 0.034 0.626       
INT -0.077 0.069 0.266     0.005  -0.051 0.135 0.705     0.001 
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Appendix 12: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Efficiency 
(cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1 cont.                           
Model summary: rs2299905   0.149 <0.001           0.148 <0.001   
Age 0.010 0.004 0.023         0.011 0.004 0.014       
BMI 0.003 0.006 0.582         0.002 0.006 0.735       
CVD risk 0.001 0.040 0.995         -0.002 0.040 0.963       
GDS -0.004 0.015 0.802         -0.005 0.015 0.739       
APOE ε4 0.312 0.059 <0.001         0.327 0.059 <0.001       
rs2299905 -0.011 0.062 0.861         -0.119 0.114 0.300       
Efficiency 0.006 0.044 0.886         -0.020 0.034 0.571       
INT -0.065 0.067 0.333     0.004   0.007 0.120 0.954     <0.001 
Model summary: rs28362727 0.137 <0.001           0.142 <0.001   0.137 
Age 0.011 0.004 0.011         0.011 0.004 0.009       
BMI 0.005 0.006 0.448         0.004 0.006 0.473       
CVD risk 0.005 0.040 0.895         0.006 0.040 0.891       
GDS 0.001 0.015 0.956         0.002 0.015 0.918       
APOE ε4 0.283 0.058 <0.001         0.284 0.058 <0.001       
rs28362727 -0.007 0.061 0.909         0.008 0.101 0.940       
Efficiency -0.033 0.042 0.436         -0.033 0.034 0.336       
INT -0.032 0.067 0.633     0.001   -0.134 0.114 0.235     0.006 
Model summary: rs11537660   0.149 <0.001           N/A     
Age 0.011 0.004 0.009                     
BMI 0.004 0.006 0.522                     
CVD risk -0.010 0.040 0.807                     
GDS -0.005 0.015 0.748                     
APOE ε4 0.302 0.058 <0.001                     
rs11537660 -0.112 0.083 0.180                     
Efficiency -0.025 0.035 0.476                     
INT -0.027 0.093 0.772     <0.001              
AQP4                           
Model summary: rs11661081   0.135 <0.001           N/A    
Age 0.011 0.004 0.012                     
BMI 0.004 0.006 0.530                     
CVD risk -0.008 0.040 0.842                     
GDS -0.005 0.015 0.735                     
APOE ε4 0.304 0.058 <0.001                     
rs11661081 -0.019 0.077 0.807                     
Efficiency -0.031 0.037 0.409                    
INT 0.018  0.078  0.818      <0.001                
Model summary rs9951307  0.151 <0.001           0.142 <0.001   
Age 0.011 0.004 0.012         0.011 0.004 0.011       
BMI 0.005 0.006 0.451         0.004 0.006 0.486       
CVD risk -0.010 0.040 0.798         -0.007 0.040 0.861       
GDS -0.005 0.015 0.750         -0.005 0.015 0.746       
APOE ε4 0.310 0.058 <0.001         0.303 0.058 <0.001       
rs9951307 -0.132 0.061 0.033         -0.064 0.100 0.522       
Efficiency -0.097 0.057 0.087         -0.026 0.035 0.464       
INT 0.112 0.069 0.107     0.010   0.002 0.094 0.984     <0.001 
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Appendix 12: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Efficiency 
(cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs7240333   0.151 <0.001           0.148 <0.001   
Age 0.011 0.004 0.013         0.011 0.004 0.012       
BMI 0.003 0.006 0.568         0.003 0.006 0.570       
CVD risk -0.001 0.040 0.995         -0.001 0.040 0.985       
GDS -0.007 0.015 0.632         -0.007 0.015 0.655       
APOE ε4 0.325 0.059 <0.001         0.319 0.059 <0.001       
rs7240333 0.064 0.075 0.392         0.017 0.263 0.949       
Efficiency -0.012 0.037 0.742         -0.017 0.033 0.603       
INT -0.030 0.083 0.719     0.001   -0.101 0.450 0.823     <0.001 
Model summary: rs68006382   0.140 <0.001           0.146 <0.001   
Age 0.011 0.004 0.012         0.010 0.004 0.017       
BMI 0.005 0.006 0.400         0.005 0.006 0.460       
CVD risk -0.004 0.042 0.931         -0.007 0.041 0.860       
GDS -0.004 0.016 0.777         -0.004 0.016 0.789       
APOE ε4 0.303 0.059 <0.001         0.306 0.059 <0.001       
rs68006382 0.051 0.070 0.469         0.232 0.186 0.215       
Efficiency -0.018 0.040 0.661         -0.018 0.034 0.587       
INT -0.023 0.079 0.776     <0.001   -0.386 0.319 0.228     0.006 
Model summary: rs71353406   0.139 <0.001           0.144 <0.001   
Age 0.011 0.004 0.014         0.010 0.004 0.023       
BMI 0.005 0.006 0.432         0.004 0.006 0.471       
CVD risk -0.010 0.041 0.806         -0.011 0.041 0.796       
GDS -0.004 0.016 0.823         -0.003 0.016 0.873       
APOE ε4 0.306 0.059 <0.001         0.301 0.059 <0.001       
rs71353406 0.071 0.062 0.256         0.209 0.134 0.121       
Efficiency -0.001 0.047 0.980         -0.017 0.034 0.612       
INT -0.052 0.067 0.442     0.003   -0.289 0.229 0.208     0.007 
Model summary: rs12968026   0.136 <0.001           0.128 <0.001   
Age 0.011 0.004 0.008         0.011 0.004 0.011       
BMI 0.004 0.006 0.487         0.003 0.006 0.600       
CVD risk -0.007 0.040 0.866         -0.006 0.040 0.888       
GDS -0.004 0.015 0.808         -0.002 0.015 0.915       
APOE ε4 0.281 0.058 <0.001         0.283 0.059 <0.001       
rs12968026 0.043 0.075 0.568         -0.030 0.207 0.717       
Efficiency -0.032 0.036 0.384         -0.026 0.034 0.439       
INT 0.047 0.084 0.577     0.001   0.038 0.204 0.852     <0.001 
Model summary: rs3875089   0.139 <0.001           0.139 <0.001   
Age 0.011 0.004 0.012         0.011 0.004 0.009       
BMI 0.004 0.006 0.516         0.004 0.006 0.510       
CVD risk -0.005 0.040 0.894         -0.011 0.040 0.786       
GDS -0.005 0.015 0.730         -0.007 0.015 0.667       
APOE ε4 0.300 0.058 <0.001         0.310 0.058 <0.001       
rs3875089 0.053 0.067 0.425         0.176 0.179 0.326       
Efficiency -0.025 0.038 0.508         -0.024 0.033 0.326       
INT -0.002 0.074 0.977     <0.001   -0.090 0.191 0.638     0.001 
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Appendix 12: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Efficiency 
(cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs162007   0.139 <0.001           0.148 <0.001   
Age 0.011 0.004 0.012         0.010 0.004 0.016       
BMI 0.003 0.006 0.568         0.004 0.006 0.480       
CVD risk -0.008 0.040 0.848         -0.005 0.040 0.893       
GDS -0.004 0.015 0.811         -0.008 0.015 0.620       
APOE ε4 0.301 0.058 <0.001         0.305 0.058 <0.001       
rs162007 -0.036 0.061 0.555         -0.508 0.308 0.100       
Efficiency -0.049 0.041 0.229         -0.033 0.033 0.323       
INT 0.063 0.069 0.361     0.003   0.374 0.219 0.088     0.012 
Model summary: rs162003   0.142 <0.001           N/A     
Age 0.010 0.004 0.015                     
BMI 0.003 0.006 0.660                     
CVD risk -0.010 0.040 0.808                     
GDS -0.005 0.015 0.751                     
APOE ε4 0.301 0.058 <0.001                     
rs162003 -0.111 0.084 0.186                     
Efficiency -0.039 0.034 0.257                     
INT 0.087 0.122 0.478     0.002               
Model summary: rs151245   0.135 <0.001           0.144 <0.001   
Age 0.010 0.004 0.014         0.011 0.004 0.009       
BMI 0.004 0.006 0.538         0.003 0.006 0.646       
CVD risk -0.007 0.040 0.856         -0.005 0.040 0.896       
GDS -0.006 0.015 0.714         -0.007 0.015 0.662       
APOE ε4 0.304 0.058 <0.001         0.305 0.058 <0.001       
rs151245 -0.001 0.063 0.997         0.123 0.087 0.159       
Efficiency -0.035 0.059 0.554         -0.012 0.035 0.738       
INT 0.011 0.071 0.874     <0.001   -0.109 0.092 0.237     0.006 
Model summary: rs151246   0.138 <0.001           0.143 <0.001   
Age 0.011 0.004 0.010         0.011 0.004 0.009       
BMI 0.004 0.006 0.507         0.003 0.006 0.615       
CVD risk -0.008 0.040 0.839         -0.007 0.040 0.868       
GDS -0.006 0.015 0.677         -0.006 0.015 0.689       
APOE ε4 0.297 0.059 <0.001         0.305 0.058 <0.001       
rs151246 0.002 0.064 0.971         0.066 0.161 0.680       
Efficiency -0.004 0.044 0.927         -0.018 0.034 0.599       
INT -0.050 0.066 0.453     0.002   -0.197 0.153 0.197     0.007 
Model summary: rs2339214   0.137 <0.001           0.139 <0.001   
Age 0.010 0.004 0.018         0.009 0.004 0.031       
BMI 0.004 0.006 0.501         0.004 0.006 0.478       
CVD risk -0.004 0.041 0.925         -0.002 0.041 0.964       
GDS -0.003 0.016 0.851         -0.003 0.016 0.852       
APOE ε4 0.303 0.059 <0.001         0.304 0.059 <0.001       
rs2339214 -0.024 0.070 0.735         0.068 0.072 0.348       
Efficiency -0.062 0.067 0.355         -0.024 0.039 0.546       
INT 0.034 0.077 0.654     0.001   -0.049 0.080 0.539     0.002 
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Appendix 12: Moderation Analysis for AQP1 and AQP4 SNPs on Sleep Efficiency 
(cont.). 
      Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs491148   0.146 <0.001           0.148 <0.001   
Age 0.011 0.004 0.012         0.012 0.004 0.005       
BMI 0.005 0.006 0.454         0.004 0.006 0.515       
CVD risk -0.009 0.040 0.815         -0.014 0.040 0.729       
GDS -0.011 0.016 0.483         -0.007 0.015 0.626       
APOE ε4 0.305 0.058 <0.001         0.317 0.058 <0.001       
rs491148 0.030 0.068 0.654         0.231 0.174 0.186       
Efficiency -0.046 0.038 0.224         -0.027 0.033 0.416       
INT 0.074 0.073 0.313     0.004   -0.016 0.183 0.932     <0.001 
Model summary statistics for all Aquaporin 1 (AQP1) and Aquaporin 4 (AQP4) 
reference single nucleotide polymorphism (SNP) markers (rs). †Genetic models: 
Dominant (heterozygote/homozygote for the minor allele (Mm or MM) vs 
homozygote for the major allele (mm)), Recessive (homozygote for the minor allele 
(MM) vs heterozygote/homozygote for the major allele (Mm/mm)); β, Coefficient of 
predictors: SE, standard error; Sig, p-value; R2, coefficient of multiple determination, 
ΔR2, multiple correlation coefficient (R) squared change; BMI, Body Mass Index; 
CVD risk, cardiovascular disease risk; GDS, Geriatric Depression Scale; APOE, 
Apolipoprotein E ε4 allele carriage (presence/absence); INT, Interaction (Sleep 
efficiency * model summary SNP). Models where the interaction term (INT) resulted 
in a statistically significant R2-change (p < 0.05) are indicated (bolded). If a model 
could not run due to that SNP variable being a constant then not applicable (N/A) is 
recorded for that model. 
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Appendix 13: Moderation Analysis for AQP1 and AQP4 SNPs on Daytime 
Dysfunction. 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1                           
Model summary: rs2075574   0.136 <0.001           0.137 <0.001   
Age 0.010 0.004 0.015         0.010 0.004 0.016       
BMI 0.005 0.006 0.439         0.005 0.006 0.427       
CVD risk -0.015 0.040 0.715         -0.013 0.040 0.751       
GDS -0.013 0.017 0.454         -0.011 0.017 0.499       
APOE ε4 0.307 0.058 <0.001         0.304 0.058 <0.001       
rs2075574 0.036 0.074 0.631         0.016 0.139 0.890       
Dysfunction 0.045 0.057 0.437         0.025 0.044 0.572       
INT -0.025 0.073 0.732     0.001   0.031 0.107 0.769     <0.001 
Model summary: rs1859838   0.148 <0.001           0.152 <0.001   
Age 0.010 0.004 0.018         0.010 0.004 0.016       
BMI 0.004 0.006 0.475         0.003 0.006 0.618       
CVD risk -0.010 0.040 0.803         -0.012 0.040 0.761       
GDS -0.011 0.016 0.493         -0.012 0.016 0.461       
APOE ε4 0.304 0.058 <0.001         0.313 0.058 <0.001       
rs1859838 -0.110 0.080 0.170         -0.352 0.170 0.040       
Dysfunction 0.010 0.004 0.018         0.010 0.004 0.016       
INT 0.004 0.006 0.475         0.003 0.006 0.618       
Model summary: rs4419722   0.137 <0.001           0.161 <0.001   
Age 0.010 0.004 0.018         0.010 0.004 0.013       
BMI 0.005 0.006 0.443         0.004 0.006 0.522       
CVD risk -0.014 0.040 0.725         -0.004 0.040 0.925       
GDS -0.012 0.017 0.453         -0.016 0.016 0.323       
APOE ε4 0.299 0.058 <0.001         0.288 0.058 <0.001       
rs4419722 -0.070 0.095 0.464         -0.369 0.804 0.647       
Dysfunction 0.020 0.044 0.646         0.022 0.040 0.580       
INT 0.068 0.095 0.472     0.002   0.637 0.512 0.215     0.006 
Model summary: rs1004317   0.144 <0.001           0.160 <0.001   
Age 0.010 0.004 0.017         0.009 0.004 0.046       
BMI 0.004 0.006 0.557         0.004 0.006 0.465       
CVD risk -0.013 0.040 0.739         -0.004 0.040 0.922       
GDS -0.012 0.016 0.458         -0.013 0.016 0.429       
APOE ε4 0.306 0.058 <0.001         0.307 0.057 <0.001       
rs1004317 -0.029 0.067 0.575         -0.268 0.119 0.025       
Dysfunction -0.029 0.067 0.668         -0.002 0.043 0.973       
INT 0.090 0.078 0.246     0.005   0.260 0.106 0.015     0.024 
Model summary: rs62449133   0.141 <0.001           0.191 <0.001   
Age 0.010 0.004 0.018         0.009 0.004 0.037       
BMI 0.003 0.006 0.578         0.002 0.006 0.786       
CVD risk -0.002 0.040 0.955         0.014 0.039 0.714       
GDS -0.009 0.017 0.600         -0.007 0.016 0.647       
APOE ε4 0.314 0.059 <0.001         0.345 0.058 <0.001       
rs62449133 -0.006 0.076 0.936         -0.494 0.151 0.001       
Dysfunction -0.002 0.055 0.965         -0.034 0.042 0.429       
INT 0.022 0.073 0.766     <0.001   0.411 0.119 0.001     0.047 
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Appendix 13: Moderation Analysis for AQP1 and AQP4 SNPs on Daytime 
Dysfunction (cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP1 cont.                           
Model summary: rs2299905   0.146 <0.001           0.181 <0.001   
Age 0.010 0.004 0.025         0.009 0.004 0.045       
BMI 0.003 0.006 0.578         0.002 0.006 0.786       
CVD risk -0.003 0.040 0.944         0.012 0.040 0.765       
GDS -0.009 0.017 0.593         -0.008 0.016 0.607       
APOE ε4 0.318 0.059 <0.001         0.339 0.058 <0.001       
rs2299905 -0.087 0.074 0.245         -0.458 0.149 0.002       
Dysfunction -0.022 0.058 0.709         -0.027 0.043 0.534       
INT 0.057 0.074 0.440     0.003   0.336 0.115 0.002     0.034 
Model summary: rs28362727   0.136 <0.001           0.131 <0.001   
Age 0.010 0.004 0.015         0.011 0.004 0.010       
BMI 0.005 0.006 0.393         0.005 0.006 0.413       
CVD risk -0.001 0.040 0.996         -0.004 0.040 0.916       
GDS -0.006 0.017 0.738         -0.007 0.017 0.690       
APOE ε4 0.286 0.058 <0.001         0.289 0.058 <0.001       
rs28362727 -0.084 0.072 0.246         -0.092 0.133 0.863       
Dysfunction -0.024 0.056 0.668         0.019 0.043 0.665       
INT 0.087 0.072 0.668     0.006   0.043 0.103 0.675     0.001 
Model summary: rs11537660   0.145 <0.001           N/A     
Age 0.010 0.004 0.017                     
BMI 0.004 0.006 0.485                     
CVD risk -0.015 0.040 0.699                     
GDS -0.013 0.016 0.446                     
APOE ε4 0.302 0.058 <0.001                     
rs11537660 -0.175 0.112 0.119                     
Dysfunction 0.026 0.042 0.541                     
INT 0.064 0.114 0.575     0.001               
AQP4                           
Model summary: rs11661081   0.135 <0.001       N/A   
Age 0.010 0.004 0.016              
BMI 0.004 0.006 0.472              
CVD risk -0.015 0.040 0.714              
GDS -0.012 0.017 0.470              
APOE ε4 0.303 0.058 <0.001              
rs11661081 -0.034 0.105 0.745              
Dysfunction 0.028 0.043 0.745              
INT 0.029 0.108 0.788     <0.001        
Model summary: rs9951307   0.165 <0.001           0.143 <0.001   
Age 0.010 0.004 0.013         0.010 0.004 0.014       
BMI 0.005 0.006 0.405         0.006 0.006 0.340       
CVD risk -0.012 0.040 0.740         -0.011 0.040 0.788       
GDS -0.009 0.016 0.593         -0.014 0.017 0.410       
APOE ε4 0.302 0.057 <0.001         0.296 0.058 <0.001       
rs9951307 -0.201 0.074 0.007         -0.179 0.124 0.152       
Dysfunction -0.067 0.058 0.245         0.018 0.042 0.667       
INT 0.165 0.072 0.023     0.021   0.126 0.111 0.256     0.005 
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Appendix 13: Moderation Analysis for AQP1 and AQP4 SNPs on Daytime 
Dysfunction (cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs7240333   0.165 <0.001           0.150 <0.001   
Age 0.012 0.004 0.007         0.010 0.004 0.016       
BMI 0.004 0.006 0.539         0.004 0.006 0.511       
CVD risk -0.003 0.040 0.949         -0.005 0.040 0.909       
GDS -0.015 0.016 0.348         -0.010 0.017 0.557       
APOE ε4 0.333 0.058 <0.001         0.315 0.059 <0.001       
rs7240333 0.174 0.088 0.049         -0.205 0.334 0.540       
Dysfunction 0.059 0.044 0.180         0.017 0.041 0.683       
INT -0.172 0.091 0.059     0.014   0.191 0.265 0.472     0.002 
Model summary: rs68006382   0.139 <0.001           0.151 <0.001   
Age 0.011 0.004 0.014         0.010 0.004 0.023       
BMI 0.006 0.006 0.355         0.005 0.006 0.442       
CVD risk -0.006 0.041 0.883         -0.012 0.040 0.765       
GDS -0.010 0.017 0.554         -0.009 0.017 0.601       
APOE ε4 0.302 0.059 <0.001         0.304 0.059 <0.001       
rs68006382 0.025 0.083 0.766         0.356 0.214 0.097       
Dysfunction 0.022 0.048 0.656         0.041 0.042 0.324       
INT 0.016 0.081 0.842     <0.001   -0.254 0.154 0.101     0.011 
Model summary: rs71353406   0.138 <0.001           0.148 <0.001   
Age 0.011 0.004 0.015         0.010 0.004 0.023       
BMI 0.005 0.006 0.403         0.005 0.006 0.431       
CVD risk -0.017 0.041 0.682         -0.017 0.040 0.668       
GDS -0.012 0.017 0.498         -0.012 0.017 0.483       
APOE ε4 0.302 0.059 <0.001         0.308 0.059 <0.001       
rs71353406 0.078 0.074 0.295         0.299 0.159 0.061       
Dysfunction 0.059 0.055 0.292         0.051 0.043 0.233       
INT -0.049 0.075 0.518     0.002   -0.205 0.128 0.110     0.011 
Model summary: rs12968026   0.137 <0.001           0.131 <0.001   
Age 0.011 0.004 0.012         0.010 0.004 0.018       
BMI 0.005 0.006 0.444         0.004 0.006 0.504       
CVD risk -0.015 0.040 0.704         -0.013 0.040 0.757       
GDS -0.012 0.016 0.479         -0.010 0.017 0.540       
APOE ε4 0.281 0.058 0.281         0.281 0.059 <0.001       
rs12968026 0.051 0.089 0.571         -0.027 0.363 0.940       
Dysfunction 0.039 0.046 0.398         0.046 0.041 0.269       
INT 0.030 0.087 0.726     0.001   -0.005 0.208 0.981     <0.001 
Model summary: rs3875089   0.140 <0.001           0.144 <0.001   
Age 0.011 0.004 0.016         0.010 0.004 0.019       
BMI 0.004 0.006 0.456         0.005 0.006 0.437       
CVD risk -0.013 0.040 0.745         -0.011 0.040 0.779       
GDS -0.013 0.017 0.438         -0.011 0.017 0.527       
APOE ε4 0.300 0.058 <0.001         0.307 0.058 <0.001       
rs3875089 0.043 0.079 0.583         0.369 0.245 0.133       
Dysfunction 0.028 0.049 0.560         0.037 0.041 0.377       
INT 0.021 0.792 0.792     <0.001  -0.207 0.163 0.206     0.007 
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Appendix 13: Moderation Analysis for AQP1 and AQP4 SNPs on Daytime 
Dysfunction (cont.). 
     Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs162007   0.136 <0.001           0.139 <0.001   
Age 0.011 0.004 0.015         0.010 0.004 0.017       
BMI 0.005 0.006 0.456         0.005 0.006 0.422       
CVD risk -0.013 0.040 0.740         -0.014 0.040 0.728       
GDS -0.013 0.017 0.449         -0.011 0.017 0.493       
APOE ε4 0.305 0.058 <0.001         0.308 0.058 <0.001       
rs162007 0.024 0.079 0.764         0.058 0.213 0.786       
Dysfunction 0.042 0.047 0.379         0.033 0.041 0.419       
INT -0.034 0.079 0.672     0.001   -0.321 0.335 0.338     0.004 
Model summary: rs162003   0.140 <0.001           N/A     
Age 0.010 0.004 0.020                     
BMI 0.004 0.006 0.566                     
CVD risk -0.011 0.040 0.784                     
GDS -0.013 0.017 0.431                     
APOE ε4 0.299 0.058 <0.001                     
rs162003 -0.019 0.117 0.872                     
Dysfunction 0.037 0.042 0.378                     
INT -0.078 0.133 0.559     0.001               
Model summary: rs151245   0.135 <0.001           0.152 <0.001   
Age 0.010 0.004 0.016         0.009 0.004 0.029       
BMI 0.004 0.006 0.472         0.005 0.006 0.404       
CVD risk -0.015 0.040 0.714         -0.003 0.040 0.933       
GDS -0.012 0.017 0.459         -0.011 0.017 0.498       
APOE ε4 0.305 0.058 <0.001         0.298 0.058 <0.001       
rs151245 -0.005 0.078 0.949         0.213 0.106 0.046       
Dysfunction 0.023 0.062 0.708         0.058 0.043 0.176       
INT 0.014 0.075 0.857     <0.001   -0.197 0.104 0.059     0.014 
Model summary: rs151246   0.137 <0.001           0.138 <0.001   
Age 0.011 0.004 0.014         0.011 0.004 0.013       
BMI 0.005 0.006 0.455         0.005 0.006 0.447       
CVD risk -0.013 0.040 0.744         -0.017 0.040 0.680       
GDS -0.013 0.017 0.441         -0.012 0.017 0.470       
APOE ε4 0.303 0.058 <0.001         0.305 0.058 <0.001       
rs151246 -0.001 0.076 0.993         -0.257 0.288 0.372       
Dysfunction 0.043 0.048 0.370         0.030 0.041 0.478       
INT -0.038 0.078 0.627     0.001   0.185 0.260 0.477     0.477 
Model summary: rs2339214   0.141 <0.001           0.138 <0.001   
Age 0.009 0.004 0.040         0.010 0.004 0.024       
BMI 0.006 0.006 0.367         0.005 0.006 0.423       
CVD risk -0.010 0.041 0.815         -0.011 0.041 0.789       
GDS -0.010 0.017 0.567         -0.009 0.017 0.583       
APOE ε4 0.296 0.059 <0.001         0.303 0.059 <0.001       
rs2339214 -0.091 0.088 0.301         0.088 0.094 0.350       
Dysfunction -0.054 0.081 0.506         0.046 0.046 0.317       
INT 0.114 0.089 0.203     0.007   -0.063 0.087 0.468     0.002 
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Appendix 13: Moderation Analysis for AQP1 and AQP4 SNPs on Daytime 
Dysfunction (cont.). 
      Dominant†           Recessive†     
  β SE Sig. R2 Sig. ΔR2   β SE Sig. R2 Sig. ΔR2 
AQP4 cont.                           
Model summary: rs491148   0.143 <0.001           0.168 <0.001   
Age 0.010 0.004 0.020         0.010 0.004 0.015       
BMI 0.005 0.006 0.394         0.005 0.006 0.384       
CVD risk -0.012 0.041 0.760         -0.007 0.040 0.866       
GDS -0.016 0.017 0.351         -0.008 0.016 0.623       
APOE ε4 0.302 0.058 <0.001         0.312 0.058 <0.001       
rs491148 0.101 0.082 0.221         0.568 0.197 0.004       
Dysfunction 0.046 0.047 0.337         0.043 0.041 0.300       
INT -0.034 0.082 0.337     0.001   -0.339 0.144 0.020     0.022 
Model summary statistics for all Aquaporin 1 (AQP1) and Aquaporin 4 (AQP4) 
reference single nucleotide polymorphism (SNP) markers (rs). †Genetic models: 
Dominant (heterozygote/homozygote for the minor allele (Mm or MM) vs 
homozygote for the major allele (mm)), Recessive (homozygote for the minor allele 
(MM) vs heterozygote/homozygote for the major allele (Mm/mm)); β, Coefficient of 
predictors: SE, standard error; Sig, p-value; R2, coefficient of multiple determination, 
ΔR2, multiple correlation coefficient (R) squared change; BMI, Body Mass Index; 
CVD risk, cardiovascular disease risk; GDS, Geriatric Depression Scale; APOE, 
Apolipoprotein E ε4 allele carriage (presence/absence); INT, Interaction (Daytime 
dysfunction * model summary SNP). Models where the interaction term (INT) resulted 
in a statistically significant R2-change (p < 0.05) are indicated (bolded). If a model 
could not run due to that SNP variable being a constant then not applicable (N/A) is 
recorded for that model. 
 
 
